Small Molecule Modulation of the Ras-SOS Interaction in Cancer by Burns, Michael Charles
SMALL MOLECULE MODULATION OF THE RAS-SOS INTERACTION IN 
CANCER 
 
By 
Michael Charles Burns 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Biochemistry 
December, 2014 
Nashville, Tennessee 
 
Approved: 
Stephen Fesik, Ph.D. 
Lawrence Marnett, Ph.D. 
Scott Hiebert, Ph.D. 
Jennifer Pietenpol, Ph.D. 
  
	  	   ii	  
 
 
 
 
 
 
 
 
To my wife and family,
	  	   iii	  
ACKNOWLEDGEMENTS 
 I would like to thank the Vanderbilt Division of Hematology and Oncology 
for awarding me the Ann Melly Scholarship in Oncology to support this work as 
well as the Vanderbilt Medical-Scientist Training Program supported by the 
Public Health Service award T32 GM07347 from the National Institute of General 
Medical Studies. This work was also supported by US National Institutes of 
Health grants including a NIH Director’s Pioneer Award to Stephen W. Fesik 
(5DP1OD006933 ), an ARRA stimulus grant to L. J. Marnett (5RC2A148375) , 
and an NCI SPORE in GI cancer to R.J. Coffey (5P50A095103-0) in addition to a 
Lustgarten Foundation Grant to Stephen W. Fesik.  I would also like to thank the 
Vanderbilt University School of Medicine, the Department of Biochemistry, the 
Vanderbilt Institute of Chemical Biology, and the VICB High-Throughput 
Screening Core as well as my thesis committee members Lawrence Marnett, 
Ph.D., Jennifer Pietenpol, Ph.D., Scott Hiebert, Ph.D., and William Pao, 
M.D./Ph.D. for their scientific insights and career advice. 
 For training me as a scientist and supporting my career ambitions without 
exception, I would like to thank Stephen W. Fesik, Ph.D.  As an advisor, Dr. 
Fesik gave me the freedom to discover the unknown and encouraged me to 
boldly blaze new trails in science. Under his guidance I have had an amazing, 
productive research experience. He has a remarkable understanding of the 
problems that face science and medicine today, and a true desire to tackle these 
dilemmas in his lab. Working with Dr. Fesik has made me a better scientist, and I 
look forward to continuing a long friendship with him in the future.  
	  	   iv	  
I would like to thank members of the Fesik group for their impact on my 
career as a physician-scientist and their contributions to the work presented in 
this dissertation. In particular, I would like to thank Olivia W. Rossanese for 
training me in the laboratory, critically examining every piece of data I ever 
produced, and mentoring me as a scientist.  She has become a good friend. My 
work on the Ras-SOS interaction would not have been realized without the 
project guidance of Alex G. Waterson and Olivia Rossanese as well as the 
insights provided by members of the Fesik lab senior leadership team including 
Edward Olejniczak, Jason Phan, and Taekyu Lee. I would like to thank Qi Sun for 
running side-by-side with me as graduate students in the Fesik lab and for 
working as the structurally biology counterpart on the Ras project. Conducting 
the fragment-based NMR screen as well as his effort to generate the cocrystal 
structures described in this dissertation have been critical.  I appreciate Jason 
Phan and DeMarco Camper for their help with the crystallography and protein 
purification as well as the entire Fesik lab structural biology team for volunteering 
to help me each time I dreamt up a new experiment. I would like to thank the 
Fesik lab chemistry team including Jason Burke, R. Nathan Daniels, J. Phillip 
Kennedy, Andrew J. Little, Alex G.Waterson, and Taekyu Lee for their organic 
synthesis contributions and medicinal chemistry efforts over the years. Past and 
present members of the cell biology team in the Fesik lab including Olivia 
Rossanese, Bhavatarini Vangamudi, Dominic Vigil, Craig Goodwin, and Jennifer 
Howes have helped me scientifically throughout my graduate career and served 
	  	   v	  
as great friends. I am truly thankful for the contributions of each member of the 
Fesik lab, and I can only hope to work with each of them again in the future.  
Finally, I would like to thank my family and friends for their unending 
support. Their love and encouragement has enabled me to accomplish great 
things and their presence makes each achievement all the better. I want to thank 
my parents for instilling in me a hard work ethic and a love of learning.  Their 
constant support of my academic pursuits has enabled me to work at the 
forefront of biomedical research and to push the boundaries of what is known in 
science and medicine. I am extremely lucky to have such a close relationship 
with each of my brothers and sisters.  I would not be the person I am today if it 
weren’t for growing up with each of them, and I look forward to many adventures 
with them in the years to come. Last but not least, I would like to thank my wife, 
Dr. Laura Burns. She has supported me through everything I have done, 
challenged me to be better, and made this journey more enjoyable at every step.  
My support system is more than any scientist could ever want or need, and for 
that I am extremely grateful.  
To all those mentioned, and the many more that were not, I could not have 
accomplished this without you.  Thank you all. 	  
	  	   vi	  
TABLE OF CONTENTS 
Page 
DEDICATION ......................................................................................................... ii 
ACKNOWLEDGEMENTS ..................................................................................... iii 
LIST OF TABLES .................................................................................................. ix 
LIST OF FIGURES ................................................................................................. x 
LIST OF ABBREVIATIONS ................................................................................. xiii 
Chapter 
I. INTRODUCTION ............................................................................................. 1 
Scope of the Dissertation ...................................................................... 1 
Introduction to Ras ................................................................................ 4 
Ras Biochemistry and Function ....................................................... 7 
Ras in Cancer ................................................................................ 18 
Approaches for Targeting Oncogenic Ras .................................... 21 
    
II. SMALL MOLECULES INHIBIT SOS-CATALYZED NUCLEOTIDE 
EXCHANGE ................................................................................................... 26 
 
Introduction ......................................................................................... 26 
Results ................................................................................................ 26 
Discussion ........................................................................................... 34 
Materials and Methods ....................................................................... 35  
Cloning, Expression and Purification  ............................................ 35 
Fragment-based Screen  ............................................................... 36 
Protein Crystalization .................................................................... 37 
X-ray Data Collection, Structure Solution, and Refinement  ......... 37 
Nucleotide Exchange Assays  ....................................................... 40 
 
III. SMALL MOLECULES ACTIVATE SOS-CATALYZED NUCLEOTIDE 
EXCHANGE ................................................................................................... 42 
 
Introduction ......................................................................................... 42 
Results ................................................................................................ 43 
Small Molecules Increase SOScat-Mediated Nucleotide Exchange 
on Ras  .......................................................................................... 43 
	  	   vii	  
Compounds Activate Nucleotide Exchange in a SOS-Dependent 
Manner that Does Not Involve Ras Binding to the Allosteric Site of 
SOS  .............................................................................................. 45 
Compounds that Activate Nucleotide Exchange Bind to a Pocket 
Identified in the Ras:SOS:Ras Complex  ...................................... 52 
Amino Acid Substitution of Residues Within the Pocket Prevents 
Compound-Induced Activation of Nucleotide Exchange  .............. 56 
Nucleotide Exchange Activators Increase Ras-GTP and Perturb 
Ras Signaling in Cells  .................................................................. 58 
Discussion ........................................................................................... 64  
Materials and Methods ....................................................................... 67  
Protein Purification  ....................................................................... 67 
Protein Crystallization  ................................................................... 69 
X-ray Data Collection, Structure Solution, and Refinement  ......... 70 
Nucleotide Exchange Assays  ....................................................... 70 
Fluorescence Anisotropy Binding Assays  .................................... 71 
NMR  ............................................................................................. 72 
Cell-based Assays  ........................................................................ 72 
 
IV. HIGH-THROUGHPUT SCREENING USING NUCLEOTIDE EXCHANGE 
ASSAY  .......................................................................................................... 75 
 
Introduction ......................................................................................... 75 
Results ................................................................................................ 76 
     Assay Development ....................................................................... 76 
     High-Throughput Screen and Follow-up  ....................................... 86 
     High-Throughput Screening Derived Activators Bind to the 
Ras:SOS:Ras Complex and Perturb MAPK Signaling  ...................... 91 
Discussion ......................................................................................... 103 
Materials and Methods ..................................................................... 105  
Protein Purification  ..................................................................... 105 
Nucleotide Exchange Assays  ..................................................... 106 
Reordering Compounds  ............................................................. 107 
Protein Crystallization, X-ray Data Collection, and Refinement  . 107 
Cell-based Assays  ...................................................................... 107 
 
V. MECHANISM OF ACTION UNDERLYING PERTURBED RAS SIGNALING IN 
CELLS  ........................................................................................................ 108 
 
Introduction ....................................................................................... 108 
Results .............................................................................................. 113 
Investigating a Similar Mechanism for MAPK Pathway Activation by 
Nucleotide Exchange Activators and Raf Inhibitors  ................... 113 
Investigating Compound-Induced Activation of a Negative 
Feedback Loop Involving EGFR ................................................. 120 
Discussion ......................................................................................... 127 
	  	   viii	  
Materials and Methods ..................................................................... 132  
Cell Culture .................................................................................. 132 
 
VI. DISCUSSION AND FUTURE DIRECTIONS  .............................................. 134 
 
Introduction ....................................................................................... 134 
Discussion and Future Directions for Inhibitors of the Ras-SOS 
Interaction  ........................................................................................ 135 
Discussion and Future Directions for Inhibitors of the Ras-SOS 
Interaction  ........................................................................................ 138 
Conclusion  ....................................................................................... 150 
 
APPENDIX  ....................................................................................................... 152 
 
I.  Final Hits from High-Throughput Screen ...................................... 152 
II.  Activity of Three Nucleotide Exchange Activators on a Panel of 
Oncology Kinases ............................................................................. 159 
 
REFERENCES  ................................................................................................. 168 
 
	  	   ix	  
LIST OF TABLES 
Table 1-1   Frequency of Ras mutations in human cancer ................................. 20 
 
Table 2-1   X-ray data collection and refinement statistics ................................. 39 
 
Table 3-1   Structure-activity relationship for compounds 1-5 ............................. 45 
 
Table 4-1   Nucleotide exchange activators identified by high-throughput 
screening ......................................................................................... 92 
 
	  	   x	  
LIST OF FIGURES 
Figure 1-1   A Simplified Ras Signaling Pathway .................................................. 6 
 
Figure 1-2   Sequence and structural alignment of Ras  ....................................... 9 
 
Figure 1-3   Schematic diagram depicting the activation of Ras by SOS ........... 14 
 
Figure 1-4   Structural basis of Ras-GTP:effector interactions ........................... 17 
 
Figure 2-1   Multiple chemotypes bind directly to K-Ras ..................................... 27 
 
Figure 2-2   Ribbon and molecular surface representations of the X-ray structures 
of K-Ras-GDP complexed to multiple ligands ............................... 29 
 
Figure 2-3   Conformational change in K-Ras observed upon ligand binding ..... 30 
 
Figure 2-4   Compounds inhibit SOS-catalyzed nucleotide exchange ................ 32 
 
Figure 2-5   Compounds compete with SOS for binding to K-Ras ...................... 34 
 
Figure 3-1   Aminopiperidine indole compounds increase SOScat-catalyzed 
nucleotide exchange on Ras ......................................................... 44 
 
Figure 3-2   Nucleotide exchange activation by aminopiperidine-indole 
compounds is SOS-dependent and does not require the allosteric 
Ras-binding site ............................................................................. 46 
 
Figure 3-3   Aminopiperidine indole compounds activate SOScat independent of 
the allosteric Ras binding site ........................................................ 48 
 
Figure 3-4   Compounds do not activate RasGRF1 ............................................ 49 
 
Figure 3-5   Activation of SOS-catalyzed nucleotide exchange is independent of 
assay conditions ............................................................................ 51 
 
Figure 3-6   Aminopiperidine indole compounds bind to the Ras:SOS:Ras ternary 
complex ......................................................................................... 53 
 
Figure 3-7   Direct binding of nucleotide exchange activators to SOS. ............... 55 
 
Figure 3-8   SOScat mutants block compound-induced activation of nucleotide 
exchange ....................................................................................... 57 
 
Figure 3-9   Mutation of the aminopiperidine indole binding site prevents 
activation of nucleotide exchange ................................................. 58 
	  	   xi	  
 
Figure 3-10  Aminopiperidine indole compounds perturb Ras signaling by acting 
at the level of the Ras-SOS interaction ......................................... 60 
 
Figure 3-11  Compounds are cell permeable and inhibit cell proliferation and 
anchorage independent growth ..................................................... 61 
 
Figure 4-1   Fluorescent nucleotide analogues increase in fluorescence when 
bound by K-Ras ............................................................................. 78 
 
Figure 4-2   Systematic assessment of high-throughput screening assay 
variables ........................................................................................ 81 
 
Figure 4-3   High-throughput screen design and analysis .................................. 84 
 
Figure 4-4   High-throughput screening progression path and statistics ............. 88 
 
Figure 4-5   HTS activators bind to the Ras:SOS:Ras ternary complex ............. 95 
 
Figure 4-6   HTS-derived activators adopt a distinct, mutually exclusive binding 
mode .............................................................................................. 97 
 
Figure 4-7   HTS- and fragment-derived nucleotide exchange activators elicit the 
same signaling downstream of Ras .............................................. 98 
 
Figure 4-8   Optimization of the benzimidazole containing HTS-derived activator 
series ........................................................................................... 102 
 
Figure 5-1   Mutations in B-Raf, not PI3K, alter signaling induced by nucleotide 
exchange activators .................................................................... 114 
 
Figure 5-2   Biphasic response in MAPK signaling converted to inhibition in cells 
harboring a P-loop mutation in B-Raf .......................................... 119 
 
Figure 5-3   Compound pretreatment time alters the responsiveness of EGFR to 
EGF. ............................................................................................ 122 
 
Figure 5-4   Desensitization of EGFR occurs after 15 minutes and is distinct from 
direct inhibition............................................................................. 122 
 
Figure 5-5   EGFR phosphorylation events in response to compound 
pretreatment and EGF stimulation .............................................. 125 
 
Figure 5-6   Silencing SOS abrogates EGFR phosphorylation on serines 1046 
and 1047 ..................................................................................... 126 
 
	  	   xii	  
Figure 6-1   Multiple sequence alignment and structural overlay of SOS with 
other GEFs provides evidence for a conserved ligand-binding 
pocket .......................................................................................... 141 
 
Figure 6-2   Building toward the Ras-SOS interface ......................................... 144 
 
 
	  	   xiii	  
LIST OF ABBREVIATIONS 
ADP, AMP, ATP adenosine 5'-mono, di-, and triphosphates 
ATCC  American Type Culture Collection 
BFA Brefeldin A 
BODIPY boron-dipyrromethene 
bp base pair 
Ca2+ calcium ion 
cAMP cyclic AMP (adenosine 3':5'-monophosphate) 
COSMIC Catalogue of Somatic Mutations in Cancer  
CTD C-terminal domain 
DAG diacylglycerol 
DAPI 4'-6-diamidino-2-phenylindole 
DH Dbl homology 
DMEM Dulbecco's modified Eagle's medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid or deoxyribonucleate 
DNA deoxyribonucleic acid or deoxyribonucleate 
DTT dithiothreitol 
ED50 effective dose, 50% 
EDTA  ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
ERK extracellular-signal-regulated kinase 
	  	   xiv	  
FBS fetal bovine serum 
FDSS  Functional Drug Screening System 
FITC fluorescein isothiocyanate 
FTI farnesyltransferase inhibitors  
G-protein guanosine nucleotide-binding protein 
GAP GTPase-activating protein 
GDP, GMP, GTP guanosine 5'-mono-, di-, and triphosphates 
GEF guanine nucleotide exchange factor 
GppNHp Guanosine 5′-[β,γ-imido]triphosphate 
GRB2 growth-factor-receptor bound protein 2 
GTP guanosine triphosphate 
GTPase  GTP-hydrolyzing protein 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HF histone-like domain (histone fold) 
HSQC  heteronuclear single quantum coherence 
HTS high-throughput screen 
IC50 concentration giving half-maximal inhibition 
ICMT1 isoprenylcysteine carboxymethyltransferase-1  
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IQ motif motif containing conserved I and Q residues  
mant methylanthraniloyl 
MAPK mitogen-activated protein kinase 
MEK mitogen-activated protein kinase/extracellular signal-
	  	   xv	  
regulated kinase kinase 
Mg2+  magnesium ion 
NF1 neurofibromin 1 
NMR nuclear magnetic resonance 
P-Loop phosphate binding loop 
PBS phosphate-buffered saline 
PCR Polymerase chain reaction 
PDB Protein Data Bank 
PDK1 phosphoinositide-dependent kinase-1 
PH pleckstrin homology 
PI3K phosphotidyl inositol 3-kinase 
PIP2, PIP3 phosphatidylinositol bisphosphate, phosphatidylinositol 
trisphosphate 
PVDF  polyvinylidene fluoride 
Raf Raf kinase 
Ral Ras-like (Ral) guanyl nucleotide-binding proteins 
RalGDS Ral guanine nucleotide dissociation stimulator 
Ras-GRF Ras protein-specific guanine nucleotide-releasing factor 
RasGRP Ras guanyl-releasing protein 
RBD Ras-binding domain  
RCE1 Ras-converting enzyme-1  
REM Ras exchange motif  
RFU relative fluorescence units 
	  	   xvi	  
RhoGEF Rho family GTPase guanine nucleotide exchange 
factors 
rmsd  root-mean-square deviation 
RNA ribonucleic acid or ribonucleate 
RTK receptor tyrosine kinase 
SD standard deviation 
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis 
SH2 SRC homology 2 domain 
SH3 SRC homology 3 domain 
siRNA small/short interfering RNA 
SOS  Son of Sevenless 
SwI, SwII Switch I, Switch II 
TEV tobacco etch viral protease 
Tris tris(hydroxymethyl)aminomethane 
VICB Vanderbilt Institute of Chemical Biology 
VU Vanderiblt University 
WT wild type 
	  	   1	  
CHAPTER I 
 
INTRODUCTION 
 
Scope of the Dissertation 
In this dissertation, I will describe my investigations into the Ras:SOS 
interaction and how this important node in Ras signaling can be modulated with 
small molecules in cancer. Ras signaling and biochemistry, the role that Ras 
plays in driving cancer, and strategies that have been applied to inhibit Ras are 
reviewed in Chapter I in order to place the work described in this dissertation into 
the broader context of Ras-related research.  
Chapter II will focus on my examination of small molecules that bind 
directly to Ras that were identified from a fragment-based screen. I demonstrate 
that these small molecules are capable of inhibiting SOS-catalyzed nucleotide 
exchange on Ras in a competitive manner. These ligands bind between the 
switch I and switch II regions of Ras, which are critical for SOS-catalyzed 
nucleotide exchange. 
In Chapter III, I will describe my investigation examining small molecules 
that activate SOS-catalyzed nucleotide exchange in vitro, bind to the 
Ras:SOS:Ras complex, and modulate Ras signaling pathways in cells. This 
study has revealed valuable tool compounds that alter the Ras-SOS interaction 
by binding to a previously uncharacterized small molecule binding site on the 
Ras:SOS:Ras complex. X-ray crystallography of Ras:SOS:Ras in complex with 
	  	   2	  
these molecules revealed that the compounds bind in a hydrophobic pocket in 
the CDC25 domain of SOS adjacent to the Switch II region of Ras. Treating cells 
with these compounds resulted in an increase in Ras-GTP levels and disruption 
of MAPK and PI3K signaling at low micromolar concentrations. These small 
molecules represent new tools to study the acute activation of Ras, highlight a 
novel pocket on SOS that may be exploited to modulate Ras signaling, and form 
the basis for a new approach to target Ras in cancer.   
Compounds from Chapter III inhibit cell proliferation and anchorage 
independent growth; however, improved molecules may aid in determining how 
these compounds could be used to inhibit Ras-driven cancers. Chapter IV 
describes my efforts to improve these molecules by identifying new starting 
points by conducting a high-throughput screen of the VICB library.  This screen 
identified multiple unique chemical series capable of activating SOS-catalyzed 
nucleotide exchange using the same pocket on SOS.  These compounds bind in 
a distinct mode compared to compounds described in Chapter III and display 
additional protein-ligand interactions. Importantly, compounds identified by high-
throughput screening elicit the same signaling as compounds described in 
Chapter III.  Biochemical, cellular, and structural data on these compounds are 
currently being used to guide the design of improved compounds for future 
studies. 
In Chapter V, I will describe ongoing investigations into the possible 
mechanisms of action underlying the perturbed signaling observed downstream 
of Ras following compound treatment. The paradoxical signaling observed in the 
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MAPK pathway following treatment with compounds from Chapters III and IV is 
reminiscent of the paradoxical activation induced by B-Raf inhibitors in the setting 
of wild-type Raf. Preliminary observations suggest that both events could be 
regulated at the level of the Ras:Raf interaction.  Alternatively, the signaling 
observed could be due to negative feedback regulation. I have identified an 
inhibitory phosphorylation site on EGFR that is regulated in both a compound 
and SOS-dependent manner.  While the mechanism underlying the perturbed 
Ras signaling following treatment with nucleotide exchange activators has yet to 
be elucidated, these two observations represent promising new avenues of 
research to uncover this mechanism. 
Chapter VI includes a discussion of the work conducted in this dissertation 
and describes future directions based on this work. Approaches to improve both 
nucleotide exchange inhibitors and activators described in Chapters II-V are 
proposed. Gaps in our understanding of how these molecules function at the 
molecular level are described, and experiments designed to further elucidate 
their biochemical mechanism of action are proposed. A discussion is included on 
the specificity of nucleotide exchange activators including their possible activity 
on closely related GEF:GTPase interactions.  Finally, similarities and differences 
in the cellular signaling elicited by these compounds and other reported 
molecules targeting the Ras pathway is discussed.   
This dissertation describes discoveries on how small molecules can both 
inhibit and activate SOS-catalyzed Ras activation.  This work has provided new 
insights into how the Ras-SOS interaction can be modulated, and how 
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specifically perturbing this important node can alter signal output through 
pathways downstream of Ras. Exciting new avenues of research have been 
realized based on this work and further investigation of this approach as a novel 
way to inhibit Ras function in cells may enable the discovery of therapeutics for 
the treatment of Ras-driven cancers. 
 
Introduction to Ras 
Ras is a 21 kDa small GTPase that functions as a binary switch 
transitioning between an inactive GDP-bound and an active GTP-bound state in 
order to relay cellular signals in response to extracellular stimuli. Ras activation is 
tightly regulated by guanine nucleotide exchange factors (GEFs) that catalyze 
nucleotide exchange and by GTPase-activating proteins (GAPs) that facilitate 
GTP hydrolysis.(1) Upon activation, Ras exerts its functions through protein-
protein interactions with effectors such as Raf kinase and phosphotidylinositol 3-
kinase (PI3K) to promote cell growth and survival (Figure 1-1).  
The key discovery in 1982 that mutations in Ras drive human cancer 
stimulated an intensive research effort on the Ras subfamily of small GTPases 
that continues to this day.(2) Despite this effort, the ultimate goal of developing 
an anti-Ras therapeutic for the treatment of cancer has been hindered by gaps in 
our knowledge of signal transduction mechanisms, negative and positive 
feedback loops, and the role that Ras plays in oncogenesis.(3) Recent 
developments in the understanding of Ras protein structure, biochemistry, and 
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biology paired with advances in drug discovery are likely to lead to new 
therapeutics to eliminate Ras-driven cancers.   
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Figure 1-1. A Simplified Ras Signaling Pathway. Growth factor binding to 
receptor tyrosine kinases (RTKs) at the cell surface results in the activation of 
receptor complexes containing adaptor proteins such as growth-factor-receptor 
bound protein 2 (GRB2).  GRB2 interacts with phosphorylated tyrosines on the 
RTK and recruits Son of Sevenless (SOS) to the membrane, which catalyzes 
nucleotide exchange on Ras and results in increased Ras-GTP levels .  Active 
Ras-GTP binds to downstream effector proteins including Raf kinase (Raf), 
phosphatidylinositol 3-kinase (PI3K), and Ral guanine nucleotide dissociation 
stimulator (RalGDS). Ras-GTP is converted back to the inactive Ras-GDP with 
the help of GTPase activating proteins (GAPs) to terminate signaling.  Aberrant 
signaling by Ras through the Raf-MEK-ERK, PI3K, RalGDS, and other effector 
pathways confers cancer cells with capabilities that represent the hallmarks of 
cancer.(4) 
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Ras Biochemistry and Function 
Detailed sequence and structural analyses have provided key insights into 
Ras proteins and their functions. The Ras superfamily of small GTPases consists 
of over 150 proteins that regulate signal transduction pathways governing 
fundamental cellular processes.(5) This superfamily can be divided into five main 
subfamilies on the basis of structural, biochemical, and functional similarities: 
Ras (cell signaling and growth), Rho (morphology and motility), Rab (membrane 
transport), Arf (vesicular transport), and Ran (nuclear transport).(1) Three Ras 
genes encode four highly conserved Ras proteins in the Ras subfamily: H-Ras, 
N-Ras, K-Ras4A, and K-Ras4B, where K-Ras4A and K-Ras4B are alternatively 
spliced products of the K-Ras gene.(6)  
Each Ras protein contains a highly conserved core GTPase domain that 
binds GDP/GTP and serves as the main functional unit of the protein.  This 
GTPase domain is composed of a β-sheet containing six β-strands and five α-
helices connected by a series of 10 loops followed by a hyper-variable C-terminal 
domain (CTD) that contains a membrane targeting sequence.(7, 8) Five of the 
loops play a key role in the high affinity of Ras for the nucleotide, and importantly, 
loops 1, 2, and 4 play a role in stabilizing the γ-phosphate of GTP.(7) Differences 
in the GTPase domain between the subfamilies include insertions, extensions, 
and additional domains, with the Ras GTPase domain serving as the minimal 
functional unit.  
The C-terminal domain, which includes amino acid residues 166-188/189, 
is highly variable among H-Ras, N-Ras, K-Ras4A, and K-Ras4B (Figure 1-2A). 
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This domain undergoes posttranslational modification responsible for the 
membrane localization of Ras, and it is required for Ras-mediated 
transformation.(9, 10) The enzyme farnesyl transferase is responsible for adding 
a farnesyl isoprenoid lipid to the C-terminal CAAX motif of Ras.(11-14) Further C-
terminal processing involves the proteolytic cleavage of the AAX motif by the 
Ras-converting enzyme-1 (RCE1) followed by methylation of the now C-terminal 
cysteine residue by isoprenylcysteine carboxymethyltransferase-1 (ICMT1).(15-
18) From here, a palmitoyl moiety is added to a cysteine in H-Ras, N-Ras, and K-
Ras4A upstream of the C-terminal farnesylated cysteine in order to stabilize 
membrane anchoring.(19, 20) This membrane association role is facilitated by a 
polybasic stretch of six lysine residues in the C-terminal domain of K-Ras4B.  
These lysines associate with the negatively charged lipid head groups of the 
membrane.(21) Ras localized to the plasma membrane is then able to function in 
response to extracellular growth factors to relay cellular signals to the nucleus. 
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Figure 1-2. Sequence and structural alignment of Ras.  (A) The four isoforms 
of Ras (H-Ras, N-Ras, K-Ras4A, and K-Ras4B) are highly conserved. Amino 
acid sequence alignment shows that the GTPase domains (residues 1-165) are 
highly homologous.  Importantly, the regions that bind GDP/GTP located within 
the first 85 amino acids, are identical between the four proteins. The C-terminal 
domain (residues 166-189 or 166-188 for the alternatively spliced K-Ras4B) 
undergoes post-translational modification and is responsible for membrane 
localization.  The conserved CAAX motif undergoes farnesylation followed by 
sequential proteolytic cleavage of the AAX motif and methylation by the enzymes 
RCE1 and ICMT1. (B) Structural overlay of H-Ras. The switch regions are 
highlighted in the GDP-bound (grey/red) and GTP-bound (grey/blue) forms.  
Nucleotide-induced conformational changes are confined to the switch I region 
(residues 30-38) and the switch II region (residues 60-76), which form a 
continuous surface on the Ras protein to interact with effector proteins. 
 
c"Terminal+Domain+
CAAX++
Mo2f+ Switch+I+
Switch+II+
GDP/GTP+
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Once localized to the plasma membrane, Ras proteins function through a 
conserved mechanism in which the bound nucleotide dictates the conformation 
adopted by the protein.  This conformational change in turn determines the ability 
of Ras to bind its signaling partners.  Structural differences between the GDP- 
and GTP-bound states of Ras are confined to two conserved regions of the 
protein termed “switch regions” (Figure 1-2B).(22) Switch I includes residues 30-
38 located on loop 2, and switch II is made up of residues 60-76 consisting of the 
loop 4 and α-helix 2 of Ras. The binding of GTP induces an inward rotation in 
threonine 35 of switch I enabling an interaction with the γ-phosphate and Mg2+ 
ion.(22) In addition, the γ-phosphate alters the orientation of switch II enabling an 
interaction with the backbone of glycine 60.(23, 24) The conformational changes 
occuring during this transition have been described as a “loaded spring” 
mechanism in which hydrolysis of GTP and subsequent release of the γ-
phosphate allows the switch regions to relax into the GDP-bound 
conformation.(23) Importantly, the switch I and switch II regions reside on a 
continuous surface of the Ras protein and form the primary interaction surface for 
effectors. The conformation adopted in the GTP-bound form allows for the 
specific interaction with effectors, which recognize Ras only in the “on-state”.(25) 
Upon GTP hydrolysis, the GDP-bound form is unable to interact with effectors, 
forming the structural basis for how Ras functions as a binary switch to regulate 
cell signaling.  
The rate-limiting step in the activation of Ras is the dissociation of bound 
GDP, an intrinsically slow process.(26) This slow dissociation rate, which is a 
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direct consequence of the high affinity of Ras for GDP/GTP, occurs with a half-
life on the order of hours and is accelerated by guanine nucleotide exchange 
factors (GEFs).(27, 28)  During the process of nucleotide exchange, the GEF 
displaces the bound nucleotide of Ras by weakening its affinity for GDP.  A 
stable GTPase:GEF intermediate is formed followed by association of GTP that 
results in the active form of GTP-bound Ras.  This mechanism of GEF-mediated 
nucleotide exchange is conserved among all GEF:GTPase interactions and has 
been extensively reviewed.(28)  
In the activation of Ras by SOS, extensive contacts with switch II are 
made to facilitate binding while the helical hairpin of SOS is wedged into Ras.(29) 
This results in the displacement of switch I on Ras and the opening of the 
nucleotide binding site.  The affinity of the bound nucleotide is further reduced by 
the side chains of the helical hairpin of SOS and the altered conformation of the 
switch II region of Ras.  This reduced affinity is due to the perturbation of the 
phosphate and magnesium binding environment, not the binding site for the base 
or the ribose of the nucleotide.  By maintaining a portion of this pocket, this 
mechanism enables the release of the bound nucleotide by its phosphates first, 
and subsequently allows association of the incoming nucleotide through its base 
first.  This mechanism of activation, in which the nucleotide-free form the GTPase 
is stabilized, has no preference for GTP over GDP.(30) Rather the active GTP-
bound Ras is generated as a result of the high excess of GTP present within the 
cell compared to GDP. 
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Ras activation is mediated by three main classes of Ras-specific GEFs 
(RasGEFs): SOS, Ras-GRF, and RasGRP, which are differentially regulated.  
Each RasGEF has a conserved ~250 amino acid CDC25 homology catalytic 
domain adjacent to a ~50 amino acid Ras exchange motif (REM domain), both of 
which are required for nucleotide exchange.(31) This minimal catalytic unit is 
flanked by different regulatory domains that respond to protein-protein 
interactions, protein-lipid interactions, binding of secondary messengers, and 
posttranslational modifications to provide specificity for how each GEF activates 
Ras.   
There are two SOS proteins, SOS1 and SOS2 each contain a tandem Dbl 
homology (DH) and pleckstrin homology (PH) domain, a histone-like domain 
(HF), and a C-terminal proline rich domain. The DH-PH unit auto-inhibits the 
RasGEF function of SOS, contains RhoGEF activity, and binds PIP2 to aid in 
membrane localization.(32-35) The HF domain is also auto-inhibitory and plays a 
role in orientation of SOS at the membrane.(36, 37) The autoinhibitory role 
played by the DH-PH and HF domains is relieved by membrane recruitment and 
Ras-GTP binding to an allosteric site on SOS.  Finally, the proline rich C-terminal 
domain interacts with the SH3 domain of GRB2 thereby coupling SOS activity to 
auto-phosphorylated RTKs (Figure 1-1).(38, 39)  
In contrast to GRB2-mediated activation of ubiquitously expressed SOS1, 
the differential regulation of Ras-GRF and RasGRP family of RasGEFs by 
various regulatory domains contributes to their distinct functions. Ras-GRF does 
not bind to GRB2 or form a complex with the activated EGFR receptor.(40) 
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Instead, Ras-GRF is activated by heterotrimeric G-proteins in the brain, 
constitutively associates with the membrane, and is regulated by Ca2+-dependent 
calmodulin association with a motif containing conserved I and Q residues (IQ 
motif).(41, 42) Ras-GRF’s play an important role in memory and learning, in 
contrast to the role that SOS plays in canonical extracellular ligand mediated 
activation of Ras in cell growth.(43) Like SOS, RasGRP family members 
associate with membranes when activated, but are uniquely regulated by Ca2+-
binding atypical EF hands and a C1 domain that binds diacylglycerol (DAG) and 
phorbol ester, each of which contributes to their important role in T cell 
development.(44-46) The roles that these various domains play highlights how 
differential regulation of RasGEFs result in distinct functions, and this paradigm 
underlies the unique responsibility that SOS has in activating Ras to control cell 
growth and resistance to apoptosis in cancer. 
Crystal structures have revealed that SOS is unique among Ras-specific 
GEFs, in having an additional allosteric Ras binding site within the catalytic unit 
composed of the CDC25 and REM domains (Figure 1-3).(35, 47, 48) Recent 
structural, in silico, and in vitro evidence shows that Ras binding to this allosteric 
site reinforces a positive feedback loop between Ras and SOS.(47, 49)   Ras 
binding at the catalytic site allows for SOS-catalyzed nucleotide exchange as 
described above, while Ras binding at the allosteric site increases the catalytic 
activity of SOS by reorienting its helical hairpin into a more active conformation 
(Figure 1-3).(48) Thus, there exists a positive feedback loop whereby SOS 
activates Ras, and activated Ras, in turn, allosterically activates SOS.  This 
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positive feedback mechanism makes SOS-mediated Ras activation more robust 
than other GEFs, enhances in vivo MAPK signaling, and makes SOS the primary 
GEF responsible for the activation of Ras in cells.(49-51) 
 
 
 
 
 
Figure 1-3.  Schematic diagram depicting the activation of Ras by SOS.  
SOS activates Ras by catalyzing the exchange of GDP for GTP .  This exchange 
is accompanied by a conformational change in the canonical switch regions of 
Ras (Switch I=30-38aa, Switch II= 60-76aa) highlighted in red and blue.  Once in 
the active, GTP-bound, state, Ras is capable of signaling to downstream 
effectors. SOS-catalyzed activation of Ras is further increased by the presence 
of an allosteric bound Ras-GTP molecule on SOS.  The presence of allosteric 
Ras places the helical hairpin of SOS in a conformationally active position 
capable of displacing bound GDP thus further increasing the oncogenic potential 
of Ras.   
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Active Ras is able to signal to downstream effectors until it returns to the 
inactive GDP-bound form by either intrinsic hydrolysis or GAP-stimulated 
hydrolysis.  Intrinsic GTP-hydrolysis by Ras is very slow, and efficient hydrolysis 
requires an interaction with a GAP.(52-54) The mechanism responsible for GAP-
mediated hydrolysis was elucidated by the X-ray crystal structure of p120GAP 
bound to Ras.(55) GAPs such as p120GAP function by stabilizing glutamine 61 of 
Ras, thereby allowing it to participate in catalysis by coordinating a water 
molecule for nucleophilc attack.  In addition, a conserved arginine in Ras-GAPs, 
called the arginine finger, is positioned in the active site of Ras to neutralize 
negative charges present during the transition state at the γ-phosphate.(55, 56) 
Through this protein-protein interaction with a GAP, active Ras is able to return 
back to the inactive GDP-bound state completing the GTPase cycle. This 
mechanism explains how oncogenic mutations in Ras at positions 12, 13, and 61 
function to keep Ras in the active state.  These mutations prevent GAP-mediated 
hydrolysis by blocking the correct orientation of the arginine finger and glutamine 
61.   
Ras signaling is accomplished through protein-protein interactions with 
downstream effectors, including Raf kinase (Raf), phosphotidyl inositol 3-kinase 
(PI3K), Ral guanine nucleotide dissociation stimulator (RalGDS), and other 
proteins. The first Ras effector identified was Raf1, which led to the discovery of 
the canonical MAPK signaling pathway linking signals from mitogen-stimulated 
receptor tyrosine kinases at the plasma membrane to cytoplasmic and nuclear 
alterations governing cell proliferation.(57-61) The role that Ras plays in 
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transformation was shown to be increasingly complex by the discovery that Ras 
binds to PI3K and RalGDS.(62-65) The finding that Ras can activate multiple 
effectors led to an understanding that these signaling pathways could cooperate, 
or function independently, in order to activate survival pathways and produce the 
diverse, often context-dependent phenotypes attributed to Ras.(4, 66, 67) This 
complexity has only increased, and today over 20 effectors of Ras are 
recognized.(31) While the structure and function of Ras effectors are diverse, 
there is a common mechanism, based on the nucleotide-dependent 
conformational changes in switch I and switch II, by which Ras engages these 
effectors. 
 Structural analyses have provided a detailed understanding of how Ras 
engages effector proteins to transduce cellular signals in response to upstream 
stimuli.  Effector proteins each contain a Ras-binding domain (RBD) that shares 
little sequence homology among binding partners, although structural studies 
have revealed that they adopt a common ubiquitin fold as shown for Raf, PI3K, 
and RalGDS.(68-71) In each case, the RBDs engage the switch I region of Ras 
and form an intermolecular antiparallel β-sheet (Figure 1-4A-C).  In addition, for 
the Ras-PI3K complex, more extensive contacts between Ras and the effector 
RBD of this partner are present, with the notable addition of interactions with 
switch II of Ras compared to Raf and RalGDS (Figure1-4B-C) .(70) Ras also 
engages the allosteric Ras-binding site on SOS in a similar manner to its 
interaction with PI3K in which residues from both switch I and switch II are 
involved (Figure 1-4D).(47)   
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Figure 1-4.  Structural basis of Ras-GTP:effector interactions. (A) Switch I 
and II regions of Ras-GTP reside on a continuous surface of the protein.   Ras 
interacts with the RBD of Raf1 (B, orange) through the switch I region; whereas, 
PI3K engages both switch I and II (C, purple).  The allosteric Ras binding site of 
SOS interacts with both switch I and II (D).  SOS is also bound to nucleotide-free 
Ras at the catalytic site (GEF-GTPase interaction). PDB IDs: 3KUD, 1HE8, & 
1NVV. 
 
 Acting as a molecular switch and playing a key role at the intersection of 
multiple signaling pathways makes Ras a critical component of signaling in 
response to growth factors.  The binding of growth factors to cell surface 
receptors, such as the Epidermal Growth Factor Receptor (EGFR), results in 
dimerization and autophosphorylation of intracellular kinase domains creating 
binding sites for adaptor molecules like GRB2 (Figure 1-1).  This results in the 
recruitment of SOS to the membrane and subsequent displacement of the bound 
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GDP of Ras.  Excess GTP in the cell is then allowed to bind generating the active 
form of Ras, which signals through downstream effectors to regulate cell survival 
and cell proliferation.  This growth signaling is negatively regulated by GAPs, 
which return Ras to its inactive GDP-bound state. Gain of function mutations, 
increased receptor signaling, or GAP inactivation in this pathway results in 
hyperactive Ras signaling.  This hyperactivation of Ras can lead to the initiation 
of uncontrolled cell proliferation and cell survival mechanisms, ultimately leading 
to cancer. 
 
Ras in Cancer 
Aberrant activation of Ras by increased upstream signaling, loss of GAP 
function, or oncogenic mutation results in the deregulation of cellular signals in 
cancer. Active Ras endows cells with capabilities that represent the hallmarks of 
cancer, including the ability to proliferate, evade programmed cell death, alter 
metabolism, induce angiogenesis, increase invasion and metastasis, and evade 
immune destruction.(4) Indeed, aberrant Ras signaling plays a role in up to 30% 
of all human cancers. 
One of the most common ways that Ras is altered in cancer is by amino 
acid substitutions at residues 12, 13, and 61 introduced through missense 
mutations in Ras.  These mutations slow the intrinsic hydrolysis of GTP and 
render Ras insensitive to GAP-mediated activation of its GTPase function.  The 
X-ray crystal structure of wild-type Ras bound to p120GAP revealed the basis for 
this insensitivity.(55) Within the complex crystal structure, the active site of 
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p120GAP bound to Ras is tightly packed in order to mimic the transition state, 
which occurs upon GTP hydrolysis.  Mutation of the glycine, at either position 12 
or 13, to an alanine is highly unfavorable and disturbs the residue arrangements 
in the transition state.  While this mechanism is responsible for keeping 
oncogenic Ras in the active GTP-bound state, our understanding of the 
biochemical and context-dependent manner in which Ras proteins control the 
complex molecular circuitry and multiple cellular processes that drive 
tumorigenesis has been shown to be very complex over the past few decades.(4) 
The highest incidence of Ras mutations occurs in carcinomas of the 
pancreas (63-90%), colon (36-50%), and lung (19-30%) (Table 1-1).(72, 73) 
Mutations in different Ras isoforms contribute to distinct forms of cancer.  K-Ras 
mutations most frequently occur in colorectal tumors, lung carcinomas, and 
pancreatic carcinomas, while H-Ras and N-Ras mutations are common in head 
and neck tumors as well as urinary tract and skin malignancies, respectively 
(Table 1-1).(4, 72)  
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Table 1-1. Frequency of Ras mutations in human cancer. 
Primary Tissue KRAS (%) HRAS (%) NRAS (%) Total (%) 
Pancreas 71 0 <1 71 
Colon 35 1 6 42 
Small Intestine 35 0 <1 35 
Biliary Tract 26 0 2 28 
Endometrium 17 <1 5 22 
Lung 19 <1 1 20 
Skin (melanoma) 1 1 18 20 
Cervix 8 9 2 19 
Urinary Tract 5 10 1 16 
Data derived from the Catalogue of Somatic Mutations in Cancer (COSMIC) 
of the Wellcome Trust Sanger Institute.  Adapted from Stephen et al. Cancer 
Cell 2014.(74) 
 
In addition to mutational activation of Ras in cancer, deregulated 
expression and/or activity of Ras and its interacting proteins can cause Ras 
activation. Ras genes are amplified or overexpressed in bladder tumors.(75)  In 
addition, many cancers are driven by a loss of GAP function or aberrant 
upstream activation by RTKs.  Ras-driven cancers resulting from loss of the GAP 
NF1 (Neurofibromin 1) occur in small cell carcinomas of the lung, 
adenocarcinomas of the colon and rectum, and ovarian carcinomas.(76) While 
the frequency of Ras mutation in breast cancer is low, Ras is commonly activated 
in breast cancer via the overexpression of upstream receptor tyrosine kinases 
including EGF and/or ErbB-2 receptors.(77, 78) Finally, overexpression or 
mutation of GEFs such as SOS also contributes to hyperactivation of Ras in 
renal cancers, endometrial and lung adenocarcinomas as well as acute myeloid 
leukemia.(79, 80) Taken together, upstream activation, loss of GAP function, and 
missense mutations in Ras make the Ras signaling pathway one of the most 
commonly altered pathways in cancer.   
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Importantly, inactivation of oncogenic Ras is a promising therapeutic 
strategy in in vitro and in vivo models of cancer. Early studies indicated that Ras-
induced transformation could be reversed using antibodies targeting Ras or 
mutant specific alleles of Ras.(81, 82) Silencing Ras in cell lines derived from 
human patient samples using siRNA reduced proliferation and induced apoptosis 
in a subset of cell lines harboring Ras mutations.(83, 84) More importantly, 
studies in murine models of lung, melanoma, and pancreatic cancer showed that 
inactivation of Ras resulted in the dramatic regression of tumors.(85-87) 
Moreover, inactivation of mutant Ras has also been shown to be promising 
therapeutic strategy even in the presence of tumors harboring multiple 
oncogenes.(88) 
 
Approaches to Target Oncogenic Ras 
Despite the clinical significance of targeting Ras, the discovery of potent 
inhibitors has been challenging due to the lack of suitable binding pockets on the 
surface of the protein. Early efforts to develop anti-Ras therapeutics focused on 
preventing its posttranslational modification or targeting upstream and 
downstream signaling components.  The lessons learned from these approaches 
paired with an improved understanding of Ras signaling and structure has led to 
a renewed interest in new approaches to develop Ras-directed therapeutics for 
the treatment of cancer.(74) 
The discovery that the C-terminal modification of Ras was required for 
transformation suggested that targeting the enzymes involved in posttranslational 
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modification of Ras may hold promise as a therapeutic strategy.(10) 
Farnesyltransferase inhibitors (FTIs), which prevent the first step of Ras 
posttranslational modification, were developed against H-Ras and early studies 
demonstrated that these inhibitors showed efficacy in in vivo models of Ras-
driven cancers.(89, 90) However, this stategy was ineffective for K- and N-Ras-
driven tumors, since these Ras proteins can incorporate a geranylgeranyl moiety 
in the presence of FTIs to produce biologically active forms of Ras that are stably 
inserted into the membrane.(91) Targeting other enzymes responsible for the 
posttranslational modification of Ras has also been evaluated, including the 
targeting of RCE1 and ICMT1, which are responsible for proteolytic cleavage and 
methylation of the C-terminus of Ras, respectively.  These strategies proved 
counterproductive as both resulted in the exacerbation of K-Ras-driven 
cancers.(92, 93) A separate approach aimed at inhibiting PDEδ, a prenyl-binding 
protein that directs the spacial distribution of Ras to cellular membranes, 
suppresses Ras signaling and prevented Ras-driven proliferation in in vitro and in 
vivo models of cancer.(94) Emerging data regarding the efficacy of this 
approach, as well as others aimed at inhibiting newly identified posttranslational 
modifications of Ras, including ubiquitination, acetylation, and nitrosylation are 
currently being evaluated as an approach for targeting Ras signaling.(95-98) 
 The identification of oncogenic mutations occurring both upstream and 
downstream of Ras paired with the rapid development of kinase inhibitors 
targeting these proteins led researchers to study the efficacy of Ras-pathway 
directed targeted therapies in Ras-driven tumors. Agents targeting receptor 
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tyrosine kinases upstream of Ras, such as erlotinib and gefitinib, caused tumor 
regression in a defined subset of patients; however, tumors harboring mutations 
in Ras have demonstrated resistance to these agents.(99, 100)  Numerous 
inhibitors targeting proteins downstream of K-Ras, including B-Raf, MEK, PI3K, 
and AKT are clinically approved or in various stages of development.  While 
these inhibitors are showing efficacy in specific subsets of patients, molecules 
targeting one Ras effector, Raf kinase, unexpectedly activated the pathway in the 
presence of Ras mutations.(101-104) Furthermore, it is unclear how effective 
MEK or PI3K inhibition alone will be for Ras-driven cancers.(74) Dual inhibition of 
MEK and PI3K has shown promise in preclinical models of Ras-driven cancers 
establishing the basis for future clinical trials; however, the toxicity profile of these 
combinations remains an unaddressed concern.(105) These findings highlight 
both the importance of this signaling pathway in cancer and the need for new 
inhibitors that can directly inhibit the activation and activity of K-Ras. 
Given the picomolar affinity of Ras for guanine nucleotides and the high 
concentrations of GDP and GTP in the cell, it is generally accepted that targeting 
the active site of Ras is impractical. Nonetheless, this strategy has been 
evaluated first through the development of reversible inhibitors that compete with 
GDP, and most recently by inhibitors targeting the nucleotide pocket that 
covalently interact with the cysteine residue in the oncogenic K-RasG12C mutant 
protein.(106, 107) Major barriers to these approaches include the affinity of Ras 
for GTP and the high concentration of GTP in the cell that must be overcome in 
order to provide a path forward.   
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Other groups have sought to target Ras outside of the nucleotide binding 
pocket. While molecules have been reported to bind directly to Ras, the structural 
basis for the mechanism of action of many of these compounds has remained 
elusive and none have advanced to the clinic to date.(108-112) Importantly, 
compounds that bind covalently to the cysteine in the mutant K-RasG12C 
underneath the switch II region of the protein were identified.(113) The structural 
basis by which these compounds trap K-RasG12C in the GDP-bound state and 
inhibit SOS-catalyzed nucleotide exchange was due to the selectivity of the 
covalent modifying head group of these compounds. How this approach can be 
used to target other mutants of Ras remains to be addressed. Nonetheless, the 
structures provided represent promising starting points for the design of improved 
Ras inhibitors.   
 Mutations at amino acid residues 12, 13, and 61 in Ras inhibit GAP-
mediated GTP-hydrolysis. Restoring the GTPase function to these mutant 
proteins using small molecules represents an unexplored strategy for inhibiting 
Ras-driven cancers.  While the intrinsic GTPase activity of Ras is slow compared 
to GAP-catalyzed GTP-hydrolysis, it may still be important in determining how 
long Ras engages effector proteins since GAPs cannot interact with Ras when 
Ras is bound to an effector. Indeed the Ras-binding domain of Raf1 slows the 
intrinsic hydrolysis rate of Ras proteins harboring amino acid substitutions at 
position 61, but not wild-type Ras.(114) Whether structure-based design or high 
throughput screening methodologies can be employed to discover compounds 
that mimic the arginine finger of Ras GAPs remains to be seen.   
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Inhibiting Ras-driven cancers by interfering with its posttranslational 
modification, preventing downstream signaling, developing covalent inhibitors, 
and restoring GTPase activity represent promising strategies that have been 
evaluated in the past and continue to be examined today. Nonetheless, these 
efforts towards inhibiting Ras signaling have been met with limited success and 
none have advanced to the clinic to date. To overcome this challenge, new 
pharmacologically tractable anticancer targets and methodologies are being 
explored by the Ras community to develop anti-Ras therapeutics. The work 
presented in this dissertation is aimed at evaluating novel points of intervention 
and unexplored mechanisms to inhibit Ras-driven cancers.  
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CHAPTER II 
 
SMALL MOLECULES INHIBIT SOS-CATALYZED NUCLEOTIDE EXCHANGE 
 
Introduction 
K-Ras inhibition represents an attractive therapeutic strategy for many 
cancers as described in Chapter I. However, Ras activation and signaling is 
accomplished primarily through protein–protein interactions. Such protein 
interfaces typically lack well-defined binding pockets and have been difficult to 
target with small molecules.(115) Despite a lack of obvious hydrophobic pockets 
on its surface, computational approaches have identified potential binding sites 
on Ras.(116, 117) The discovery of a Ras inhibitor would be aided by structural 
and functional data investigating small molecules that bind to such pockets. This 
chapter describes biophysical, structural, and biochemical experiments 
conducted to discover novel small molecules that bind directly to K-Ras between 
switch I and switch II and inhibit SOS-catalyzed K-Ras activation. 
 
Results 
A fragment-based screen using uniformly 15N-labeled GDP-bound K-Ras 
(G12D) was conducted by Qi Sun in the Fesik lab to identify compounds that 
bind directly to K-Ras.(118-120) This NMR-spectroscopy-based screen of 11,000 
fragments yielded approximately 140 fragments that bound to GDP-bound K-Ras 
(G12D) (hit rate=1.3%). Representative examples of some of the hits that were 
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identified in the fragment-based screen (1, 2, 3) as well as analogues that were 
synthesized to increase water solubility and binding affinity (4, 5, 6) are depicted 
in Figure 2-1. These compounds bind to K-Ras (G12D) with affinities of 1.3–2 
mM. The fragment hits identified in the screen were found not only to bind the 
G12D mutant of K-Ras but also bind to wild-type K-Ras, K-Ras (G12V), and H-
Ras, thus indicating that these compounds bind to a site that is conserved among 
Ras isoforms and different K-Ras mutants.  
 
Figure 2-1. Multiple chemotypes bind directly to K-Ras. Chemotypes 
identified in the fragment-based screen include indoles (1), phenols (2), and 
sulfonamides (3). Analogues of these compounds (4, 5, 6) were synthesized to 
increase their water solubility and binding affinity. 
 
 
To determine how the fragment hits and analogues bind to K-Ras, 
cocrystal structures were obtained. Initial attempts to cocrystallize K-Ras (G12D) 
with these compounds failed to produce suitable crystals. Owing to the limited 
number of space groups available to this mutant form of the protein, we 
performed crystallization screens of both wild-type and G12V mutant K-Ras. Both 
proteins crystallized across a broad range of conditions in multiple space groups 
and yielded high-resolution cocrystal structures. In all 25 cocrystal structures 
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obtained thus far, the compounds occupy a hydrophobic pocket located between 
the α2 helix of switch II (60–74) and the central β sheet of the protein. Figure 2-
2A depicts a high resolution structure of 4, an analogue of the screening hit 1, 
complexed to the GDP-bound form of wild-type K-Ras. The indole of 4 binds into 
a hydrophobic pocket formed in part by the movement of side chain of Tyr-71 
and a portion of the molecule lies flat in an adjacent binding cleft formed. This 
pocket is flexible and has the ability to accommodate other ligands. This is 
supported by the indole moiety in 5, which is rotated towards the α2 helix and the 
switch II loop region (Figure 2-2B). In addition, compounds from a phenol and 
sulfonamide containing series were also able to bind into this hydrophobic 
pocket, as demonstrated by the X-ray structures of compounds 2 and 6 bound to 
K-Ras (Figure 2-2C-D).   
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Figure 2-2. Ribbon and molecular surface representations of the X-ray 
structures of K-Ras-GDP complexed to multiple ligands.  (A) 4 (PDB code 
4EPV), (B) 5 (PDB code 4EPW), (C) 2 (PDB code 4EPT), and (D) 6 (PDB code 
4EPX). 
 
Analysis of the ligand–protein cocrystal structures revealed that all the 
compounds bind to a pocket that is not readily observed in the ligand-free form 
(Figure 2-3A) but in an “open” form of the protein (Figure 2-3B). The pocket is 
created by a conformational change (Figure 2-3C) in which the α2 helix moves 
away from the central β-sheet, and the side chain of Tyr-71 breaks the hydrogen-
bond network present in the ligand-free form. Moreover, the side chain of Met-67 
rotates out of the way to form a secondary binding cleft. This rotation creates a 
new binding site for small molecules that is not present in the “closed” form. In 
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subsequent X-ray structures obtained of ligand-free K-Ras under different 
experimental conditions as well as recently published molecular dynamics 
simulations, the “open” form has been observed, thus suggesting that the “open” 
and “closed” conformations are present in equilibrium.(121, 122)  
 
      
 
Figure 2-3. Conformational change in K-Ras observed upon ligand binding. 
Electrostatic surface representations (red negative, blue positive) of GDP–K-Ras 
(A) in the absence of a ligand (PDB code 4EPR) and (B) in the “open” form 
showing the primary hydrophobic binding pocket and the adjacent 
electronegative cleft. (C) Schematic representation of the transition of GDP–K-
Ras from the “closed” form (green) to the “open” form (cyan). 
 
The secondary binding cleft is electronegative in character (Figure 2-3B) 
and contains two acidic residues, Glu-37 and Asp-38. To bind to this region of 
the protein, medicinal chemists in the Fesik lab synthesized amide-linked amino 
acid analogues of the indole-benzimidazole fragment 7 containing positively 
charged amine groups (Figure 2-4A). Improved binding to K-Ras was observed 
for several of these analogues. The best compound in this series contains an 
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isoleucine (12) and binds to K-Ras with an affinity of 190 µM, an improvement of 
roughly 10-fold over the unsubstituted analogue 7. We were able to obtain a 
high-resolution X-ray structure of analogue 13 complexed to GDP-bound K-Ras 
(G12V) (Figure 2-4B). As designed, the indole is located in the primary binding 
pocket, and the positively charged amino group of the amino acid interacts with 
the carboxylic acid side chain of Asp-38 in the secondary binding cleft (Figure 2-
4B).  
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Figure 2-4. Compounds inhibit SOS-catalyzed nucleotide exchange. (A) 
Compound binding affinity with K-Ras-GDP (G12D) and functional activity in a 
SOS-catalyzed nucleotide exchange assay. B) Ribbon and molecular surface 
representations of GDP-bound K-Ras complexed to 13 (PDB code 4EPY). C) 
Effect of compound 12 on SOS-mediated K-Ras activation. Comparison of 
intrinsic (black) and SOS-catalyzed nucleotide exchange in the absence (blue) or 
presence of increasing concentration of compound 12. Exchange assays were 
performed by addition 1 µM K-Ras (G12D) to a mixture containing 1 µM SOS, 1 
µM BODIPY-GTP, and 250 µM (orange), 500 µM (green), or 1 mM (red), 
respectively. D) K-Ras/13 X-ray structure overlaid with a reported H-Ras–SOS 
complex crystal structure (PDB code 1BKD).(29) 
 
To examine the functional consequences of binding to K-Ras, compounds 
were tested for their ability to inhibit SOS-mediated nucleotide exchange. In this 
assay, unlabeled GDP is exchanged for the fluorescently labeled nucleotide 
BODIPY-GTP; this exchange is catalyzed by SOS and results in an increase in 
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fluorescence.(123) The extended analogues with binding affinities below 500 µM 
inhibited the nucleotide exchange process at a concentration of 1 mM (Figure 2-
4A). For example, the analogue containing an isoleucine (12) inhibited nucleotide 
exchange at 78% (Figure 2-4C). The inhibition of SOS-mediated nucleotide 
exchange that we observe can be rationalized from a model that was prepared 
by overlaying the X-ray structure of the K-Ras/13 complex onto a reported 
structure of H-Ras complexed with SOS (Figure 2-4D).(29) The amino acid of 13 
clashes with the αH helix of SOS. The model predicts that SOS would not be 
able to bind to K-Ras when complexed to a small molecule that extends into this 
space (e.g., 8–13). This model is supported by NMR experiments in which the 
1H/15N HSQC spectrum of 15N-labeled K-Ras (G12D) when complexed to 
unlabeled SOS dramatically changed upon the addition of compound 13. This 
new spectrum resembles that of the K-Ras/13 complex without SOS (Figure 2-5). 
Furthermore, in the absence of K-Ras, compound 13 did not bind to SOS, and an 
analogue of 13 with the indole moiety N-methylated did not bind to K-Ras and did 
not inhibit SOS-mediated nucleotide exchange.  
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Figure 2-5. Compounds compete with SOS for binding to K-Ras. 1H-15N 
HSQC spectra of uniformly 15N-labeled GDP-bound K-Ras (G12D) with and 
without SOS and compound 13. A). [U-15N] K-Ras (50 µM). B). [U-15N] K-Ras (50 
µM) / SOS (200 µM). C). [U-15N] K-Ras (50 µM) / SOS (200 µM) / Compound 13 
(4 mM). D). [U-15N] K-Ras (50 µM) / Compound 13 (1 mM). Addition of an excess 
of SOS causes K-Ras resonance peaks to shift, broaden, and disappear when 
compared to K-Ras alone (A vs. B). Addition of compound 13 to the K-Ras/ SOS 
complex causes peaks to reappear (C) which results in a spectrum similar to that 
obtained for the K-Ras/Compound 13 complex (D). 
 
Discussion 
In conclusion, by using a fragment-based screen, we have identified small 
molecules that bind to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 
in the apo-Ras crystal structure. Using structure-based design, we obtained 
analogues of the fragment hits with improved binding affinity as well as functional 
activity in a SOS-catalyzed nucleotide exchange assay. These compounds bind 
to K-Ras and block binding to SOS, thereby causing the inhibition of SOS-
mediated nucleotide exchange. These molecules represent a starting point for 
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obtaining probe molecules that may be useful in elucidating new insights into Ras 
signaling and for discovering K-Ras inhibitors for the treatment of cancer. 
 
Materials and Methods 
Cloning, Expression and Purification 
The gene encoding the GTPase domain (residues 1-169) of oncogenic mutant K-
Ras (G12D) was synthesized with codon optimization for E. coli overexpression. 
A C118S mutation was introduced to increase the stability of the protein during 
the NMR experiments and is present in all of the K-Ras proteins described 
here.(124) The expression construct was designed to include the tobacco etch 
viral protease (TEV) recognition sequence at the 5’ end. This construct was 
inserted into a donor vector (pDONR-221) and transferred by recombinational 
cloning into the pDEST-HisMBP vector for expressing a fusion protein.(125) 
(pDEST-His-MBP and TEV vector provided by Dr. David S. Waugh) The K-Ras 
protein was expressed in Rosetta 2 (DE3) E.coli strain by induction with 1 mM 
IPTG at a cell density corresponding to an absorbance of OD600=1.0. Isotopically-
labeled K-Ras was prepared in M9 minimal media containing 1.0 g/L 15NH4Cl. 
The fusion protein was purified on a Ni-IDA (ProBond from Invitrogen) column. 
TEV protease was added at a 1:20 molar ratio, and the solution was incubated at 
4°C overnight. The reaction mixture was applied to a Ni-NTA column, and the K-
Ras protein was collected in the flow through and exchanged into a low salt 
buffer. Wild-type K-Ras and other K-Ras mutants were expressed and purified in 
similar fashion. The catalytic domain of human SOS (residues 564-1049) was 
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inserted into a donor vector (pDONR-221) and transferred by recombinational 
cloning into the pDEST-544 vector for expressing a His6-tagged fusion protein. 
The SOS protein was expressed in BL21-CodonPlus-RIL E.coli strain by 
induction with 0.2 mM IPTG at a cell density of OD600=1.0. The protein was 
expressed at 18°C overnight and then was purified on a Ni-IDA (ProBond from 
Invitrogen) column. Purified proteins were concentrated with Amicon ultra 
centrifugal columns (Millipore) and flash frozen in liquid N2 and stored at -80°C. 
Fragment-based Screen  
Compound binding was detected using two-dimensional sensitivity-enhanced 
1H/15N- HSQC spectra collected on a Bruker DRX500 spectrometer equipped 
with a cryoprobe and a Bruker Sample Jet sample changer. Each sample 
contained 50 µM GDP-bound K-Ras (G12D) protein and 12 fragments at a 
concentration of 650 µM. Positive hits were deconvoluted by testing samples 
containing the individual ligands. All screening compound plates were generated 
and data tracked using the sample handling capabilities of the Vanderbilt Institute 
of Chemical Biology (VICB) High Throughput Screening (HTS) Core facility. 
Screening data were processed using Bruker TOPSPIN and analyzed by 
comparing spectra with and without compounds. Dissociation constants were 
obtained for selected compounds in fast exchange by monitoring the chemical 
shift changes of resonances as a function of compound concentration using 
standard fitting software. 
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Protein Crystallization 
GDP-bound K-Ras (G12D/C118S, G12V/C118S or C118S) protein was 
exchanged into crystallization buffer (20 mM HEPES, 150 mM NaCl pH 8.0) and 
concentrated to 40 mg/mL. Protein-ligand complexes were prepared by adding a 
concentrated DMSO stock solution of the ligand to a final ligand concentration of 
10-15 mM. All crystallization experiments were set up using the Mosquito 
crystallization robot (TTP Labtech, Royston UK) or performed manually using 
either the sitting or hanging-drop vapor diffusion method at 18 °C. Apo GDP-
bound K-Ras (G12D/C118S) crystallized under a condition containing 30% 
PEG4000, 0.2 M Li2SO4 and 0.1 M sodium phosphate pH 7.5. The K-
Ras(C118S)/2 complex was crystallized from 30% PEG8000, 0.2 M sodium 
acetate and 0.1 M MES pH 6.5. The K-Ras(C118S)/4 complex was crystallized 
from 25% PEG1500, 0.1 M MMT pH 4. The K-Ras(C118S)/5 complex was 
crystallized from 32% PEG1500 and 0.7% 1-butanol. The K-Ras(G12V/C118S)/6 
complex was crystallized from 28% PEG8000, 0.1 M sodium acetate pH 4.5 and 
5% DMSO. Complexes containing compounds 13 crystallized from 28% 
PEG4000, 0.2 M NH4Cl and 0.1 M MMT pH 4. Single crystals were obtained 
after multiple rounds of microseeding. Crystals containing compounds 4, 6 and 
13 were cryo-protected with 10% ethylene glycol for low temperature data 
collection.  
 
X-ray Data Collection, Structure Solution, and Refinement  
X-ray diffraction data were collected at 100K in the oscillation mode on single 
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flash-cooled crystals using a Bruker-NoniusMicrostar rotating anode X-ray 
generator equipped with a Proteum PT 135 CCD area detector. The instrument is 
located in the Biomolecular Crystallography Facility in the Vanderbilt University 
Center for Structural Biology. Data were processed with HKL-2000, and 
structures were determined by molecular replacement using the coordinates of 
H-Ras G-domain (residues 1-166; PDB Entry 1AGP). The program package 
CCP4 and Phenix were employed for phasing and refinement, and model fitting 
was performed with COOT.(126-128) Data collection and restrained refinement 
statistics are summarized in Table 2-1. The refined models were validated with 
PROCHECK and Phenix. 
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Table 2-1. X-ray data collection and refinement statistics. Last resolution 
shell numbers are in parentheses 
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Table 2-1. (Continued) 
 
 
Nucleotide Exchange Assays  
Purified, recombinant GDP-bound K-Ras is added to a mixture of SOS and 
BODIPY-GTP. Bound GDP is exchanged for BODIPY-GTP, resulting in an 
increase in fluorescence with time. The reaction was performed as an 
association-dissociation experiment in which BODIPY-GTP first associates with 
K-Ras followed by a dissociation step in which excess unlabeled GTP 
outcompetes the analog returning fluorescence to baseline. The rate of 
nucleotide exchange was determined by fitting a single exponential decay 
function to the dissociation phase of the experiment. Reactions were performed 
under increasing concentrations of compound in a buffer containing 25 mM Tris 
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(pH 7.5), 50 mM NaCl, 1 mM DTT, and 20 µM MgCl2 with final component 
concentrations of 1 µM, 1 µM, 1 µM, and 200 µM for Ras, SOS, BODIPY-GTP 
and unlabeled GTP, respectively. 
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CHAPTER III 
 
SMALL MOLECULES ACTIVATE SOS-CATALYZED NUCLEOTIDE 
EXCHANGE 
 
Introduction 
The GEF Son of Sevenless (SOS) catalyzes the rate-limiting step in the 
activation of Ras by exchanging GDP for GTP.(129) During nucleotide exchange, 
Ras engages in a protein-protein interaction with SOS to form a complex 
containing one SOS and two Ras molecules (Ras:SOS:Ras).(47) SOS is unique 
among Ras-specific GEFs in having an allosteric Ras binding site that increases 
its catalytic activity(47, 48) and can potentiate the oncogenic effects of mutant K-
Ras through the activation of wild-type H- and N-Ras.(130) Signaling from these 
wild-type isoforms of Ras can support the growth of cancer cells harboring 
oncogenic Ras mutations(131), and inhibiting nucleotide exchange is a possible 
approach to abrogate signaling arising from both mutant and wild-type Ras.(111) 
As a key control point for the activation of multiple Ras isoforms and propagation 
of RTK-Ras signaling, SOS represents a promising point of intervention for Ras-
driven cancers. Here we describe the discovery and characterization of small 
molecules that bind to a functionally relevant, chemically tractable binding pocket 
on the Ras:SOS:Ras complex and disrupt signaling downstream of Ras.  
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Results 
Small Molecules Increase SOScat-Mediated Nucleotide Exchange on Ras 
 In Chapter II, we reported small molecules that bind to Ras and inhibit 
SOScat-catalyzed nucleotide exchange.(132) During these studies, I also 
identified molecules from a related chemical series that have the opposite effect 
and increase the rate of nucleotide exchange in vitro (Figure 3-1). Compound 1, 
a 3-(4-aminopiperidinyl)methyl-indole with an attached glycine, weakly increased 
SOScat-catalyzed nucleotide exchange, as indicated by an increase in the 
exchange of BODIPY-GDP for unlabeled GTP. To improve the activity of these 
molecules, we synthesized additional compounds based on the aminopiperidine 
indole core. The addition of a tryptophan resulted in compound 2, which activated 
nucleotide exchange in a concentration-dependent manner (Figure 3-1B, 3-1E) 
and was more potent than 1 (Table 3-1). The addition of a methyl or halide group 
to the 5-position of the indole (compounds 3 and 4) produced a further increase 
in nucleotide exchange activation and lower EC50 values (Table 3-1). Compound 
4 increased SOScat-catalyzed nucleotide exchange with an EC50 of 14 µM (Figure 
3-1C, 3-E). Replacement of the methylene linker between the indole and 
piperidine ring with a carbonyl resulted in a complete loss of activity (compound 
5; Figure 3-1D - 3-E). Unlike our previously reported inhibitors of nucleotide 
exchange (132), the structure-activity relationship of this series did not correlate 
with direct binding to Ras (Table 3-1). It was therefore important to understand 
how these molecules function at the molecular level.   
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Figure 3-1. Aminopiperidine indole compounds increase SOScat-catalyzed 
nucleotide exchange on Ras. (A) Chemical structures of compounds 1-5. 
SOScat-catalyzed nucleotide exchange assays conducted with increasing 
concentrations of 2 (B), 4 (C), and 5 (D). Compound was added (at 10 seconds) 
to BODIPY-GDP-loaded Ras followed by a second addition of excess GTP ± 
GEF (at 120 seconds). Kinetics of nucleotide exchange were monitored as a 
decrease in fluorescence with time. Ras alone (blue) and Ras + SOScat (red) 
DMSO-matched controls are shown. Compound was added in a 10-point, 2-fold 
dilution series with a top concentration of 100 µM (black curves). Experiments 
shown in (B-D) were conducted in triplicate; mean rate was calculated and is 
plotted (± SD) for each compound as a function of concentration (E). 
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Table 3-1. Structure-activity relationship for compounds 1-5. 
Compound 
 
Nucleotide 
Exchange EC50 
(µM) 
Relative 
Percent 
Activation* 
NMR KD 
(µM) to                 
K-
RasG12D 
FITC-4 
Competition 
Experiment 
IC50**  
1  >100 19.4 322 >100 
2  >100 48 279 >100 
3  25.1 91.8 868 20 
4  14 100 1346 43 
5  >100 -5.4 1283 >100 
*Calculated at 100 µM concentration for each compound. 
**Conducted using 10 µM SOScat and 300 nM FITC-4.  
 
Compounds Activate Nucleotide Exchange in a SOS-Dependent Manner 
that Does Not Involve Ras Binding to the Allosteric Site of SOS 
To determine how the compounds activate nucleotide exchange, we 
examined previously reported GEF-independent and GEF-dependent 
mechanisms. No increase in intrinsic nucleotide exchange on Ras was observed 
upon the addition of up to 400 µM of compound 4 (Figure 3-2A), indicating that 
chelation of magnesium or destabilization of bound nucleotide is not responsible 
for the activity. (133, 134) Comparison of the exchange rates between intrinsic 
and SOScat-catalyzed exchange revealed that compound 4 activates nucleotide 
exchange in a SOS-dependent manner (Figure 3-2B). 
Crystal structures and biochemical experiments have identified an 
allosteric Ras binding site on SOS that increases its catalytic activity.(47, 48) 
Indeed, titration of RasY64A, a mutant form of Ras that binds to the allosteric site 
of SOS but does not undergo nucleotide exchange (15), resulted in a 
concentration-dependent increase in the rate of SOScat-catalyzed nucleotide 
exchange. GTP-bound RasY64A was more effective than GDP-bound RasY64A at 
stimulating nucleotide exchange (EC50 = 0.74 µM), consistent with its role as the 
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preferred binding partner for the allosteric site of SOS (Figure 3-2C - 3-D).(35) 
Under the same conditions, addition of 100 µM of compound 4 produced an 
intermediate rate of nucleotide exchange, suggesting that the compound effect 
on nucleotide exchange is physiologically relevant when compared to the 
activation resulting from Ras binding at the allosteric site (Figure 3-2E).   
 
 
 
Figure 3-2. Nucleotide exchange activation by aminopiperidine-indole 
compounds is SOS-dependent and does not require the allosteric Ras-
binding site. (A) Intrinsic nucleotide exchange in the presence of compound 4 
(10-point, 2-fold dilution, 400 µM top concentration). Intrinisic and SOScat-
catalyzed controls are shown in blue and red, respectively. (B) SOScat-catalyzed 
and intrinsic nucleotide exchange displayed as a function of compound 
concentration (n=3, ± SD). Nucleotide exchange with RasY64A loaded with GDP 
or GTP is shown in (C) and (D), respectively (10-point, 2-fold dilution, 16 µM top 
concentration). (E) Quantification of SOScat-catalyzed nucleotide exchange with 
the indicated activator present (n=3, ± SD). (F) Nucleotide exchange, in the 
presence or absence of 100 µM compound 4, catalyzed by SOScatW729E, 
SOScatL687E/R688A, or SOSDH-PH-cat. (G) SOScat-catalyzed nucleotide exchange rates 
displayed as a function GTP-loaded RasY64A concentration in the presence or 
absence of 100 µM compound 4. 
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To test whether binding of Ras to the allosteric site on SOS is required for 
the compound-mediated increase in nucleotide exchange, we used two 
previously reported mutants, SOScat-W729E and SOScat-L687E/R688A, as well as the 
longer SOSDH-PH-cat construct to prevent Ras binding to the allosteric site.(35) 
Consistent with reported data, SOScat-W729E, SOScat-L687E/R688A, and SOSDH-PH-cat 
had slightly slower basal nucleotide exchange rates than wild-type SOScat (Figure 
3-3). Addition of 100 µM of compound 4 to either SOScat-W729E or SOScat-
L687E/R688A, resulted in activation of nucleotide exchange, suggesting compound-
mediated activation does not require Ras binding to the allosteric site (Figure 3-
2F and 3-3). Nucleotide exchange reactions catalyzed by the longer construct of 
SOS containing both the autoinhibitory Dbl homology-pleckstrin homology (DH-
PH) and catalytic domains, SOSDH-PH-cat, revealed that compound 4 is also 
capable of activating nucleotide exchange catalyzed by autoinhibited SOS 
(Figure 3-2F and 3-3). Probing allosteric Ras binding and compound in 
combination revealed that compound 4 can further activate SOS-catalyzed 
nucleotide exchange, even in the presence of saturating levels of GTP-bound 
RasY64A (Figure 3-2G). These data strongly support the hypothesis that these 
compounds activate nucleotide exchange through a distinct mechanism, which 
can be elicited regardless of the presence or absence of Ras bound at the 
allosteric site. 
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Figure3-3. Aminopiperidine indole compounds activate SOScat independent 
of the allosteric Ras binding site. (A) Direct comparison of nucleotide 
exchange assays catalyzed by wild-type SOScat, SOScat-W729E, SOScat-L687E/R688A, 
and SOSDH-PH-cat. Activation of SOScat-catalyzed, SOScat-W729E-catalyzed, SOScat-
L687E/R688A-catalyzed, and SOSDH-PH-cat-catalyzed nucleotide exchange in the 
presence or absence of compound 4 (B-E, respectively). Ras alone and Ras + 
compound 4 controls are included for comparison purposes.   
 
Addition of 100 µM of compound 2 to nucleotide exchange reactions 
catalyzed by murine Ras-GRF1, an alternate RasGEF, resulted in no activation, 
suggesting that these compounds maintain a degree of specificity for SOS 
(Figure 3-4A). This finding is consistent with a sequence alignment of the CDC25 
domains of SOS1 and Ras-GRF1, which have a 30% overall identity (Figure 3-
4B).  
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Figure3-4. Compounds do not activate Ras-GRF1. (A) Nucleotide exchange 
catalyzed by 0.1 µM Ras-GRF in the presence of the indicated activator (n=3, ± 
SD). (B) Sequence alignment of the CDC25 domain of SOS1 and Ras-GRF1. 
Residues highlighted in blue show identity between the two proteins. Residues in 
green show identity within the API binding pocket, while residues highlighted in 
yellow represent substitutions within the pocket. Secondary structure 
representations are shown below the sequence as red α-helices and green β-
sheets.   
 
While not an activator, Brefeldin A inhibits GEF-catalyzed nucleotide 
exchange by acting as an interfacial inhibitor of a GEF:GTPase interaction.(135) 
Under our conditions, the decrease in fluorescence observed upon nucleotide 
release from Ras would not preclude the formation of a dead end Ras:SOS 
complex. To examine this possibility, we tested the ability of compound 4 to 
activate nucleotide exchange using a range of Ras (50 nM to 8 µM) and SOScat 
(25 nM to 3.5 µM) concentrations. A similar activation was observed at high 
Ras:SOS ratios, which would require multiple catalytic turnovers (Figure 3-5A – 
3-5B). EC50 values remained consistent irrespective of Ras or SOScat 
concentrations (Figure 3-5C - 3-5D). Compound 4 also activated nucleotide 
exchange using unlabeled Ras followed by the addition of a mixture of SOScat 
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and BODIPY-GTP (Figure 3-5E). GDP release, intermediate complex formation, 
and BODIPY-GTP association must occur to observe an increase in 
fluorescence.(21) Activation of nucleotide exchange under these conditions 
supports the conclusion that these compounds activate the full process of 
nucleotide exchange, unlike interfacial GEF:GTPase inhibitors.  
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Figure 3-5. Activation of SOS-catalyzed nucleotide exchange is 
independent of assay conditions. Compound 4 activates nucleotide exchange 
irrespective of Ras or SOScat concentrations. Raw nucleotide exchange curves 
conducted in the presence of varying concentrations of BODIPY-GDP loaded 
Ras (7.15-0.05 µM), 1 µM SOScat, and varying concentrations of compound 4 
(10-point, 2-fold dilution, 200 µM top concentration) are shown in (A). The same 
data is presented using a log scale on the Y-axis for improved visualization (B). 
Nucleotide exchange rates from (A) were plotted as a function of compound 4 
concentration for each concentration of BODIPY-GDP loaded Ras (C) (0.05 µM 
Ras data excluded).  Nucleotide exchange was conducted in the presence of 
varying concentrations of SOScat (3.5-0.05 µM) and varying concentrations of 
compound 4 (10-point, 2-fold dilution, 200 µM top concentration). Rates from this 
experiment were plotted as a function of compound 4 concentration for each 
concentration of SOScat (D). Nucleotide exchange was conducted using Ras 
loaded with unlabeled GDP at time 0, adding compound 4 (10-point, 2-fold 
dilution, 200uM top concentration) at 10 seconds, and a mixture containing 
SOScat and BODIPY-GTP at 120 seconds (E). Under these conditions, nucleotide 
exchange is monitored as an increase in fluorescence with time. Intrinsic 
exchange and SOScat-catalyzed exchange controls are shown in blue and red, 
respectively.   
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Compounds that Activate Nucleotide Exchange Bind to a Pocket Identified 
in the Ras:SOS:Ras Complex  
 We obtained X-ray structures of multiple compounds bound to the H-
Ras:SOScat:H-RasY64A(GppNHp) ternary complex (Ras:SOS:Ras)(Figure 3-6). 
The ligand-bound Ras:SOS:Ras complex structures were obtained using both 
soaking and co-crystallization methods, under multiple conditions, and in different 
crystal packing lattices. The H-Ras isoform was found to crystallize more readily 
in this complex than K-Ras. K-Ras and H-Ras have no residue changes within 
close proximity to the binding pocket, suggesting that the compounds are not 
likely to be specific for activating one isoform of Ras over another. 
 The crystal structures revealed that the compounds bind to the 
Ras:SOS:Ras complex in a hydrophobic pocket that is formed by the CDC25 
domain of SOS adjacent to the Switch II (SwII) region of Ras (Figure 3-6A - 3-
6B). The pocket is formed principally by the αE and αF helices of the SOS 
catalytic domain, which are connected by an exposed helical turn involving 
P894.(29) The remainder of the pocket is formed by residues from the coiled 
region and helical turn connecting the αD and αE helices of SOS. Some of the 
residues of SOS that form the pocket (e.g., N879, Y884, and H905) have 
previously been reported to directly interact with Ras.(29) Notably, R73, located 
in the SwII region of Ras at the catalytic site of SOS, forms a stacking interaction 
with Y884 and interacts with the backbone carbonyl of N879 (Figure 3-6B). 
Importantly, N879 and Y884 form the anterior wall of the binding pocket (Figure 
3B) and provide a direct link from the compound to the SwII region of Ras, which 
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is critical for binding to the catalytic domain of SOS.(136) 
 
 
 
Figure 3-6. Aminopiperidine indole compounds bind to the Ras:SOS:Ras 
ternary complex. (A) X-ray cocrystal structure of compound 2 bound to the H-
Ras:SOScat:H-RasY64A(GppNHp) ternary complex. SOScat(orange) is bound by 
RasY64A-GppNHp (gray, switch regions blue) at the allosteric site and nucleotide-
free Ras (gray, switch regions red) at the catalytic site. (B) The hydrophobic 
pocket is formed by the CDC25 domain of SOS adjacent to the SwII region of 
Ras. Important residues forming the pocket are labeled. (C-E) Surface depictions 
with aminopiperidine indole compounds 1, 2, and 3. 
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 The structure-activity relationships of aminopiperidine indole-based 
compounds can be rationalized from the X-ray cocrystal structures. All 
compounds bind in a similar fashion, with the core indole occupying the most 
hydrophobic portion of the pocket (Figure 3-6C - 3-6E). The NH of the core indole 
forms a hydrogen bond at the bottom of the pocket with the backbone carbonyl of 
M878, while the aminopiperidine moiety is surface exposed and rotated toward 
D887. For compound 1, the terminal amine is oriented towards the solvent 
(Figure 3-6C). The tryptophan moiety of compound 2 folds back and occupies a 
hydrophobic pocket located at the helical turn formed by P894 (Figure 3-6D). 
Compound 1, which lacks this tryptophan moiety, cannot access this pocket 
(arrow in Figure 3-6C).  
 The increased activity of compound 2 could be due to the additional 
interactions made by the tryptophan moiety. Methyl substitution at the 5-position 
of the core indole (compound 3) further improved compound activity (Table 3-1). 
The methyl group points towards a space unoccupied by the unsubstituted indole 
of compound 2 (Figure 3-6D arrow, Figure 3-6E). Compound 4, the most active 
compound (Table 3-1), was unable to be crystallized due to limited compound 
solubility. However, it is hypothesized to bind similar to compound 3 with the 
chloro-substitution occupying the same space as the methyl group of 3. Based 
on the crystal structures, fluorescein isothiocyanate (FITC) conjugated 
derivatives of compounds 2 and 4 were designed. Saturation binding and 
competition experiments conducted with these probes indicate that improved 
compounds bind SOS with a higher affinity (Figure 3-7A – 3-7B, and Table 3-1). 
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This crystallographic and biochemical data suggests that the activity of the 
compounds is determined by their ability to optimally fill the pocket. 
 
Figure3-7. Direct binding of nucleotide exchange activators to SOS. 
Saturation and competition binding experiments conducted using FITC-
conjugated compounds. (A) Chemical structures of compounds FITC-2 and 
FITC-4. (B) Saturation binding experiments conducted by titration of increasing 
amounts of SOScat to a well containing FITC-conjugated compound 2 or 4 (300 
nM final concentration; n=3, ±SD). (C) Increasing concentrations of unlabeled 
compounds 1-5 were used to outcompete SOScat (10 µM) binding to FITC-
conjugated compound 4 (300 nM; n=3, ±SD). 
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Amino Acid Substitution of Residues Within the Pocket Prevents 
Compound-Induced Activation of Nucleotide Exchange  
Residues in this pocket have been previously identified as being mutated 
in developmental RASopathy disorders. Two mutations in the CDC25 domain of 
SOS, E846K and P894R, cause Noonan Syndrome.(137) E846K profoundly 
perturbs intracellular signaling and P894R slightly activates nucleotide exchange 
on Ras, compared to wild-type SOS.(138, 139) Of particular note, P894 forms 
the helical turn that defines the pocket occupied by the tryptophan moiety of 
compounds 2 and 3 (Figure 3-6B), further supporting the hypothesis that the 
binding pocket occupied by the compounds in the cocrystal structures is 
important for the activation of Ras by SOS. 
We used the crystal structures to design mutations that would be 
predicted to perturb compound binding. Nine mutants of SOScat (D887A, D887E, 
D887H, D887N, D887V, F890L, L901M, L901K, and H905M) were cloned, 
expressed, and purified. Mutations of F890, L901, and H905 were designed to 
reduce the space available at the bottom of the hydrophobic pocket; whereas, 
mutations of D887 were used to determine the importance of this residue for 
binding (Figure 3-6B). Nucleotide exchange rates were determined for each 
mutant form of SOScat from experiments conducted in the presence of DMSO or 
100µM of compound 2 (Figure 3-8, Figure 3-9B). All mutant forms of SOScat 
catalyzed nucleotide exchange, confirming the proper folding and function of the 
mutant proteins (Figure 3-8). Mutation of F890, L901, and H905 prevented 
compound-induced activation of nucleotide exchange, suggesting that compound 
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activity is mediated predominantly by hydrophobic interactions in the pocket 
(Figure 3-9A – 3-9C). In contrast, mutation of D887 did not prevent the ability of 
compound 2 to activate nucleotide exchange (Figure 3-9B – 3-9C). These data 
strongly support the conclusion that this binding pocket is functionally important 
for the activation of Ras by SOS and is responsible for the compound-mediated 
activation of SOScat-catalyzed nucleotide exchange.  
 
Figure3-8.  SOScat mutants block compound-induced activation of 
nucleotide exchange. Raw curves from nucleotide exchange experiments, 
catalyzed by the indicated exchange factor, in the presence or absence of 100 
µM compound 2 (n=3). Final reactions contain 1 µM BODIPY-GDP loaded Ras, 1 
µM exchange factor, and 200 µM unlabeled GTP.  
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Figure 3-9. Mutation of the aminopiperidine indole binding site prevents 
activation of nucleotide exchange. (A) Nucleotide exchange was conducted 
with each mutant form of SOScat, in the presence of DMSO or 100 µM compound 
2, as shown for SOScat-L901K. (B) Nucleotide exchange rates, in the presence of 
DMSO or 100 µM compound 2 (n=3, ± SD). (C) Percent increase in nucleotide 
exchange rate following addition of compound to each mutant. 
 
Nucleotide Exchange Activators Increase Ras-GTP and Perturb Ras 
Signaling in Cells  
HeLa cells treated with FITC-conjugated compound 4 (FITC-4), and 
subsequently washed with PBS, showed a strong intracellular fluorescence 
signal, confirming that these compounds are suitable for use in cell-based 
experiments (Figure 3-11A). HeLa cells were treated for 15 minutes with DMSO, 
the inactive compound 5, or the active compounds 2 and 4 to assess the ability 
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of these compounds to activate endogenous Ras. Ras-GTP levels were 
determined using a Ras-binding domain (RBD) pulldown assay. No increase in 
Ras-GTP levels was observed in cells treated with the inactive compound 5. In 
contrast, treatment with compound 4 resulted in a 3-fold increase in Ras-GTP 
levels (Figure 3-10A), while compound 2 resulted in a smaller increase, 
consistent with their relative in vitro nucleotide exchange activity (Table 3-1). 
Treatment of HeLa cells with 100 µM of compound 4 led to elevated Ras-GTP 
levels within 5 minutes that remained elevated for the entirety of a 30-minute 
timecourse (Figure 3-10B). These experiments demonstrate that the compounds 
activate nucleotide exchange in the cellular setting containing full-length, 
endogenous SOS and Ras proteins.  
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Figure 3-10. Aminopiperidine indole compounds perturb Ras signaling by 
acting at the level of the Ras-SOS interaction. (A) Endogenous Ras-GTP 
levels from HeLa cells treated for 15 minutes with DMSO or 100 µM of compound 
5, 2, or 4. (B) Endogenous Ras-GTP levels from HeLa cells treated with 100 µM 
of compound 4 for 0-30 minutes. (C) HeLa cells treated for 30 minutes with 
compounds 2-5, and analyzed by western blot. EGF (50 ng/mL, 10 min) was 
used as a positive control. (D) Lysates from CHL-1, SK-MEL-2, and MALME-3M 
cells treated for 30 minutes with compound 4 or dabrafenib were analyzed by 
western blot. (E) HeLa cells were serum starved overnight, preteated for 5 min 
with DMSO or 100µM compound 4, and stimulated with EGF (50ng/mL) for 0-15 
minutes. Half-maximal inhibitory concentrations for cell proliferation (F) and 
anchorage independent growth (G) following treatment with compound 4 or 5.  
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Figure3-11. Compounds are cell permeable and inhibit cell proliferation and 
anchorage independent growth. (A) HeLa cells were treated for 30 minutes 
with FITC-4, washed 3 times with ice cold PBS, fixed, mounted, and imaged on a 
confocal microscope to assess cell permeability. (B) Compounds 4 and 5 were 
tested for their ability to alter cell proliferation (closed circles) after 3 days or 
anchorage independent growth (open circles) in soft agar after 7 days. Data were 
normalized to DMSO control (n=3, ±SD). Corresponding IC50 values are 
presented in Figure 3-10F – 3-10G.   
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 We determined the effect of compounds 2-5 on Ras-mediated signaling in 
the MAPK and PI3K pathways. Treatment with compounds 2-4 causes a biphasic 
response in the MAPK pathway that is characterized by inhibition of ERK 
phosphorylation at high compound concentration, followed by a peak of 
increased ERK phosphorylation as compound concentration decreases (Figure 
3-10C). This signaling pattern is most evident with compounds 3 and 4. Due to 
the decreased potency of compound 2, only the increased ERK phosphorylation 
is visible in this concentration range. Compounds 2-4 also inhibit PI3K pathway 
signaling, as evidenced by a decrease in AKT phosphorylation. Importantly, the 
peak in ERK phosphorylation correlates with the IC50 for inhibition of 
phosphorylation of AKT (Figure 3-10C), suggesting that the two are regulated by 
the same underlying mechanism. As expected, the inactive compound 5 had no 
effect on ERK or AKT phosphorylation.  
 The biphasic response in ERK phosphorylation closely resembles the 
signaling induced by inhibitors of the B-Raf kinase in cells containing wild-type 
Raf.(104) To investigate this paradoxical activation mechanism, we examined 
compound effects on Ras signaling in melanoma lines harboring well-
characterized mutations in the Ras pathway. In the context of wild-type Ras 
(CHL-1) or N-RasQ61L (SK-MEL-2) the B-Raf inhibitor dabrafenib and compound 
4 elicited a biphasic response in both MEK and ERK phosphorylation (Figure 
5D). In MALME-3M cancer cells, which harbor a B-RafV600E mutation, dabrafenib 
was able to potently inhibit MEK and ERK phosphorylation, as expected (Figure 
3-10D). Compound 4, however, had no effect on MEK or ERK phosphorylation, 
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suggesting that this compound acts by a unique mechanism of action at the level 
of the Ras-SOS interaction, upstream of Raf kinase.  
 To further test the hypothesis that these compounds act at the level of the 
Ras-SOS interaction, serum-starved HeLa cells were pretreated with DMSO or 
100µM compound 4, then stimulated with EGF. Compound 4 prevented EGF-
induced activation of MEK and ERK, but had no effect on the activation of EGFR 
upstream of Ras, as shown by an increase in tyrosine 1068 phosphorylation 
(Figure 3-10E). These data support the conclusion that the compounds act at the 
level of the Ras-SOS interaction, downstream of EGFR and upstream of Raf, and 
establish a means to study acute Ras-mediated signaling using an approach that 
is distinct from other small molecules targeting this pathway.   
 Compounds 4 and 5 were assessed for their ability to affect cell growth 
and transformation. Consistent with the signaling observed in these cell lines, 
both wild-type (HeLa and CHL-1) and mutant Ras (SK-MEL-2 and PANC-1) 
harboring cancer cells showed a decrease in cell proliferation and anchorage 
independent growth following treatment with compound 4 (Figure 3-10F – 3-10G 
and 3-11B – 3-11F). In contrast, inactive compound 5 had little or no effect at 
concentrations up to 100 µM. This evidence suggests that compound binding to 
the Ras:SOS:Ras complex does not enhance cell growth, but may instead 
represent a mechanism to inhibit cell proliferation and transformation. 
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Discussion 
 We have discovered small molecules that increase the rate of SOS-
catalyzed nucleotide exchange in a GEF-dependent manner that does not 
involve chelation of magnesium or destabilization of bound nucleotide. 
Compounds activate nucleotide exchange regardless of mutation or Ras 
occupancy at the allosteric site on SOS, suggesting that activation occurs 
through a distinct mechanism. Consistent with this hypothesis, the compounds 
bind to a hydrophobic pocket on the CDC25 domain of SOS, adjacent to the SwII 
region of Ras at the catalytic site of SOS. Importantly, mutations, both naturally-
occurring and designed, support the conclusion that this pocket is functionally 
important for regulating the activation of Ras by SOS.  
The structure of the Ras:SOS:Ras cocomplexed with compound 3 was 
superimposed on the known structures of the CDC25 domain core of SOS1 
(aa780-1049, excluding the helical hairpin aa929-976) (RSCB Protein Data Bank, 
PDB: 1BKD, 1NVU, 1NVV, 1NVW, 1NVX, 1XD2, 1XD4, 2II0, 3KSY). The 
structure of the ligand-bound CDC25 domain closely resembles that of the 
CDC25 domain in the ligand-free structures (rmsd of 0.24 ± 0.08 Å in the Cα 
positions). The pocket is available for compound binding in 77% of the known 
structures. Two structures contain the side chain of H905 occupying the indole 
binding pocket (PDB: 1XD4, 3KSY). While the evidence presented here suggests 
that the pocket is available when SOS is in either the active or autoinhibited 
state, how ligand binding is affected by membrane localization of SOS (which 
has been shown to be important for the activation of Ras) remains to be 
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determined.(140)  
Residues forming this pocket in SOS1 have a 30% identity with the Ras-
specific GEF Ras-GRF1. No activation of Ras-GRF1-catalyzed nucleotide 
exchange was observed upon compound addition. While this result suggests that 
these compounds maintain a degree of specificity for SOS1 over Ras-GRF1, 
sequence and structural alignments of the CDC25 domain of SOS1 with other 
GEF proteins suggest that a similar pocket may exist in other GEFs. Targeting 
this conserved pocket may represent a unique approach to alter the function of 
these closely related proteins.  
Based on our in vitro biochemical studies, we hypothesized that treatment 
of cells with these nucleotide exchange activators would result in an increase in 
downstream signaling of the MAPK and PI3K pathways. Indeed, Ras-GTP levels 
increase following treatment of HeLa cells with the compounds, consistent with 
the increase in nucleotide exchange activity. However, we did not expect the 
observed biphasic response in MAPK signaling nor the inhibition of PI3K 
signaling downstream of Ras.  
A similar pattern of biphasic MAPK signaling has been observed in other 
instances. Notably, B-Raf inhibitors induce a paradoxical activation of MAPK 
signaling in cells with wild-type B-Raf, and this is intensified by the presence of a 
mutant Ras.(104) In this same setting, compound 4 elicited signaling similar to 
Raf inhibitor-induced paradoxical activation. However, in contrast to dabrafenib, 
no effect was seen following treatment with compound 4 in MALME-3M cancer 
cells, which harbor a V600E mutation in B-Raf. This suggests that the common 
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biphasic signaling pattern elicited by these two compound classes is brought 
about through distinct mechanisms. Raf dimerization underlies the paradoxical 
activation in the case of B-Raf inhibitors, and, while Ras has been implicated in 
this, the biochemical and structural role of Ras in this process remains to be 
elucidated.(101, 141) Based on the importance of Ras in Raf inhibitor-induced 
paradoxical activation and the data presented here, it is tempting to hypothesize 
that the signaling observed following treatment with compound 4 is regulated at 
the level of the Ras-Raf interaction. Further investigation of how these 
compounds alter other interactions, such as the Ras-Raf interaction, how they 
affect Ras and SOS localization, and how they influence negative feedback loops 
governing signal output will be required to fully understand their effects.   
X-ray crystallographic studies provided a detailed understanding of how 
these compounds bind and can be used to rationalize the structure-activity 
relationships. The observation of additional binding pockets not exploited by the 
current compounds lead us to believe that further improvements in activity will be 
obtained by the design and synthesis of new analogues. In addition, the close 
proximity of the compound binding site to the SwII region of Ras suggests that it 
may be used as a starting point for the design of interfacial inhibitors. An 
example of an interfacial GTPase:GEF inhibitor is provided by Brefeldin A, which 
targets the Arf1-Sec7 domain complex.(135) Analogous interfacial inhibitors, 
anchored in this newly identified pocket on SOS, could render Ras incapable of 
engaging effector proteins by forming a dead end GEF:GTPase complex.  
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Despite being considered one of the most validated targets in cancer, the 
inhibition of oncogenic Ras remains a significant challenge. The scientific 
community has sought unique, functionally active small-molecules to provide a 
path forward for the discovery of Ras-targeted therapeutics(142), and recent 
work has aimed at validating new strategies to achieve this goal.(113) The 
identification and characterization of a functionally important small molecule 
binding site on the Ras:SOS:Ras complex provides another innovative approach 
to target Ras signaling. Further elucidation of how this pocket regulates Ras 
activity and investigation of this approach as a way to inhibit Ras function in cells 
may enable the discovery of new therapeutics for the treatment of Ras-driven 
tumors. 
  
Materials and Methods 
Protein Purification 
For nucleotide exchange assays, recombinantly expressed K-RasG12D 
(referred to as Ras, aa 1-169) and human SOS1 (SOScat, aa 564-1049, and 
SOSDHPHcat, aa 197-1049) were purified as described previously.(132) Synthetic 
gene of K-RasG12D/C118S was cloned into a pDEST-HisMBP vector (pDEST-
HisMBP and TEV protease were a gift from Dr. David Waugh, NCI). The plasmid 
was transformed into the Rosetta 2 (DE3) E.coli strain, expressed, and the His-
tagged protein was purified on a Ni-IDA (ProBond, Invitrogen) column. TEV 
protease was added at a 1:20 molar ratio, and the solution was incubated at 4°C 
until cleavage was complete. The reaction mixture was applied to a Ni-NTA 
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column, and the Ras protein was collected in the flow-through. H-Ras was 
expressed and purified in similar fashion. Full-length human SOS1 in a Gateway 
Entry Vector was purchased from Thermo Scientific Open Biosystems. SOScat 
and SOSDHPHcat were amplified by PCR and cloned with a 5' TEV cleavage site 
and a 3' stop codon into Gateway Entry Vector pDONR-221. SOScat was 
transferred into Gateway expression vector pDEST-17 carrying an N-terminal 
His6 tag for purification, and expressed in BL21-RIL E.coli at 18°C for 7 hours 
followed by purification on a Ni-IDA column. SOScat mutants were generated 
using a QuickChange method (Agilent) and purified similar to SOScat. Synthetic 
murine RasGRF1 gene was purchased from GenScript with codon optimization 
for BL21 bacterial strain and subcloned into pDEST-17 as before. 
For X-ray crystallographic studies, Ras and SOScat were first cloned and 
expressed as described above. Ras was further purified using an additional 
Superdex 75 column. For SOScat, the terminal His6 tag was cleaved, the mixture 
was applied to a Ni-NTA column, and SOScat protein was collected in the flow 
through. Concentrated SOScat was then applied to a HiTrap Q column (5 mL). H-
RasY64AGppNHp was prepared by first incubating concentrated protein with 
10mM EDTA for 30min at 37°C. EDTA was removed by buffer exchange, 2.5mM 
GppNHp was added with apyrase (5µL/mL)(Sigma), and the mixture was 
incubated at 37°C for 2 hours. 5 mM MgCl2 and an additional 2 mM GppNHp was 
added, and the H-RasY64A(GppNHp) was purified using a Superdex 75 column. 
The H-RasWT:SOScat:H-Ras(GppNHp) complex was prepared as 
described previously.(47) H-RasWT and SOScat were dialyzed into a buffer 
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containing 25mM Tris-HCl (pH 7.5), 50mM NaCl, and 2mM DTT. The SOScat:Ras 
binary complex was prepared by adding 4-fold excess of H-RasWT to SOScat in 
the presence of EDTA. The mixture was incubated overnight at 4°C, and the 
SOScat:Ras binary complex was purified using a Superdex 200 column. The 
binary complex was concentrated, a 4-fold excess of H-RasY64AGppNHp was 
added, and the mixture was incubated at 4°C for 2 hours.  The H-
RasWT:SOScat:H-RasY64A(GppHNp) was then purified using a Superdex 200 
column.   
 
Protein Crystallization 
H-RasWT:SOScat:H-RasY64A:GppNHp was exchanged into a buffer 
containing 25 mM Tris, 50 mM NaCl, 2 mM DTT, pH 7.5 and concentrated to 25 
mg/mL. Protein-ligand complexes were prepared by adding a concentrated 
DMSO stock solution of the ligand to a final concentration of 2-5 mM. All 
crystallization experiments were set up using the Mosquito crystallization robot 
(TTP Labtech, Royston UK) or performed manually using hanging-drop vapor 
diffusion method at 4 °C. The apo ternary complex crystallized from 0.1 M 
sodium acetate, 1.8 M sodium formate, pH 4.5. Crystals appeared within a week. 
To obtain cocrystal structures of ternary complex with compound 2, apo crystals 
were transferred into a reservoir solution containing 20 mM compound 2 and 
soaked overnight. The ternary complexes containing compounds 1 and 3 
crystallized under conditions containing 0.1 M sodium acetate, 2.0 M sodium 
formate, pH 4.0.  
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X-ray Data Collection, Structure Solution, and Refinement 
X-ray diffraction data were collected using synchrotron radiation (APS, 
Argonne, beamline 21 LS-CAT). Data were processed with HKL-2000 (143), and 
structures were determined by molecular replacement using the coordinates of 
H-RasWT:SOScat:H-RasY64A:GppNHp (PDB Entry 1NVV, 1NVX). The program 
packages CCP4 (144) and Phenix (145) were employed for phasing and 
refinement, and model fitting was performed with COOT (146). The refined 
models were validated with MolProbity program implemented in Phenix. 
 
Nucleotide Exchange Assays 
Nucleotide exchange assays were conducted using BODIPY-GDP (Life 
Technologies; excitation: 485, emission: 510) loaded Ras in a buffer containing 
25 mM Tris (pH 7.5), 50 mM NaCl, and 1 mM MgCl2. Baseline fluorescence was 
recorded for 10 seconds followed by addition of compound, or RasY64A, when 
specified. A second addition of excess GTP ± SOScat was performed at 120 
seconds. Nucleotide exchange was monitored as a decrease in fluorescence 
with time. Final reactions contained 1 µM BODIPY-GDP loaded Ras, 200 µM 
unlabeled GTP, and 0.5 µM SOScat (Figure 3-1, 3-2 and Table 3-1) or 1 µM 
SOScat (Figure 3-8 and 3-9). Alternative GEFs and compounds were used as 
indicated.  
Changes in fluorescence were monitored using a Hamamatsu FDSS 6000 
with readings conducted every 3 seconds for 30 minutes. Assays were 
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conducted using 40 µL final volume in a 384-well clear bottom, black Aurora 
microplate. Raw fluorescence data was fit to a single exponential decay function 
using XLfit (IDBS) software. Derived rates were plotted as mean ± SD. EC50 
values were calculated by plotting derived rates as a function of compound 
concentration and fit using a four-parameter dose-response curve (XLfit). 
Relative nucleotide exchange activation in Table 3-1 was calculated as the 
percent activation for each compound at 100µM, normalized between exchange 
rates calculated for DMSO or saturating amounts of compound 4, which served 
as an internal control. All raw nucleotide exchange traces presented were 
normalized to the mean fluorescence per well prior to the addition of compound 
and graphed using Prism 5 (Graph Pad Software Inc.). Rates were derived from 
raw fluorescence data.   
 
Fluorescence Anisotropy Binding Assays 
 Fluorescence anisotropy assays were performed in a black 384-well, flat 
bottom plate (Greiner Bio-One) using an EnVision plate reader (PerkinElmer) as 
described previously.(147, 148) For saturation binding experiments, FITC-
conjugated compound 2 or 4 was incubated with increasing amounts of SOScat in 
a buffer containing 50 mM NaCl, 25 mM Tris (pH 7.5), and 1 mM MgCl2. Final 
wells contained 25 µL volume with 300 nM FITC-conjugated compound present.  
Reactions were incubated for 20 minutes, and anisotropy measurements were 
taken using an excitation wavelength of 480 nm and an emission wavelength of 
535 nm. Data was analyzed using Prism 5 (Graph Pad Software Inc.). Curves 
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were fit and dissociation constants were determined using a single-site binding 
model (One site- Total binding).  
For competition experiments, serial dilutions of 1-5 were added to a well 
containing 10 µM SOScat and 300 nM FITC-4 (final concentrations), and 
incubated for 20 minutes before measurement on the EnVision. Data was 
analyzed by plotting fluorescence anisotropy values as a function of compound 
concentration. IC50 values were determined using a four-parameter dose-
response (variable slope) equation in Prism 5 (Graph Pad Software Inc.). 
 
NMR 
Compound binding was detected by 1H | 15N SO-FAST HMQC 
spectra.(149) Each sample contained 50 µM K-Ras protein, and dissociation 
constants were obtained by monitoring the chemical shift changes of resonances 
as a function of compound concentration.   
 
Cell-based Assays 
HeLa cells, cultured in DMEM supplemented with 10% fetal bovine serum, 
were treated with DMSO control or compound as indicated. Lysates from each 
sample were analyzed by SDS-PAGE and Western blotting using Immobilon-FL 
PVDF membranes (Millipore) and scanned on Odyssey imager (LiCor). Levels of 
endogenous Ras-GTP were determined using a Ras-binding domain pull-down 
assay according to the manufacturer’s protocol (Millipore). Antibodies for ERK, 
phospho-ERK, MEK, phospho-MEK, AKT, phospho-AKT473, and phospho-
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EGFR (Y1068) were obtained from Cell Signaling. Pan-Ras antibody used for 
Ras-GTP pulldowns was from Millipore.   
CHL-1, SK-MEL-2, MALME-3M, and PANC-1 cells were obtained from the 
ATCC and cultured in complete growth media as recommended. Dabrafenib 
(Selleck) was dissolved in DMSO and used at the concentrations indicated. For 
Figure 3-10 HeLa cells were serum-starved overnight, prior to compound 
pretreatment and EGF stimulation (R&D Systems). 
For microscopy experiments, HeLa cells were plated at 30,000 cells/well 
in 8-chamber slides (BD Falcon). After 24 hours, cells were treated for 30 
minutes with FITC-conjugated compound 4, and washed extensively with ice cold 
PBS. Cells were fixed in 3.7% paraformaldehyde/PBS for 20 minutes at room 
temperature. Cells were rinsed four times with PBS and mounted on a coverslip 
with Vectashield (Vector Laboratories) mounting medium containing DAPI. Slides 
were imaged on a confocal microscope (Zeiss LSM 710). 
Cell proliferation experiments were conducted in a 96-well plate (Thermo). 
Cells were plated at 1000 cells/well, incubated overnight, followed by treatment 
with the indicated concentration of compound for 3 days at 37°C. Cell 
proliferation was assessed using a CellTiter-Glo assay (Promega) according to 
the manufacturer’s protocol. Anchorage independent growth assays were 
conducted by first plating a 0.6% agar base layer. After the agar solidified, each 
well received another 100 ul of 0.4% agar in culture medium containing 5,000 
cells. Plates were incubated overnight, followed by treatment with the indicated 
concentrations of compound for 7 days. Growth was assessed using CellTiter-
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Blue reagent (Promega) according to the manufacturer’s protocol. Data were 
normalized to DMSO control. IC50 values were again determined using a four-
parameter dose-response (variable slope) equation in Prism 5 (Graph Pad 
Software Inc.).   
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CHAPTER IV 
 
HIGH-THROUGHPUT SCREENING USING A NUCLEOTIDE EXCHANGE 
ASSAY  
 
Introduction 
Additional molecules with different chemical scaffolds that activate SOS-
catalyzed nucleotide exchange would be useful for providing further evidence 
that the observed activities are not due to off-target driven effects. In addition, 
new molecules may serve as better starting points for the discovery of improved 
compounds. Finally, the close proximity of the compound-binding site to the SwII 
region of Ras suggested that these compounds may be useful for the design of 
interfacial inhibitors. In order identify additional compounds that activate or inhibit 
SOS-mediated nucleotide exchange, I conducted a high-throughput screen of the 
VICB library.   
With a novel fluorescence-based guanine nucleotide exchange assay 
utilizing BODIPY-GTP, I performed a >160,000 compound high-throughput 
screen for inhibitors of SOS-catalyzed nucleotide exchange on Ras using a 
Hamamatsu Functional Drug Screening System in the high-throughput screening 
facility. Given the difficulty with targeting Ras (See Chapter I), this screen was 
designed to identify any biologically active molecules, including inhibitors and 
activators. The results of this study could provide a path forward for the discovery 
of Ras-directed therapeutics. From this effort, multiple unique chemical series 
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capable of activating SOS-catalyzed nucleotide exchange were identified. While 
these novel compounds act by binding to the same pocket on SOS characterized 
in Chapter III, they bind in a distinct mode and have additional ligand-protein 
interactions. Importantly, these compounds identified by high-throughput 
screening elicit the same signaling as compounds described in Chapter III.  
Biochemical, cellular, and structural data on these compounds are currently 
being used to aid in the design of improved compounds. 
Results 
Assay Development  
Nucleotide exchange assays using fluorescently labeled nucleotide 
analogs are well described and have been conducted to study GEF:GTPase 
interactions for nearly three decades; however, these assays are traditionally 
conducted in a time and labor intensive cuvette-based format.(27, 150, 151) To 
adapt this assay for high-throughput screening, the assay needed to be 
miniaturized to a 384-well plate format, a systematic assessment of assay 
variables needed to be conducted, and an appropriate plate reader was required 
to read kinetic data from 384-wells simultaneously.  
In order to develop a suitable assay for high-throughput screening, an 
alternative to mant-labeled nucleotide analogues commonly used in the Ras field 
was first required.  The mant fluorophore is covalently attached to the 2’ or 3’ 
position of the ribose ring of GDP or GTP (Figure 4-1A). Mant-labeled 
nucleotides increase in fluorescence when bound to proteins including GTPases 
such as Ras.(27, 152)  The environmental sensitivity of these analogues can 
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therefore serve as an indicator of nucleotide exchange differentiating between 
protein-bound nucleotide and free nucleotide in solution. Compound libraries 
have been previously reported to interfere more frequently with fluorophores 
such as mant- that contain shorter wavelengths in fluorescence-based high-
throughput assays.(153, 154)  BODIPY-FL-GTP was therefore preferentially 
chosen as the nucleotide analogue of choice rather than mant-GTP (Figure 4-
1B). It has previously been used in the Ras field and has a longer wavelength 
than mant-GTP with an Excitation/Emission of 485/510 versus 360/440, 
respectively.(140) In addition to reducing interference artifacts arising from 
autofluorescent compounds or quenching compounds, BODIPY analogues are 
advantageous because they preserve the fluorophore attachment to the 2’ or 3’ 
position of the ribose ring and have spectral characteristics similar to fluorescein 
(FITC) or the Alexa Fluor 488 dye making the appropriate excitation/emission 
filters readily available in most laboratories (Figure 4-1A-B).  
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Figure4-1.  Fluorescent nucleotide analogues increase in fluorescence 
when bound by K-Ras. (A) Chemical structures of fluorescent nucleotide 
analogues used in nucleotide exchange assays for Ras include mant-GTP 
(ex/em: 360/440) and BODIPY-GTP (ex/em: 485/510). (B) Screening assay 
design: SOS and BODIPY-GTP are present in the assay plate at time 0.  
Baseline fluorescence is monitored followed by the addition of compound.  
Compound fluorescence is monitored prior to the addition of K-RasG12D.  Upon 
the addition of K-RasG12D, SOS catalyzes the exchange of the unlabeled-GDP 
for the BODIPY-GTP resulting in an increase in fluorescence intensity.  Excess 
GTP (200uM ) is added resulting in the dissociation of fluorescent nucleotide and 
return of fluorescence to baseline. (C) Diagrammatic representation of the 
nucleotide exchange assay showing SOS-catalyzed exchange of GDP for 
BODIPY-GTP for the association phase, and SOS-catalyzed exchange of 
BODIPY-GTP for unlabelled GTP for the dissociation phase. 
 
 
mant%GTP)
SOS1$
Ras$Ras$
λex$ λem$ λex$ λem$
Ras$
λex$ λem$
SOS1$
Excess$GTP$
Associa/on) Dissocia/on)
Compound(
(10(uL)(
K/Ras(
(10uL)(
Unlabeled(GTP(
(10uL)(
SOS1(+(
BODIPY/GTP(
(20uL)(
Re
la
Bv
e(
Fl
uo
re
sc
en
ce
(U
ni
ts
(
Time((Seconds)(
A)
B)
C)
D)
	  	   79	  
For the purposes of screening, the assay was designed to be run in an 
association-dissociation format in which BODIPY-GTP first associates with 
unlabeled Ras followed by a dissociation step in which excess unlabeled GTP 
outcompetes the labeled analogue returning fluorescence to baseline (Fig 4-1C-
D). Purified, recombinant GDP-bound K-RasG12D is added to a mixture of SOS 
and BODIPY-GTP; the bound, unlabeled-GDP is exchanged for BODIPY-GTP, 
resulting in a significant increase in fluorescence with time (Fig 4-1C-D). This 
association-dissociation is catalyzed by SOS and the rate of nucleotide exchange 
can be determined as the slope of the association curve following the addition of 
Ras or the rate of the dissociation curve following unlabeled GTP addition (Figure 
4-1C). Ras undergoes a conformational change during the transition from the 
GDP-bound form to the GTP-bound form, and the association-dissociation format 
was chosen to detect compounds that bound to either form of Ras. Compounds 
that blocked the unlabeled-GDP!BODIPY-GTP transition were hypothesized to 
bind to Ras-GDP as described in Chapter II, while compounds that inhibited the 
BODIPY-GTP!unlabeled-GTP transition were hypothesized to bind to Ras-GTP.  
Alternatively, inhibition of either transition could be accounted for by compounds 
that bound directly to SOS or the Ras:SOS complex as reported for other 
GEF:GTPase interactions.(135)   
Nucleotide exchange assays in the Ras field are traditionally run in a 
labor-intensive 1-2 mL cuvette-based format, which is unsuitable for high-
throughput screening. Initial miniaturization was accomplished by keeping the 
Ras and SOS protein concentrations, buffer components, and fluorophore fixed 
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while converting nucleotide exchange assays to a 384-well format.(133) Initially, 
the concentration of either Ras or SOS was varied while holding the other 
constant (Figure 4-2A-B) (See also Figure 3-5). Varying the concentration of 
SOS revealed that appreciable rates of nucleotide exchange could be detected 
with as little as 125nM SOS. As expected, higher concentrations of SOS 
provided faster kinetics (Figure 4-1A) (See also Figure 3-5).  Nucleotide 
exchange experiments conducted by varying the concentrations of Ras while 
holding SOS constant at 1 µM revealed a linear increase in the rate of nucleotide 
exchange as Ras concentrations increased until a maximum rate of exchange 
was achieved at higher concentrations (Figure 4-1B). On the basis of these 
studies, final concentrations of 1 µM Ras and 1 µM SOS were chosen for our 
experiments. These conditions provided an appreciable rate of SOS-catalyzed 
nucleotide exchange above the intrinsic nucleotide exchange by Ras (Figure-4-
1A), and we hypothesized that maximizing this window would facilitate the 
discovery of competitive inhibitors of the Ras-SOS interaction or activate SOS-
mediated nucleotide exchange. The rapid rate of SOS-catalyzed nucleotide 
exchange using 1µM SOS also allowed each plate to be screened in a timely 
manner. Higher concentrations than 1 µM were not used in order to conserve 
SOS protein reagent, the large-scale production of which is labor and time 
intensive. 
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Figure 4-2. Systematic assessment of high-throughput screening assay 
variables. (A) Real time monitoring of nucleotide exchange kinetics in the 
presence of varying concentrations of SOS (conducted using 1µM Ras). (B)  
Rate of nucleotide exchange varies with the concentration of Ras (conducted 
using 1µM SOS).  The effect of varying the concentration of magnesium on (C) 
SOS-catalyzed and (D) intrinsic nucleotide exchange. Exchange reactions 
conducted in the presence of 25µM magnesium are indicated for reference. (E) 
Competition experiment demonstrating decreased BODIPY-GTP association with 
Ras in the presence of unlabeled GTP.  Rates plotted as a function of unlabeled 
GTP concentration. 
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Magnesium has been well described as a cofactor for the high affinity 
interaction of the nucleotide for Ras and for the required displacement of it during 
the process of nucleotide exchange. While systematically testing each assay 
component, I showed that concentrations of magnesium in 10-fold excess or 
greater over Ras inhibited nucleotide exchange, and that SOS increased the rate 
of nucleotide exchange over the intrinsic nucleotide exchange regardless of the 
concentration of magnesium (Figure 4-2C-D).  These data were consistent with 
previously reported observations that GEF-catalyzed nucleotide exchange on 
Ras involves a Mg2+-independent as well as a Mg2+-dependent mechanism, and 
that free magnesium negatively regulates both intrinisic and GEF-catalyzed 
nucleotide exchange.(133, 155) Based on these data, nucleotide exchange 
reactions were performed using 20 µM MgCl2 in all assay buffers for the primary 
screen.   
No known inhibitors or activators of the Ras-SOS interaction were known 
prior to conducting this screen; however, we needed to demonstrate that this 
assay was capable of detecting chemical entities that inhibited SOS-catalyzed 
nucleotide exchange.  Therefore, in addition to using excess magnesium to 
inhibit this reaction in Figure 4-1C, I used unlabeled GTP to serve as a 
competitive inhibitor and prevent the labeled BODIPY-GTP association with Ras.  
This experiment demonstrated the ability of the assay to identify nucleotide 
exchange inhibitors (Figure 4-2E). Inhibition of SOS-catalyzed BODIPY-GTP 
association with Ras was observed at concentrations of unlabeled GTP equal to 
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and above the concentration of the labeled BODIPY-GTP consistent with a 
competitive mechanism of inhibition.   
In order to simultaneously measure 384 non-identical experiments in a 
kinetic format with multiple additions, we employed a Hamamatsu Functional 
Drug Screening System (FDSS) 6000 located in the VICB High-Throughput 
Screening Core. The Hamamatsu FDSS 6000 has fluorescence detection 
capabilities, integrated liquid handling, and data analysis software.  This permits 
kinetic measurements to be acquired from 384 wells by a camera located below 
the assay plate while reagents are simultaneously added from above (Figure 4-
3A-B). Changes in fluorescence were monitored with readings conducted every 3 
seconds for 12 minutes.  
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Figure 4-3. High-throughput screen design and analysis. (A) Simultaneous 
monitoring of 384 kinetic reactions with positive (red) and negative (green) 
controls checkerboarded in columns 1, 2, 23, and 24. (B) Additions are made 
from above the plate while measurements are simultaneously taken using a 
Hamamatsu Functional Drug Screening System (FDSS).  (C) Liquid handling 
(blue) and compound fluorescence (red) are assessed prior to conducting the 
nucleotide exchange assay in an association-dissociation format. Hits were 
picked by fitting a single exponential function to the dissociation phase of the 
experiment (pink). (D) Highlighted well shows a putative inhibitor of SOS-
catalyzed Ras activation with a reduced rate of BODIPY-GTP association and 
dissociation (grey) compared to the SOS-catalyzed control (green).  
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Two additional measurement phases were incorporated prior to the 
association-dissociation phase of the experiment to maximize the information 
obtained from each plate and to reduce false positives. Since the rate of 
nucleotide exchange is dependent on the amount of SOS protein in each 
reaction (Figure 4-2A), wells containing too little or too much SOS could result in 
false positive hits for inhibition or activation, respectively.  Care must be taken to 
ensure each well receives an equal amount of SOS protein. 20 µL of a 
homogenous mixture of BODIPY-GTP and SOS protein was added to each well 
and the baseline fluorescence was recorded for 10 seconds (Figure 4-1C and 4-
2A and 4-3C). This first 10-second window allowed the evaluation of the liquid 
handling procedures used to build the assay.  Any well containing a fluorescence 
greater or less than three standard deviations from the mean fluorescence within 
the 384 wells during this 10 second window could be flagged, evaluated, and/or 
repeated later during follow-up hit picking.  
After taking a baseline reading, 10 µL of test compound was added to 
each well and fluorescence was measured for a 2 minute period in which grossly 
fluorescent or fluorescence quenching compounds could be identified (Figure 4-
1C and 4-3C). Again any well containing a fluorescence greater or less than 
three standard deviations from the mean fluorescence of the 384 wells during 
this second phase of the experiment was marked. Wells containing fluorescence 
or quenching compounds could be evaluated and/or repeated later when picking 
hits.  
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Finally, the nucleotide exchange reaction was intiated by the addition of 10 
uL of Ras, and run in an association-dissociation format. Final reactions in the 
association phase contained 40 µL with 1 µM BODIPY-GTP, 1 µM SOS, 1µM 
Ras, and 10 µM compound.  These were conducted in a buffer containing 25 mM 
Tris (pH 7.5), 50 mM NaCl, and 20 µM MgCl2, and the dissociation phase was 
initiated by the addition of 10µL of 200 µM unlabeled GTP bringing the volume to 
50µL at the end of the assay. 
The raw fluorescence data from the dissociation phase was fit to a single 
exponential decay function to determine the rate of nucleotide exchange in each 
well (Figure 4-3C). Compounds that activated or inhibited nucleotide exchange 
were defined as those with a nucleotide exchange rate greater or less than 3 
standard deviations from the mean. Fitting a single exponential function to the 
dissociation phase of the experiment proved capable of identifying hits that 
altered the initial rate of nucleotide exchange (either association or dissociation) 
(Figure 4-2D), while being less susceptible to artifacts occurring after the second 
or third addition (e.g. bubbles from liquid handling). Both activators and inhibitors 
were identified as hits and reserved for follow-up experiments.   
Conducting and Analyzing the Results from the High-Throughput Screen 
The Vanderbilt Compound Collection, containing ~160,000 samples, was 
screened using the nucleotide exchange assay to identify chemical entities that 
alter the rate SOS-catalyzed exchange on Ras.  Negative and positive controls 
were checkerboarded in columns 1, 2, 23, and 24 of the 384-well plates (Figure 
4-3A). No true chemical entity has been reported that could alter the rate of SOS-
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catalyzed nucleotide exchange on Ras and therefore serve as a control 
compound.  A magnesium concentration of 160µM inhibited this reaction by 75% 
and was chosen as a positive control for this screen. The ability of this assay to 
identify active compounds was assessed by calculating Z-prime, a coefficient 
reflective of both the assay signal dynamic range and the data variation 
associated with the signal measurements, for each plate from the control 
wells.(156) Plates with a Z-prime <0.7 were repeated. Alternative control options 
included conducting the experiment in the absence of one protein component 
such as SOS or in the presence of excess unlabeled GTP.  Removing an assay 
component was decided against since all the wells testing unknowns have all 
assay components present, and this control artificially increases the calculated 
assay signal dynamic range.  Unlabeled GTP could only be used as a control for 
the association phase of the experiment, so was not applicable to the 
dissociation phase, which proved best for identifying active compounds.  
Compounds that altered the rate of nucleotide exchange were picked 
based on Z-score, exchange rate >±3 standard deviations from the mean of the 
vehicle control, and B-score, which accounts for the presence of within-plate 
systematic effects such as row or column effects.(157) Because Z-score is 
sensitive to outliers, and we were interested in identifying any molecules that 
altered the Ras-SOS interaction, two iterative rounds of hit picking were 
conducted for each plate.  Measures such as this were taken in the primary 
screening phase in order to reduce false negatives, even at the expense of 
increasing the rate of false positives.  No known compounds that alter Ras-SOS 
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interaction had been reported previously, and protein-protein interactions such as 
this typically lack well defined binding pockets. Therefore, molecules that altered 
this interaction, even weakly, were important to identify and could prove of 
interest to the Ras field of study. Figure 4-4 depicts a summary of our screening 
results, from the primary screen, 2880 hits were identified (1.8% Hit Rate).   
 
Figure 4-4. High-throughput screening progression path and statistics. 
Final compounds prioritized for reordering including VUID, structures, and 
properties are provided in Appendix I.  
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The ability of each compound to alter nucleotide exchange was confirmed 
by repeating the nucleotide exchange assay under the same conditions as the 
primary screen. Confirmation was performed in duplicate for each hit. 
Compounds that hit 2 out of 3 times (once in the primary screen and once in 
confirmation) were reserved for further follow up. Only 10% of the compounds 
confirmed upon confirmation testing, resulting in 244 confirmed hits (Figure 4-4).  
The low rate of confirmation at this stage of screening was likely due to multiple 
factors; however, the low threshold for picking hits and iterative rounds of hit 
picking used in the primary screen likely increased the rate of false positives and 
was the primary contributor to the poor confirmation rate.   
Following confirmation, hits were filtered to remove pan-assay interference 
compounds and were evaluated by medicinal chemists in the Fesik lab to remove 
compounds that frequently hit in other screens, unstable molecules, and potential 
irreversible modifiers from consideration for additional follow-up.(158) Of the 244 
confirmed hits, 94 compounds (38.5%) were determined to be undesirable 
compounds. The majority of the compounds filtered out during this stage came 
from hits that were initially identified as inhibitors.  The SOS protein is less stable 
than Ras, and the concentration of SOS is directly related to the rate of 
nucleotide exchange (Figure 4-2A).  Therefore, any compounds that covalently 
modified, precipitated, or non-specifically inhibited SOS would be identified as an 
inhibitor.  This mechanism could account for why the majority of the compounds 
filtered out at this stage were initially identified as inhibitors.  
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Confirmed hits were further tested in the nucleotide exchange assay in a 
10-point, 2-fold dilution series to determine if these compounds demonstrated 
concentration-dependent, saturable activity and to prioritize hits for follow-up.  Of 
the 150 compounds tested in concentration response, 103 compounds, 
composed of 68 inhibitors and 35 activators, displayed concentration dependent 
activity (Figure 4-4). Additionally, the concentration-response curves generated 
from this experiment identified those chemical series that lacked tractable 
structure-activity relationships, including one series containing over 30 
compounds that resulted in a 30% inhibition of nucleotide exchange at all 
concentrations tested.  A few compounds were also identified by this analysis as 
being fluorescent when titrated to higher concentrations.  These compounds 
were identified as active in the primary screen and confirmation rounds but were 
likely picked as active due to their fluorescence, which at the screening 
concentration was just below the threshold used to rule out fluorescence 
artifacts.  From the concentration-response curves, we identified the most potent 
hits and prioritized 40 compounds for reordering, including 30 inhibitors and 10 
activators (See Appendix I for VUID, structures, and properties). Of these, 20 
inhibitors and 10 activators were commercially available to reorder (Figure 4-4).  
After confirming the activity of repurchased compounds, each compound 
was tested for its ability to bind to Ras or SOS by NMR. The majority of inhibitors 
did not bind to either protein.  Those inhibitors that did bind were determined to 
be covalently bound based on the their increased potency observed with time, 
and an inability of these compounds to dissociate from Ras or SOS following 
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dilution and buffer exchange. The structures of the inhibitors prioritized for 
reordering are shown in Appendix I.   
 
High-Throughput Screening Derived Activators Bind to the Ras-SOS-Ras 
Complex and Perturb MAPK Signaling 
  Molecules identified by high-throughput screening that activated SOS-
catalyzed nucleotide exchange contained similarities in their structures and bind 
to SOS (Table 4-1). These compounds displayed distinct and tractable structure-
activity relationships that we reasoned could be exploited for future compound 
design. For example, the pyrimidine-based hits VU0063275 and VU0063036 
(EC50= 13.1 and 13.9, respectively) represent one of the most potent series of 
HTS hits, while the benzimidazole analogs VU0061570 and VU0120832 (EC50= 
4.1 and 13.1, respectively) are members of another highly represented chemical 
template. The presence of a benzyl amine or aniline on each molecule suggested 
a common binding mode for these compounds.   
 
 
	  	   93	                           
Table 4-1.  Nucleotide exchange activators identified by 
High-throughput screening. 
VUID%
Molecular%
Weight%
X4Ray%Crystal%
Structure%
Obtained%
VU0063275 270.4 Yes%
VU0006265 289.8 No%
VU0063036 350.8 Yes%
VU0002032 428.0 Yes%
VU0087471 384.5 No%
VU0019562 336.5 No%
VU0061570 281.3 Yes%
VU0145298 326.8 Yes%
VU0124029 404.0 Yes,%ParBal%
Density%
VU0120832 291.4 Yes%
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           While the compounds identified by high-throughput screening have 
distinct chemical structures from those activators described in Chapter III, I 
hypothesized that the HTS-derived nucleotide exchange activators bound to the 
same pocket on the Ras:SOS:Ras complex based on the similar biochemical 
effect that these molecules elicited in vitro.  X-ray co-crystal structures were 
obtained by Qi Sun and DeMarco Camper with these hits in complex with the 
Ras:SOS:Ras complex.  Of the 10 activators reordered from the high-throughput 
screening campaign, 7 were crystallized with the Ras:SOS:Ras complex (Table 
4-1), and the structures of these cocomplexes were determined by x-ray 
crystallography. Compounds with poor solubility or weaker activity either did not 
produce suitable crystals for X-ray diffraction or did not contain density for the 
ligand.   
The X-ray structures obtained revealed that all of the activators identified 
by HTS bind to the same site on the CDC25 domain of SOS as the amino-
piperidine indoles shown in Figure 3-6.  This hydrophobic pocket is formed by the 
CDC25 domain of SOS adjacent to the Switch II (SwII) region of Ras bound at 
the catalytic site. Residues of SOS forming the pocket that directly interact with 
Ras and the compounds include N879, Y884, and H905. Surface representations 
of VU0063275, VU0120832, VU0145298, and VU0063036 bound to this pocket 
are shown in Figure 4-5A-D. The binding modes of the HTS hits are extremely 
similar as shown by an overlay of the compounds within the pocket Figure 4-4E.  
In each case, an aromatic benzyl amine or aniline extends into a large 
hydrophobic space underneath phenylalanine 890.  Initial HTS hits, including 
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VU0002032, VU0063036, VU0061570, and VU0145298 (Table 4-1) 
demonstrated that halogen substitution at the 3- and 4- positions of this aromatic 
ring was permitted. The space occupied by the indole moiety from the amino-
piperidine indole series described in Chapter III is filled by the benzimidazole of 
VU0120832 (Figure 4-5B).  Alternatively, a butyl group or a methylene furan are 
tolerated in this space as shown by the pyrimidine-based hits VU0063275 (Figure 
4-5A) and VU0063036 (Figure 4-5D). 
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Figure 4-5. HTS activators bind to the Ras:SOS:Ras ternary complex.  
Surface projections with initial hits bound to the Ras:SOS:Ras ternary complex  
including (A) VU0063275, (B) VU0120832, (C) VU0145298, and (D) VU0063036. 
(E) An overlay of the high-throughput screening derived hits bound to the CDC25 
domain of SOS.  
A" B"
C" D"
E"
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          While the overall binding modes of the HTS activators are extremely 
similar, a comparison of the X-ray co-crystal structures obtained with the HTS 
hits versus those obtained with the amino-piperidine indole series revealed two 
differences (Figure 4-6A-B).  For the HTS hits, phenylalanine 890 has rotated 
into an upward conformation. A stacking interaction is formed in which the HTS 
compounds are sandwiched between the aromatic side chains of phenylalanine 
890 and tyrosine 884 (Figure 4-6C). In contrast, the phenylalanine is rotated 
downward in the X-ray co-crystal structures containing the amino-piperidine 
indole series of compounds (Figure 4-6C).  The two binding modes appear to be 
mutually exclusive. The upward rotation of the phenylalanine observed with the 
HTS compounds partially occludes the second hydrophobic pocket occupied by 
the peripheral tryptophan moiety of compounds 2 and 3 described in Chapter III.  
Alternatively, when the phenylalanine is rotated in the downward position, the 
space occupied by the benzyl amine or aniline of the HTS compounds no longer 
exists.  Whether this phenylalanine residue can move further allowing a mix and 
match strategy to be employed in the design of future improved molecules that 
exploit interactions made by both HTS- and fragment-derived activators remains 
to be determined and is currently under investigation. 
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Figure 4-6. HTS-derived activators adopt a distinct, mutually exclusive 
binding mode. (A) HTS-derived activators closely resemble the binding mode 
adopted by the quinazoline series compound VU0063036 (blue).  90 degree 
rotation is shown for clarity.  (B) The amino indole piperidine series (green), 
adopts a distinct conformation as shown by the dissimilar overlay with the 
quinazoline series compound VU0063036 (blue). (C) The large differences 
between the two binding modes observed can be explained by the rotation of 
phenylalanine 890 (bright orange) in and out of the pocket. 
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          As described in Chapter III, the amino-piperidine indole series of activators 
inhibit signaling downstream of Ras. To test whether activators with very different 
structures displayed the same effects, we examined the ability of HTS-derived 
activators to perturb signaling downstream of Ras.  Importantly, these molecules 
elicited a similar signaling pattern downstream of Ras as the amino-piperidine 
indole series (Figure 4-7). For example, VU0063275 inhibits the PI3 kinase 
pathway, as evidenced by a decrease in phosphorylation of AKT at serine 473, 
and elicits a biphasic response in the MAP kinase pathway characterized by 
inhibition of ERK phosphorylation at high compound concentration and a peak of 
increased ERK phosphorylation as the compound concentration decreases 
(Figure 4-7).   
 
Figure 4-7. HTS- and fragment-derived nucleotide exchange activators elicit 
the same signaling downstream of Ras. HeLa cells were treated for 30 
minutes with varying concentrations of the indicated compounds.  Lysates were 
analyzed by Western blot.  
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        Interestingly, we have discovered multiple series of chemically unrelated 
molecules that bind to a single site on the CDC25 domain of SOS, activate SOS-
mediated nucleotide exchange, and inhibit Ras signaling in cells. Based on our in 
vitro biochemical studies, we hypothesized that treatment of cells with these 
nucleotide exchange activators would result in an increase in downstream 
signaling of the MAPK and PI3K pathways. However, we did not expect the 
observed biphasic response in MAPK signaling nor the inhibition of PI3K 
signaling downstream of Ras. The fact that different compounds within unique 
chemical series elicit the same signaling downstream of Ras supports the 
conclusion that the observed cellular signaling response to these compounds is 
specific to our proposed mechanism of action at the level of the Ras-SOS 
interaction and not merely driven by off-target activities.  
 In order to further rule out off-target based activities, compound 4 from 
Chapter III, VU0486993 a more active analogue of VU0063036, and VU0484204 
an analogue of VU0145298 were tested for their ability to inhibit 342 kinases.  At 
a concentration of 20 µM compound 4 only inhibited 1 out of 342 kinases 
supporting the conclusion that it has little or no activity on this class of signaling 
proteins.  VU0484204 also inhibited only a few kinases at 20 µM; whereas 
VU0486993 significantly inhibit over 100 kinases indicating a possible liability to 
be considered when progressing this quinazoline-containing chemical series in 
the future. Further investigation of how these compounds alter other interactions, 
such as the Ras-Raf interaction, how they might affect Ras and SOS localization, 
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or how they influence negative feedback loops governing signal output will be 
required to fully understand how this signaling is brought about.   
To provide additional information on the interactions between activators 
and SOS, I screened the hits identified by HTS against the mutants of SOS 
designed to prevent compound binding, which I reported in Chapter III (Figure 4-
8A). The L901K mutation in SOS prevented all HTS compounds as well as 
compounds from the amino-piperidine indole series from activating nucleotide 
exchange consistent with this mutation blocking the most hydrophobic portion of 
the pocket. Mutation of D887 had little effect on compound 4-mediated activation 
of nucleotide exchange as described in Chapter III.  However, many of the ten 
best HTS hits, including VU0124029, VU0019562, and VU0002032 significantly 
lost activity when tested against the D887A and D887H mutant forms of SOS 
(Figure 4-8A). From these experiments, we hypothesized that these compounds 
interact directly with the D887 residue of SOS. Futhermore, we hypothesized that 
this interaction may be mediated through the common piperizine or piperidine 
moieties highlighted in red in Figure 4-8B, which would be positively charged at 
pH 7.5. Utilizing this information, Dr. Andrew Little, combined the benzimidazole 
core common to multiple HTS hits with a halogen substituted aniline ring and 
piperidine moiety to produce the most potent (EC50 = 1.7 µM) activator 
synthesized to date. A more water soluble derivative of this compound without 
the methyl groups was crystallized by Qi Sun to the Ras:SOS:Ras complex 
(Figure 4-8C).  This structure revealed a charge-charge interaction between the 
piperidine ring and D887 side chain as hypothesized.  The high-throughput 
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biochemical assay and diversity of chemical structures presented in this chapter 
paired with the chemistry and structural biology resources within the Fesik lab 
has enabled a multidisciplinary effort to optimize these compounds using mix and 
match combination strategies.  The rapid optimization of the HTS compounds 
containing a benzimidazole highlights this approach (Figure 4-8). The goal of 
these efforts is to improve these compounds so they are active at low nanomolar 
concentrations and have suitable biochemical and physicochemical 
characteristics for examination of in vivo activity.  
Figure 4-8. Optimization of the benzimidazole containing HTS-derived 
activator series. (A) High-throughput screening hits were tested individually for 
their ability to activate wild-type SOScat, SOScatL901K, SOScatD887A, or 
SOScatD887H (n=1). VU0124029, VU0019562, and VU0002032 lost activity 
when tested against SOScatD887A and SOScatD887H in contrast to other 
nucleotide exchange activators. (B) A mix and match strategy was employed to 
incorporate the highlighted portions of each molecule resulting in the most active 
benzimidazole-based nucleotide exchange activator series. EC50s are provided 
for each compound. (C) X-ray crystallography confirmed the presence of a 
charge-charge interaction with D887.   
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Discussion 
We sought to identify improved molecules to aid in determining how these 
compounds can inhibit Ras-driven cancers. Towards this end, the high-
throughput screen of the VICB library that I conducted identified multiple, unique 
chemical series capable of activating SOS-catalyzed nucleotide exchange by 
binding to the same pocket on SOS.  These compounds bind in a distinct mode 
and have additional ligand-protein interactions not utilized by the compounds 1-4 
described in Chapter III. Importantly, the compounds identified by high-
throughput screening elicit the same signaling in cells as compounds 1-4. Finally, 
I have shown how biochemical, cellular, and structural data on these compounds 
is currently driving a multidisciplinary effort to improve these compounds for 
future studies. 
 Significant effort was made to collect as much data from each well during 
this high-throughput screen as possible, and re-examining that data may prove 
fruitful for the identification of compounds that perturb the Ras-SOS interaction in 
an unexpected way.  The use of a single exponential decay function to extract a 
rate constant from each well during the dissociation phase reduces the vast 
amount of data from each well to a single point to simplify “hit picking”.  
Alternative endpoints could be considered, and reanalyzing the data already 
obtained in an unbiased manner may reveal unexpected hits.  For example, 
compounds that that affected the association of BODIPY-GTP to Ras in this 
assay would not be identified from the dissociation phase of the experiment. 
Given the difficulty with identifying small molecules that directly inhibit Ras, any 
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compounds that perturb Ras function may be of potential interest to the Ras 
community. One approach to identify such compounds is to subtract the 
nucleotide exchange curve obtained from the negative control containing Ras 
and SOS from each test well.  This approach would enable the examination of 
only the residual values and allows any deviation from the negative control to be 
identified throughout the entire 12 minute experiment. Given the vast amount of 
data collected, the ease of reanalyzing these data, and the high value that 
additional chemical matter capable of altering the Ras-SOS interaction 
represents to the scientific community, this represents a promising direction for 
future work. 
 The identification of activators that bind to the same pocket as identified in 
Chapter III on the Ras:SOS:Ras complex will enable significant improvements in 
these molecules.  The unique binding mode identified enables new protein-ligand 
interactions to be designed into future molecules in order to improve the activity 
of these molecules.  Incorporating additional interactions, such as a charge-
charge interaction with D887, to each chemical series provides a systematic 
approach to improve the activity of the compounds. Understanding the flexibility 
within this pocket, as highlighted by the movement in F890, will also aid in 
determining which substitutions can be tolerated at various positions.  These 
efforts are currently underway in the Fesik lab, and these improved molecules 
may aid in understanding their mechanism of action, serve as chemical tools to 
better understand Ras signaling, and be useful for the treatment of Ras-driven 
tumors. 
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Materials and Methods 
Protein Purification 
Recombinantly expressed K-RasG12D (referred to as Ras, aa 1-169) and 
human SOS1 (SOScat, aa 564-1049) were purified as described in chapter II and 
III for high-throughput screening assays.(132) Briefly, K-RasG12D/C118S was cloned 
into a pDEST-HisMBP vector (pDEST-HisMBP and Tev protease were a gift from 
Dr. David Waugh, NCI) and expressed in the Rosetta 2 (DE3) E.coli strain.  The 
His-tagged protein was purified on a Ni-IDA (ProBond, Invitrogen) column, 
followed by subsequent cleavage of the HisMBP tag using TEV protease. An 
additional Ni-NTA column was used for the final step in the purification process, 
and the Ras protein was collected in the flow-through. H-Ras was expressed and 
purified in similar fashion. SOScat was transferred into the Gateway expression 
vector pDEST-17 carrying an N-terminal His6 tag for purification, and expressed 
in BL21-RIL E.coli at 18°C for 7 hours followed by purification on a Ni-IDA 
column. SOScat mutants were generated using a QuickChange method (Agilent) 
and purified similar to SOScat.  
Nucleotide Exchange Assays 
Nucleotide exchange assays were conducted using BODIPY-GDP (Life 
Technologies; excitation: 485, emission: 510) in a buffer containing 25 mM Tris 
(pH 7.5), 50 mM NaCl, and 20 µM MgCl2. Baseline fluorescence of a mixture of 
SOS and BODIPY-GTP was recorded for 10 seconds followed by addition of 
compound. A second addition of Ras was performed at 120 seconds for the 
association phase, followed by a 3rd addition of unlabeled GTP at 7 minutes. 
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Nucleotide exchange was monitored as a decrease in fluorescence with time. 
Final reactions contained 1 µM BODIPY-GTP, 1µM Ras, 200 µM unlabeled GTP, 
and and 1 µM SOScat.  
Changes in fluorescence were monitored using a Hamamatsu FDSS 6000 
with readings conducted every 3 seconds for 30 minutes. Assays were 
conducted using 50 µL final volume in a 384-well clear bottom, black Aurora 
microplate. Raw fluorescence data was fit to a single exponential decay function 
using XLfit (IDBS) software. Details of hit picking methodologies are provided in 
the text above.  For concentration response curves, derived rates were plotted as 
a function of compound concentration and fit using a four-parameter dose-
response curve (XLfit).  
Automation of the high-throughput screen was accomplished with the 
support of Vanderbilt Institute of Chemical Biology’s High-throughput Screening 
core.  Compounds were pipetted into 384 greiner addition plates using an Echo 
Liquid Handler.  SOS/BODIPY-GTP mixture was pippetted to 384 Aurora 
microplates using a Bravo Pipettor. All automation was controlled using Thermo-
CRS Polara scheduling software and a Thermo-CRS F3 articulated robot arm. 
Robotic accessories included a barcode reader, re-grip station, delidder, and 
plate carousel. A Velocity11 VSpin was used for automated centrifugation. 
Additions conducted during screening were accomplished using liquid handling 
capabilities of the Hamamatsu FDSS. 
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For Figure 4-8, nucleotide exchange rates were normalized with the rate a 
of SOS-catalyzed exchange in the absence of compound equal to 100 and Ras 
intrinisic exchange equal to 0.   
Reordering compounds 
 High-throughput screening hits were reordered as dry powders in 5 
milligram quantities from Sigma Aldrich Market Select 
(http://www.aldrichmarketselect.com).  Compounds were suspended at a 
concentration of 20mM in DMSO and stored at -20°C.  
Protein Crystallization, X-ray Data Collection, and Refinement 
 Protein crystallization, X-ray data collection, and refinement were 
conducted as described in chapter III.   
Cell-based Assays 
HeLa cells, cultured in DMEM supplemented with 10% fetal bovine serum, 
were treated with DMSO control or compound as indicated. Lysates from each 
sample were analyzed by SDS-PAGE and Western blotting using Immobilon-FL 
PVDF membranes (Millipore) and scanned on Odyssey imager (LiCor). 
Antibodies for ERK, phospho-ERK, MEK, phospho-MEK, AKT, phospho-AKT473, 
and phospho-EGFR (Y1068) were obtained from Cell Signaling.  
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CHAPTER V 
 
MECHANISM OF ACTION UNDERLYING PERTURBED RAS SIGNALING IN 
CELLS 
 
Introduction 
Based on our in vitro biochemical studies, we hypothesized that treatment 
of cells with these nucleotide exchange activators would result in an increase in 
downstream signaling through the MAPK and PI3K pathways. Indeed, Ras-GTP 
levels increased following treatment of HeLa cells with these compounds, 
consistent with the increase in nucleotide exchange activity in vitro. However, we 
did not expect the observed biphasic response in MAPK signaling nor the 
inhibition of PI3K signaling downstream of Ras. Understanding how this signaling 
is brought about may reveal new insights into how the Ras-SOS interaction 
governs signal output downstream of Ras as well as aid in identifying new 
opportunities for therapeutic intervention in cancer.  Two hypotheses for how this 
signaling may arise include: 1.) compounds directly alter how Ras interacts with 
effectors, or 2.) compounds trigger a negative feedback loop thereby 
downregulating the activity of proteins involved in the Ras pathway. 
One hypothesis to explain the signaling observed following treatment with 
the nucleotide exchange activators identified in Chapter III and IV is that these 
compounds directly alter the manner in which Ras engages its effectors.  This 
hypothesis was formed based on the similarity to biphasic MAPK signaling that 
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has been observed in other instances. Notably, B-Raf inhibitors induce a 
paradoxical activation of MAPK signaling in cells with wild-type B-Raf, and this is 
intensified by the presence of a mutant Ras.(104) Raf dimerization underlies this 
paradoxical activation in the case of B-Raf inhibitors. Ras association and 
induction of Raf dimerization is implicated in this paradoxical activation.(101, 
141) The common response, inhibition of ERK phosphorylation at high 
compound concentration followed by a peak in ERK phosphorylation as 
compound concentration decreases, observed with nucleotide exchange 
activators and B-Raf inhibitors in the MAPK pathway, suggests the possibility of a 
common underlying mechanism. While the exact biochemical and structural role 
of Ras in the process of paradoxical activation remains to be elucidated, the 
recent discovery of an autoinhibitory phosphorylation site on Raf involved in this 
process and work presented in this chapter on compound-mediated Ras 
activation provide evidence of an overlapping mechanism for both.(103) 
Specifically, strong support for a common path to the increase in ERK 
phosphorylation elicited by these two compound classes is provided below, and 
suggestions for future experiments are provided in Chapter VI. 
In contrast to directly influencing Ras-effector interactions, an alternative 
hypothesis is that a negative feedback loop underlies the unanticipated signaling 
observed following treatment with these compounds. Based on how canonical 
signal transduction pathways have been described, one would expect an 
increase in Ras-GTP levels to result in a flow of information to Raf!MEK!ERK 
and PI3K!AKT.  An improved understanding of signal transduction has brought 
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to the forefront the concept of signaling networks, in which canonical pathways 
interact with and affect one another. Signaling pathways, including the MAPK 
and PI3K pathways, crosstalk with each other, and they are further regulated by 
the presence of negative feedback and positive feedforward loops that govern 
signal output.(159) A possible explanation for the observed signaling is that 
overstimulation of these pathways using a nucleotide exchange activator triggers 
a negative feedback loop, which in turn reduces the signal output following 
treatment with compound.   
Multiple negative feedback loops have been reported to govern Ras-
pathway signal output. ERK negatively regulates Raf-1 through the 
phosphorylation of multiple sites.(160, 161) These inhibitory phosphorylation 
events were further shown to inhibit the Ras-Raf interaction as well as the 
formation of Raf heterodimers.(160, 162, 163) While negative feedback loops 
such as these that act downstream of Ras may be responsible for the signaling 
observed in one pathway, they cannot account for how both the MAPK and PI3K 
signaling pathways are perturbed. For example, the counterintuitive observation 
that AKT phosphoyration is inhibited by nucleotide exchange activators that 
increased Ras-GTP levels cannot be explained by compounds that merely alter 
the Ras-Raf interaction or the MAPK pathway. Nonetheless, they are worth 
investigating even with the possibility remaining that separate feedback loops 
regulate each pathway independently. 
Regulation of the PI3K and MAPK signaling pathways has been well 
described in literature, and a common negative feedback loop governing these 
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two pathways represents a possible mechanism underlying the observed 
signaling following treatment with nucleotide exchange activators.(159, 164, 165) 
For example, ERK phosphorylates SOS at multiple negative regulatory sites 
resulting in the dissociation of the Grb2-SOS complex and loss of the ability of 
SOS to catalyze nucleotide exchange of Ras.(50, 166-168) A decrease in SOS 
activity could account for both the decrease in AKT and ERK phosphoryation at 
high concentrations of compound. In addition to SOS, downregulation of 
components common to both the MAPK and PI3K pathway, such as the 
epidermal growth factor receptor (EGFR), could account for the observed 
signaling.   
Multiple early and delayed feedback loops that regulate EGFR could 
underlie the observed signaling following compound treatment including receptor 
endocytosis, covalent modification, and degradation.(169) Following ligand 
stimulation EGFR is internalized after which the receptor can be recycled to the 
membrane or subsequently degraded.(170) Internalization and transfer to 
endosomes of EGFR prolongs MAPK signals while terminating PI3K–AKT 
signaling.(171, 172) Eliciting a similar sort of response could provide a possible 
explanation for why PI3K signaling is solely inhibited while a biphasic response is 
observed in MAPK signaling following compound treatment.  Multiple 
mechanisms have been shown to control receptor internalization, the net result is 
reduced signaling downstream of EGFR.(173) One mechanism governing 
receptor internalization and downregulation is through an inhibitory 
phosphorylation event on EGFR.(174) Phosphorylation of serines 1046 and 1047 
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induces ligand-mediated internalization and downregulation.(175-178) The 
engagement of this feedback loop offers a possible explanation for the 
mechanism of action underlying biphasic MAPK response and PI3K inhibition 
observed following treatment with nucleotide exchange activators. 
In this chapter, I will provide evidence that EGFR responsiveness to 
extracellular ligand is negatively regulated in a time dependent manner following 
compound treatment. The autophosphorylation of multiple tyrosines on the 
kinase domain of EGFR following compound treatment is inhibited, and an 
inhibitory phosphorylation is increased in a reciprocal manner.  This inhibitory 
autophosphorylation event requires the presence of both compound and SOS.  
This work provides a possible mechanism responsible for the observed signaling 
with nucleotide exchange activators, and future experiments examining EGFR 
localization and degradation are proposed in Chapter VI based on this work.  
The Ras-Raf interaction and EGFR regulation are each controlled by a 
complex network of signaling proteins and the context-specific nature of how 
these each are regulated may influence the signaling observed with these 
compounds.(179) Regulatory feedback loops often work in a coordinated fashion 
to govern dynamic signal output from the MAPK pathway downstream of Ras, 
and the assumption that one mechanism governs how these nucleotide 
exchange activators perturb cellular signaling may be an oversimplification.(180, 
181) Further complicating our efforts to elucidate the mechanism underlying this 
perturbed signaling is the fact that many of the crosstalk and regulatory feedback 
mechanisms reported have been shown to be cell-type specific and context-
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dependent.(168) Further investigation of how these compounds alter effector 
interactions, such as the Ras-Raf interaction, how they affect Ras and SOS 
localization, and how they influence negative feedback loops governing signal 
output will be required in the future to fully understand their effects and potential 
utility.   
 
Results 
Investigating a Similar Mechanism for MAPK Pathway Activation by 
Nucleotide Exchange Activators and Raf Inhibitors 
 In order to study the mechanism underlying the biphasic response in ERK 
phosphorylation reported in Chapter III, I conducted an expanded investigation 
into how these compounds effect Ras signaling in cancer lines harboring well-
characterized mutations in the Ras pathway. As described previously, in the 
context of wild-type Raf (CHL-1), the B-Raf inhibitor dabrafenib and compound 4 
elicited a biphasic response in both MEK and ERK phosphorylation (Figure 5-
1A). In addition, in MALME-3M cancer cells, which harbor a B-RafV600E mutation, 
dabrafenib was able to potently inhibit MEK and ERK phosphorylation, as 
expected (Figure 5-1B). Compound 4, however, had no effect on MEK or ERK 
phosphorylation, suggesting that this compound acts by a unique mechanism of 
action at the level of the Ras-SOS interaction, upstream of Raf kinase. 
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Figure 5-1. Mutations in B-Raf, not PI3K, alter signaling induced by 
nucleotide exchange activators. Lysates from (A) CHL-1, (B) MALME-3M, (C) 
RKO, and (D) MDA-MB-231 cells treated for 30 minutes with varying 
concentrations of compound 4 or dabrafenib were analyzed by western blot. 
Each experiment was conducted three or more times, representative western 
blots are shown above.  
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          The lack of responsiveness of cell lines harboring V600E mutations in B-
Raf to nucleotide exchange activators supported the hypothesis that the 
perturbed MAPK signaling originated upstream of Raf kinase; however, cell lines 
harboring mutations in the p110α subunit of PI3K did not alter the signaling 
elicited by these compounds in the PI3K pathway. In RKO cells, which harbor 
mutations in both PI3K and B-Raf, phosphorylation of AKT decreased in a 
concentration dependent manner despite the presence of an H1047R mutation in 
PIK3CA (Figure 5-1C).  This mutation in the kinase domain increases the 
catalytic activity of PI3K and was expected to prevent the inhibition of signaling in 
this pathway.(182) This result suggests that the observed PI3K pathway 
inhibition occurs downstream of PI3K, and is supported by similar results 
obtained in cell lines that harbor activating E545K mutations in the helical domain 
of PIK3CA or inactivating mutations in PTEN (data not shown).  
 In contrast to the PI3K pathway, RKO cells, which also contain a V600E 
mutation in B-Raf, showed no inhibition or increase in MAPK signaling with 
compound 4 from Chapter III as evidenced by no change in the phosphorylation 
of MEK or ERK (Figure 5-1C).  These cells were still sensitive to dabrafenib, 
which is capable of inhibiting mutant B-Raf (Figure 5-1C). These results are 
consistent with results obtained in the MALME-3M cell line, which also harbor a 
V600E mutation in B-Raf.  This evidence provides support that the perturbed 
signaling in the MAPK and PI3K pathways observed following treatment with 
these compounds is regulated by unrelated mechanisms.  The lack of an effect 
by mutations in the PI3K pathway on the signaling elicited by these compounds 
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suggests that either the inhibition of this pathway occurs at a level downstream of 
PI3K or that the inhibition can simply still be observed in the presence of these 
mutations. In either case, it is unlikely that the MAPK pathway is downregulating 
the PI3K pathway through a cross-inhibition mechanism based on the results 
obtained in the RKO cell line, where no change in phosphorylation of ERK is 
observed, yet phosphorylation of AKT is still reduced. Further experiments are 
required to elucidate the mechanism responsible for the perturbed signaling 
observed with compound in the PI3K pathway.  
 Recently, new insights were provided into the mechanism responsible for 
the paradoxical activation of the MAPK pathway induced by inhibitors of the B-
Raf kinase. I hypothesize that a similar mechanism of action could underly how 
nucleotide exchange activators elicit a similar signaling response.  The 
biochemical mechanism of wild-type Raf activation by multiple Raf inhibitors was 
assessed using a kinetic analysis of purified BRafV600E and wild-type Raf 
enzymes.(103) An inhibitory autophosphorylation of the phosphate-binding loop 
keeps Raf inactive in a normal cell. When this autoinhibitory phosphorylation was 
disrupted, either by pharmacologic or genetic alterations, activation of Raf and 
the mitogen-activated protein kinase (MAPK) pathway was observed. Mutations 
in the P-loop of Raf prevented this autoinhibitory phosphorylation and thereby 
activated Raf in cancer. This was shown using an overexpression system in 
which phospho-mimetic and phospho-dead mutants of serine 359 in C-Raf alter 
the paradoxical activation response to Raf inhibitors. MDA-MB-231 cancer cells 
that harbor a G464V mutation in B-Raf, which prevented this autoinhibitory 
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phosporylation, were also used. Treatment of MDA-MB-231 cells with a RAF 
inhibitor reduced pERK levels, and importantly, no activation was observed 
suggesting that P-loop phosphorylation of BRAF is critical for compound-induced 
paradoxical activation of the MAPK pathway.  
 A mechanism involving the P-loop of Raf could in part account for the 
compound-mediated activation of the MAPK pathway observed with nucleotide 
exchange activators.  To test this, I treated MDA-MB-231 cells with either 
compound 4 or dabrafenib.  As reported in literature, dabrafenib only inhibited 
MAPK signaling in these cells, and no activation was observed (Figure 5-
1D).(103) In a similar manner, compound 4 only inhibited MAPK signaling in 
these cells, and no activation was observed (Figure 5-1D).  These data suggest 
that the peak in ERK phosphorylation observed with nucleotide exchange 
activators is mediated by relief of the autoinhibitory phosphorylation of the P-loop 
of Raf. In contrast to normal cells, in cells in which this autoinhibitory 
phosphorylation is not possible, such as the MDA-MB-231 cells shown, only the 
inhibition phase elicited by these compounds is observed. This was further 
shown in Figure 5-2 which contrasts the signaling observed in HeLa cells (wild-
type Raf) with that observed in MDA-MB-231 cells (P-loop mutant) as elicited by 
compound 4 or three distinct Raf inhibitors.  In each case, paradoxical activation 
was seen with both the Raf inhibitor and compound 4 in HeLa cells, and was 
changed to an inhibitory phenotype in MDA-MB-231. These data support the 
hypothesis that the observed activation of MAPK signaling in cells following 
nucleotide exchange activator treatment results in part from the activation of Raf 
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through relief of an autoinhibitory phosphorylation on the P-loop.  These data do 
not however explain how the inhibition phase observed with these compounds in 
the MAPK pathway is brought about.  Further investigation into whether this is 
also regulated at the level of the Ras-Raf interaction is warranted and 
experiments to test this hypothesis are proposed in Chapter VI.  
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Figure 5-2. Biphasic response in MAPK signaling converted to inhibition in 
cells harboring a P-loop mutation in B-Raf. Lysates from HeLa and MDA-MB-
231 cells treated for 30 minutes with varying concentrations of compound 4 or (A) 
sorafenib, (B) vemurafenib, (C) dabrafenib were analyzed by western blot.  
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Investigating Compound-Induced Activation of a Negative Feedback Loop 
Involving EGFR 
 Engaging a common negative feedback loop governing the MAPK and 
PI3K pathways represents an alternative hypothesis for how the perturbed 
signaling downstream of Ras may be brought about by nucleotide exchange 
activators.  During the characterization of compound 4 described in Chapter III, I 
showed that pretreatment with compound 4 had little to no effect on the ability of 
EGF to stimulate EGFR as evidenced by autophosporylation of tyrosine 1068 in 
response to EGF (Figure 5-3A). Treatment with compound did however block 
EGF stimulation of AKT and ERK phosphorylation supporting the hypothesis that 
these compounds act at the level of the Ras-SOS interaction downstream of the 
receptor tyrosine kinase. When this experiment was repeated to investigate the 
effect of longer pretreatment times, a lack of EGFR responsiveness to EGF was 
observed as shown in Figure 5-3B.   
 In order to investigate this further, an experiment was conducted in which 
the pretreatment time with compound 4 was varied followed by stimulation with 
EGF for 5 minutes (Figure 5-4).  This experiment revealed that EGFR was 
desensitized to extracellular ligand stimulation after 15 minutes of treatment with 
compound 4, and that longer pretreatment times resulted in greater 
desensitization. This desensitization process was also contrasted with direct 
inhibition of EGFR.  Erlotinib (10 µM) produced a complete inhibition of EGFR 
response to EGF within 2 minutes of treatment with no time dependence 
observed.  This suggests that the observed responsiveness of EGFR to 
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extracellular ligand was not due to direct inhibition, but rather an indirect 
desensitization of the receptor. In addition, the time dependent nature of this loss 
in responsiveness to extracellular ligand stimulation led me to hypothsize that a 
negative feedback loop may have been triggered, which in turn downregulates 
EGFR and possibly signaling to downstream pathways. 
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Figure 5-3. Compound pretreatment time alters EGFR responsiveness to 
EGF. HeLa cells were pretreated for either (A) 5 minutes or (B) 1 hour with 
100µM compound 4 followed by stimulation with 50 ng/ml EGF. Lysates were 
analyzed by western blot.  
 
 
 
 
 
Figure 5-4. Desensitization of EGFR occurs after 15 minutes and is distinct 
from direct inhibition. HeLa cells were pretreated with either compound 4 
(100µM) or Erlotinib (10µM) for 0-60 minutes followed by stimulation with 50 
ng/ml EGF for 5 minutes. Lysates were analyzed by western blot.  
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 Extracellular ligand binding results in receptor dimerization, 
autophosphorylation, activation of downstream signaling, and receptor 
internalization each of which is regulated by the phosphorylation of specific 
residues on EGFR.  In order to investigate the mechanism underlying compound-
mediated desensitization of EGFR to EGF, I repeated the experiment varying the 
compound pretreatment time and probed by western blot for multiple 
phosphorylation sites on EGFR using phosphospecific antibodies available from 
Cell Signaling Technology (Figure 5-5).  Notably, different tyrosine 
phosphorylation patterns were observed.  A time-dependent desensitization of 
EGFR was observed as a reduction in phosphorylation in response to EGF at 
residues Y845, Y992, Y1045, Y1068, and Y1173.   
 Each of the tyrosine residues that demonstrated a loss of responsiveness 
to EGF following compound pretreatment is responsible for regulating different 
functions of the protein. Phosphorylation of Y845 by c-Src stabilizes the 
activation loop of EGFR, keeps it in the active form, and serves as a docking site 
for substrate proteins.(183, 184) PLCγ binds to phosphorylated Y992 and 
activates downstream signaling.(185) When phosphorylated, Y1045 is bound by 
c-Cbl allowing for receptor ubiquitination and subsequent degradation.(186, 187) 
The MAPK signaling pathway is activated by GRB2 relaying signals to SOS 
when EGFR is phosphorylated at Y1068.(188) Phosphorylation of Y1173 allows 
for further activation of the MAPK signaling pathway by serving as a docking site 
for Shc, another adaptor protein.(189)  
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 Two phosphorylation sites on EGFR showed distinct phosphorylation 
patterns in response to compound pretreatment when I compared the five 
tyrosines described above. T669, an inhibitory phosphorylation site on the 
juxtamembrane region of EGFR, showed no change.(190)  Even more 
noteworthy, phosphorylation of serine residues S1046/S1047 increased with 
longer pretreatment times of compound 4. The timing of the increase in 
phosphorylation of S1046/S1047 signaling pattern was similar to the timing of 
desensitization at the other tyrosine sites.  Phosphorylation at these serines has 
been reported to regulate internalization and downregulation of EGFR, and 
internalization of the receptor could offer an explanation for the lack of 
responsiveness of EGFR to EGF observed at the other sites.   
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Figure 5-5. EGFR phosphorylation events in response to compound 
pretreatment and EGF stimulation. HeLa cells were pretreated with either 
Compound 4 (100µM) or Erlotinib (10µM) for 0-60 minutes followed by 
stimulation with 50 ng/ml EGF for 5 minutes.  Lysates were analyzed by western 
blot.  
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  I sought to determine whether the phosphorylation of EGFR at serines 
1046 and 1047 was specific to the proposed mechanism of action of nucleotide 
exchange activators at the level of the Ras-SOS interaction.  In order to test this, 
I used siRNA to silence SOS in HeLa cells. Following transfection with SOS1 and 
SOS2 targeting siRNAs or a non-targeting control siRNA, HeLa cells were 
cultured for four days at which point cells were pretreated with compounds and 
stimulated with EGF as conducted previously.  Protein was collected and 
analyzed by western blotting to determine the expression levels of SOS1 protein. 
siRNA constructs targeting SOS efficiently reduced SOS protein levels as shown 
in Figure 5-6. Phosphorylation of S1046/S1047 increased in a time-dependent 
manner in the non-targeting control, and this phosphorylation was abrogated by 
silencing of SOS protein levels.  Despite prevention of this phosphorylation event 
by SOS silencing, no rescue of the sensitivity or EGFR responsiveness to EGF 
or rescue of downstream signaling was observed.   
 
 
Figure 5-6. Silencing SOS abrogates EGFR phosphorylation on serines 
1046 and 1047. Lysates from HeLa cells were pretreated with either compound 4 
(100µM) or Erlotinib (10µM) for 0-60 minutes followed by stimulation with 50 
ng/ml EGF for 5 minutes. 
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Discussion 
Nucleotide exchange activators, discovered using fragment-based and 
high-throughput screening methodologies, increased Ras-GTP levels in cells and 
perturbed signaling downstream of Ras.  Despite the increased Ras-GTP levels, 
the signaling downstream of Ras observed following compound treatment did not 
conform to a linear increase in signaling through the canonical PI3K and MAPK 
signaling pathways as expected.  Paradoxically, biphasic MAPK pathway 
signaling response is accompanied by an inhibition of signaling in the PI3K 
pathway.  Possible explanations for this signaling may be due to: 1.) off-target 
activities of the compounds that are not specific to the Ras-SOS interaction or 2.) 
a specific, as of yet uncharacterized, mechanism of action involving Ras and 
SOS .  Experiments to test each of these have been reported throughout the 
course of this dissertation. 
Global and candidate approaches have been taken to identify possible off-
target activities and distinguish those from the activities specific to the ability of 
the compounds identified in Chapters III and IV to alter the Ras-SOS interaction. 
Defined structure-activity relationships are present within the amino-piperidine 
indole series identified in Chapter III as well as the benzimidazole series and 
quinazoline series from Chapter IV.  This knowledge, paired with structure-based 
ligand design, has enabled the discovery of closely related compounds that lack 
activity in in vitro nucleotide exchange assays to serve as negative control 
compounds for cell-based experiments. These closely related negative controls 
indeed elicited no response in the MAPK or PI3K pathways. In addition to 
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negative control compounds, I was able to show in Chapter III that the activity of 
nucleotide exchange activators in cells closely correlates with their activity in 
biochemical nucleotide exchange experiments.  While the mechanism underlying 
the signaling is still under investigation, the ability of multiple distinct chemical 
series to activate nucleotide exchange in a manner that correlates closely with 
their biochemical activity provides strong evidence that the observed signaling is 
specific to the ability of these compounds to alter the Ras-SOS interaction.  
A candidate approach was also  used to further rule out potential off-target 
activities. Since the observed signaling following treatment with compounds was 
rapid and involved perturbed signaling in well-described kinase signaling 
cascades involved in cancer, we sought to exclude any direct activities on 
kinases within these pathways.  To do this and rule out activity on this diverse 
class of small molecule targets, three nucleotide exchange activators were tested 
at 20 µM in kinase assays conducted using 342 oncology related kinases in vitro. 
These experiments were conducted by Reaction Biology Corp. While the 
quinazoline series identified in Chapter IV displayed activity against a significant 
number of kinases, compound 4 from Chapter III and VU0484204 a more active 
analogue of VU0145298 showed vitrually no activity on any of these kinases at 
20 µM, a concentration at which each perturbs Ras-signaling in cells.  
In addition to testing large kinase panels for off-target activities, a 
candidate approach was taken to test whether these compounds had activity on 
closely related Ras-GEFs.  Residues forming the ligand binding pocket in SOS1 
have a 30% identity with the Ras-specific GEF Ras-GRF1. No activation of Ras-
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GRF1-catalyzed nucleotide exchange was observed upon compound addition. 
While this result suggests that these compounds maintain a degree of specificity 
for SOS1 over Ras-GRF1, sequence and structural alignments of the CDC25 
domain of SOS1 with other GEF proteins suggest that a similar pocket may exist 
in other GEFs. If these compounds perturb cellular signaling due to their activity 
on a protein other than SOS, then it is likely that one of these GEFs with a 
closely related ligand-binding pocket is responsible for that activity.   
siRNA experiments in cells in which the expression of SOS1 and SOS2 
was silenced in order to distinguish specific SOS activities from others only 
resulted in a partial loss of signaling following treatment with compounds. This 
partial rescue in signaling made it difficult to draw conclusions regarding 
specificity from this experiment.  The partial remaining signaling could be due to 
a small amount SOS protein remaining in the cells or activity on a closely related 
Ras-GEF.  It should also be considered that as these molecules are modified and 
improved, any off target activities these compounds do have is likely to change.  
Repeated specificity experiments should be conducted in the future to provide a 
better understanding of the mechanism of action of these compounds and to 
guide lead optimization to avoid off-target activities.   
In parallel to investigating potential off-target driven activities of these 
compounds, negative feedback loops regulating Ras-signaling that could account 
for the biphasic MAPK response and inhibition of PI3K signaling were 
investigated.  Two separate emerging hypotheses are that this signaling is 
regulated at the level of the Ras-Raf interaction or due to a negative feedback 
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loop involving EGFR.  Experiments to support each of these has been provided 
in this chapter; however, further investigation is required in order to gain a 
complete understanding of how this signaling occurs. 
The paradoxical signaling observed in the MAPK pathway is reminiscent 
of the paradoxical activation induced by B-Raf inhibitors in the setting of wild-type 
Raf. This observation suggests that both events may be regulated at the level of 
the Ras:Raf interaction.  In cells with wild-type B-Raf, paradoxical activation of 
MAPK signaling is observed with B-Raf inhibitors, and this is intensified by the 
presence of a mutant Ras.(104) In this same setting, compound 4 elicited 
signaling similar to Raf inhibitor-induced paradoxical activation. However, in 
contrast to dabrafenib, no effect was seen following treatment with compound 4 
in MALME-3M cancer cells or RKO cells, which each harbor a V600E mutation in 
B-Raf. This suggests that the common biphasic signaling pattern elicited by 
these two compound classes is brought about through distinct mechanisms.  
Raf dimerization underlies the paradoxical activation in the case of B-Raf 
inhibitors, and, while Ras has been implicated in this, the biochemical and 
structural role of Ras in this process remains to be elucidated.(101, 141) The 
new discovery of an autoinhibitory phosphorylation site on Raf led me to conduct 
experiments wherein I showed that mutation in the P-loop of Raf changes the 
biphasic signaling observed to only an inhibition phase. Based on the importance 
of Ras in Raf inhibitor-induced paradoxical activation and the data presented in 
this chapter, it is tempting to hypothesize that the entire signaling observed 
following treatment with compound 4 is regulated at the level of the Ras-Raf 
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interaction. The experiments shown in this chapter only suggests that the peak in 
ERK phosphorylation observed with nucleotide exchange activators is mediated 
by relief of the autoinhibitory phosphorylation of the P-loop of Raf.(103) Further 
investigation of how these compounds alter the Ras-Raf interaction, and other 
interactions, will be required to understand how the inhibition of MAPK signaling 
is brought about.  
An alternative hypothesis to altering Ras-effector interactions is that 
signaling events presented here result from negative feedback regulation, and I 
have identified an inhibitory phosphorylation site on EGFR that is regulated in 
both a compound and SOS-dependent manner.  The discovery that S1046 and 
S1047 are phosphorylated following compound treatment represents a significant 
finding because this phosphorylation event was inhibitory and regulated 
internalization and downregulation of EGFR.(174-178) EGFR is a common 
component to both the MAPK and PI3K signaling pathways, and its 
downregulation could account for the inhibitory phase of both. The observation 
that the phosphorylation of S1046/S1047 is abrogated following siRNA silencing 
of SOS demonstrates that this event is specific to our proposed target identified 
in vitro. The lack of rescue of EGFR responsiveness to EGF and a failure to 
prevent perturbed ERK signaling following SOS siRNA make it difficult to draw 
any firm conclusion. If this phosphorylation was truly regulating these signaling 
events, then a lack of phosphorylation should have prevented them. It is possible 
that a small amount of phosphorylation, below the limit of detection, was still 
present and accounted for the continued desensitization and reduction in 
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signaling. Further experiments will be required to determine this, and to 
determine if this phosphorylation results in a subsequent internalization and 
degradation of the receptor as suggested in literature.  It may be possible that the 
phosphorylation event is unrelated to the observed signaling downstream. 
Nonetheless, it will be important to investigate because it is specific to both 
compound and SOS, and it may hold implications for how these compounds can 
be used for the treatment of cancer.  
 
Materials and Methods 
Cell Culture 
HeLa cells, cultured in DMEM supplemented with 10% fetal bovine serum, 
were treated with DMSO control or compound as indicated. CHL-1, RKO, 
MALME-3M, and MDA-MB-231 cells were obtained from the ATCC and cultured 
similarly in complete growth media as recommended. Lysates from each sample 
were analyzed by SDS-PAGE and western blotting using Immobilon-FL PVDF 
membranes (Millipore) and scanned on Odyssey imager (LiCor). Antibodies for 
ERK, phospho-ERK, MEK, phospho-MEK, AKT, phospho-AKT473, phospho-
EGFR (Y1068), phospho-EGFR (T669), phospho-EGFR (Y845), phospho-EGFR 
(Y992), phospho-EGFR (Y1045), phospho-EGFR (S1046/S1047), phospho-
EGFR (Y1173), and total EGFR were obtained from Cell Signaling. Dabrafenib, 
Vemurafenib, Sorafenib, and Erlotinib were obtained from Selleck Chemicals, 
dissolved in DMSO, and used at the concentrations indicated.  
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For Figures 5-3 through 5-6, HeLa cells were serum-starved overnight, 
prior to compound pretreatment and EGF stimulation (R&D Systems).  For Figure 
5-6, cells transfected with SOS1 and SOS2 targeting siRNAs (Dharmacon) were 
cultured for four days at which point cells were serum-starved and treated as 
described. Cells were plated in 12-well dishes at a seeding density of 50,000 
cells/well and transfection was conducted with DharmaFECT1 transfection 
reagent. Protein was collected and analyzed by western blotting to determine 
expression levels of SOS1 protein.  
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CHAPTER VI 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Introduction 
Targeting Ras with small molecule inhibitors has proved challenging for 
the scientific community. However, new methodologies and an improved 
understanding of its biology has reinvigorated efforts to target Ras, arguably the 
most common oncogene in human cancer.(74) Attempts to inhibit Ras in cancer 
include by direct targeting, hindering membrane localization, and blocking 
downstream effectors. Ongoing approaches to target Ras include inhibiting 
synthetic lethal interaction partners and/or targeting Ras with an interfacial 
inhibitor, while it is engaged in a protein-protein interaction. While significant 
obstacles must be overcome before a bona fide Ras-directed therapeutic will be 
available in the clinic, each of these approaches holds promise for patients with 
Ras-driven cancers. 
The work presented in this dissertation has focused on the direct targeting 
of Ras with small molecules and targeting Ras through its interaction with the 
guanine nucleotide exchange factor SOS.  Both approaches have resulted in the 
discovery of small molecules that modulate the Ras:SOS interaction, either by 
inhibition or activation, and each has provided insights into how this important 
node in Ras signaling can serve as a novel point of intervention in cancer. 
Outstanding questions must be addressed to fully understand the mechanism of 
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action underlying the how the function of these activators in both biochemical 
assays and in cells.  A discussion of the work described in Chapters II-V is 
provided here along with possible future experiments stemming from this work.  
Discussion and Future Directions for Inhibitors of the Ras-SOS Interaction 
Small molecules that bind directly to Ras were identified from a fragment-
based screen in Chapter II, and I demonstrate that these small molecules were 
capable of inhibiting SOS-catalyzed nucleotide exchange on Ras in a competitive 
manner. These ligands bind between the switch I and switch II regions of Ras, 
which are critical for SOS-catalyzed nucleotide exchange. 
The work presented in Chapter II, and a similar effort by Maurer et al., 
showed that molecules that bind to Ras between switch I and switch II inhibit 
SOS-catalyzed nucleotide exchange through a competitive mechanism of 
action.(21) The binding site is in a functionally important location between the 
switch I and switch II regions of Ras, which are involved in Ras-GEF, Ras-GAP, 
and effector interactions.  Indeed this binding site overlaps with the SOS-
interaction area, which suggested that they would inhibit SOS-binding. The 
finding that the inhibition of nucleotide exchange by compounds 8-13 in Chapter 
II was due to preventing Ras binding to SOS as shown by NMR, was supported 
by independent affinity pulldown experiments conducted by Mauer et al.(21) 
SOS1 and RasGRF1 share sequence and structure homology and the hydrogen 
bonding interactions between Ras and SOS are likely conserved in the complex 
of Ras and RasGRF1 suggesting that this interaction could also be inhibited.  
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Experiments to examine the ability of compounds identified in Chapter II to 
inhibit effector binding are warranted in the future. These molecules must be first 
tested to deterimine if and how they bind to GTP-bound K-Ras. Switch I and 
switch II undergo conformational changes when transitioning from GDP to GTP 
enabling effector binding when Ras is in the GTP-bound “on-state”.  Smaller 
compounds including DCAI and early fragment hits identified in Chapter II do not 
extend over switch I and therefore would not be able to interfere with effectors 
such as Raf that bind solely to switch I.  
Extended molecules such as the amide-linked amino acid analogues of 
the indole-benzimidazole fragment 7 in Chapter II, which contain positively 
charged amine groups, do reach over switch I. X-ray crystal structures showed 
that the amino acid side chain does indeed extend over switch I and the 
positively charged amino group of the amino acid interacts with the carboxylic 
acid side chain of Asp-38 in the secondary binding cleft (Figure 2-4B). This would 
be predicted to interfere with Raf binding based on structural overlays with the 
Ras-Raf complex; however, it assumes that the compounds bind to GTP-bound 
K-Ras in a similar manner to how they bind GDP-bound K-Ras.  While ligands 
that contain an indole moiety, including DCAI and compounds 8-13 from Chapter 
II, bind to the GTP-bound form of Ras, the space available in the electronegative 
secondary cleft is reduced.  This may prevent compounds 8-13 from reaching 
over switch I when Ras is in the GTP-bound form affecting their ability to inhibit 
effector binding.  Further investigations into how these compounds and next 
generation Ras binders influence protein-protein interactions when Ras is in 
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either the GDP- or GTP-bound form may provide insights into how to design an 
inhibitor that prevents signaling through all effector arms downstream of Ras. 
The possibility remains that the compounds identified in Chapter II may 
alter the function of Ras through an unforeseen or untested mechanism. 
Compounds in Chapter II were specifically tested using in vitro biochemical and 
biophysical assays for their ability to bind to Ras and block protein-protein 
interactions. Due to their high micromolar binding affinities to Ras, these 
compounds were not tested in cell-based experiments.  It is plausible that these 
compounds could inhibit Ras by altering its localization or triggering its 
degradation in cells.  Membrane localization of Ras is required for Ras-mediated 
transformation, and evidence that DCAI was able to inhibit effector recruitment 
and EGF stimulated Ras signaling suggests that further investigation of these 
compounds in cells is warranted.(9, 10, 21)  Molecules with improved affinity and 
suitable cell permeability will allow for conclusions to be drawn from such 
experiments with increased confidence.  
 For the small molecules reported in Chapter II, the challenge moving 
forward is to discover analogs with large improvements in affinity. Structure-
based drug design efforts will by aided by the X-ray crystal structures provided.  
However, the lack of nearby hydrophobic pockets presents a challenge as shown 
by the design efforts in Chapter II in which large compounds that were able to 
reach into the electronegative binding cleft only yielded an affinity as low as 190 
µM.  Compounds have been discovered that bind to a pocket between the α2 
and α3 helices, on the other side of the switch II region as the compounds in 
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Chapter II.(113) This site is similar to where SCH-54292 was hypothesized to 
bind to Ras based on NMR data.(106) By linking compounds that bind to these 
two sites, a large improvement in binding affinity could be obtained.(118)  
However, doing so would either require a linker that goes around the entire 
switch region or buries through the protein, each of which remains a significant 
obstacle. An alternative to linking to a distant second site binder that has been 
reported would be to screen to fragments that bind to a nearby second site.  
Efforts to accomplish this task are currently underway in the Fesik Lab, and they 
represent a possible approach to improve the affinity of these molecules. 
Future Directions for Activators of SOS-catalyzed Nucleotide Exchange on 
Ras  
Chapters III-VI report the discovery and characterization of small 
molecules that activate SOS-catalyzed nucleotide exchange in vitro, bind to the 
Ras:SOS:Ras complex, and modulate Ras signaling pathways in cells. These 
molecules were identified in two separate screens: a fragment-based NMR 
screen for direct binding ligands to Ras which serendipitously led to compounds 
that activated SOS-mediated nucleotide exchange and a high-throughput screen 
for compounds that altered the rate of SOS-catalyzed nucleotide exchange on 
Ras. Biochemical, cellular, and structural data on these compounds are being 
used to drive the design of improved compounds for future studies, while the 
mechanism of action underlying the biphasic MAPK response and inhibition of 
PI3K is under investigation.   
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The discovery of activators of SOS-catalyzed nucleotide exchange that 
bound to the CDC25 domain of SOS in the Ras:SOS:Ras complex was 
unanticipated from the fragment screen. The initial NMR fragment-based screen 
described in Chapter II was conducted with the aim to identify small molecules 
that bound directly to K-RasG12D.  During the course of this investigation, 
focused chemical libraries were prepared around each NMR hit, and compounds 
were subsequently tested for the binding affinity to Ras by NMR and for their 
ability to inhibit SOS-catalyzed nucleotide exchange.  That select molecules 
activated nucleotide exchange at a concentration an order of magnitude below 
the affinity of any molecules that bound to directly to Ras at the time presented 
an opportunity to investigate an important, albeit unanticipated observation.  The 
X-ray crystal structures revealed that binding to Ras was irrelevant and defined 
the pocket on the Ras:SOS:Ras complex as the cause for their activity. 
Mutational analyses vased on the X-ray structures confirmed that this pocket was 
responsible for the compound-induced activation of nucleotide exchange.   
Residues forming this pocket in SOS1 have a 30% identity with the Ras-
specific GEF Ras-GRF1, and a conserved pocket can be observed in other 
GEFS and adaptor proteins containing a CDC25-homology fold. No activation of 
Ras-GRF1-catalyzed nucleotide exchange was observed upon compound 
addition. This result suggests that these compounds maintain a degree of 
specificity for SOS1 over Ras-GRF1. Nevertheless, sequence and structural 
alignments of the CDC25 domain of SOS1 with other GEF proteins suggest that 
a similar pocket exists in other GEFs (Figure 6-1). For example, Ras-GRF1 
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adopts a similar fold with the helices closely aligning with the αD, αE, and αF 
helices of SOS1 that form the compound-binding pocket. The conservative 
change from tyrosine to phenylalanine at position 884 corresponding to SOS 
would be unlikely to account for the inactivity of these compounds with respect to 
RasGRF-catalyzed nucleotide exchange. Changes in the bottom of the pocket 
such a F890!W or changes to critical side chains involved in forming the pocket 
such as D887!K or H905!Q could account for the loss of activity (Figure 6-1B) 
(numbering corresponding to residues of SOS1). Indeed each of these residues 
was mutated in Chapter III and IV, and each is important for compound binding.   
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Figure 6-1.  Multiple sequence alignment and structural overlay of SOS with 
other GEFs provides evidence for a conserved ligand-binding pocket.  (A) 
Multiple sequence alignment of SOS1 with eight selected GEFs shows 
conservation of the ligand-binding pocket identified.  Highlighted residues 
indicate identity with human SOS1. Version number and GI are provided for 
referencing. (RasGRF1= alignment 3, SH2 containing protein 3A= alignment 9) 
(B) Structural overlay of the Ras:SOS:Ras:Compound 1 (SOS, Ras, and 
compound are colored in grey, red, and blue, respectively) complex from Chapter 
III with human RasGRF1 (Orange, PDB: 2IJE).  Residues changes located in the 
ligand-binding pocket are shown as sticks and labeled. (C) 
Ras:SOS:Ras:Compound 1 overlayed with SH2 containing protein 3A (BCAR3) 
(Green, PDB: 3T6A). Four residue changes are indicated; however, further 
changes were excluded for visualization purposes. 
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        The similarity between the pocket on SOS1 and other GEFS suggests likely 
candidates through which off-target driven activities could arise for these 
molecules in related GEF family members. On the other hand, this discovery also 
suggests that targeting this conserved pocket may represent a unique approach 
to alter the function of these closely related proteins. For example, RasGRP 
proteins play an important role in tumorigenesis in skin- and hematological-
cancers, and the molecules presented here may serve as starting points for the 
discovery molecules targeting these proteins.(191) The effect of similar 
compounds that bind to SH2 domain-containing protein 3A (a.k.a BCAR3), a 
CDC25-homology fold containing protein that has lost enzymatic activity and 
serves as an adapter protein for cellular signaling, would also be of interest to 
target.(192)  
 While these proteins share little sequence homology with SOS overall 
(Figure 6-1A), the CDC-25 homology fold and conservation of a similar binding 
pocket (Figure 6-1C) suggests that analogues of the nucleotide exchange 
activators can be found that bind to this protein. A wide variety of nucleotide 
exchange activator series were identified in Chapters III and chapters IV, and 
>1000 analogues of these activators that have been either purchased or 
synthesized within the Fesik lab since the start of this project. This allows the 
possibility of conducting a focused screen. Screening a focused library of 
nucleotide exchange activator-like molecules for activity against these closely 
related GEF proteins would be feasible and likely to identify molecules active 
against these targets of potential interest and compounds that could display off-
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target activities.  
In addition to designing molecules targeting closely related proteins, the X-
ray crystal structures obtained suggest approaches to switch the function of 
these activators to inhibitors.  Given the close proximity of the compound binding 
site to the SwII region of Ras, it may be possible to design interfacial inhibitors 
using the activators identified as a starting point. An example of an interfacial 
GTPase:GEF inhibitor is provided by Brefeldin A, which targets the Arf1-Sec7 
domain complex by interacting both with the switch II region of the GTPase and 
the GEF.(135) Analogous interfacial inhibitors, anchored in this newly identified 
pocket on SOS, could render Ras incapable of engaging effector proteins by 
forming a dead end GEF:GTPase complex.  
An obvious approach to build molecules that extend towards the switch II 
region of Ras is provided by the space located between the side chains of Y884 
and H905 (Figure 6-2). Not only is this a direction to build toward, but it also 
offers an indication of the space available since multiple water molecules have 
been crystallized in this cleft. One possible criticism of this approach is the 
caveat that if nucleotide exchange activators reduced signaling through 
downstream pathways, would an inhibitor increase it. The effects cannot be 
anticipated and will only be revealed when such a molecule is obtained. 
Secondly, as shown best by studies involving B-Raf inhibitors, each new probe 
capable of targeting a different point within the Ras-signaling pathway has the 
potential to reveal new aspects of Ras biology.  This in turn can provide insight 
	  	   144	  
into how to best use the therapeutics available or how to develop the next 
generation of improved therapies.  
 
Figure 6-2. Building toward the Ras-SOS interface. Surface projection of 
compound 2 bound to the Ras:SOS:Ras complex.  SOS (grey) is bound by Ras 
(orange) at the catalytic site and ligand (blue). Unoccupied space located 
between residues H905 and Y884 is indicated by the arrow.  
 
 
H905% Y884%
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The structure of the ligand-bound CDC25 domain closely resembles that 
of the CDC25 domain in the ligand-free structures. In Chapter III, the structure of 
the Ras:SOS:Ras cocomplexed with compound 3 was superimposed on the 
known structures of the CDC25 domain core of SOS1, and the pocket was 
available for compound binding in 77% of the known structures. Two structures 
contain the side chain of H905 occupying the indole binding pocket (PDB: 1XD4, 
3KSY).  In all of the previously reported structures, phenylalanine 890 occupies 
the “down” position. This implies that this is the native conformation for SOS 
alone or when bound by Ras in a binary or ternary complex. There may be an 
energy cost to flippling this residue into the up position.  Whether this has an 
implication for the affinity of the high-throughput screening derived compounds, 
which bind with the F890 in the “up” position, has not been determined.  
The maximum rate of nucleotide exchange induced by different nucleotide 
exchange activators varies.  Compounds have been identified that activate 
nucleotide exchange by 50, 100, or even 200% compared to the rate of SOS-
catalyzed nucleotide exchange over the intrinsic value. Two parameters for 
nucleotide exchange can therefore be measured: the half maximal effective 
concentration (EC50) and the maximal percent activation (maximum rate elicited 
by an individual compound). This observation draws into question whether the 
binding affinity of these compounds dictates EC50 or maximal percent activation.  
Further investigations into this question will require the development of an assay 
to directly measure compound binding affinity instead of biochemical activity.  In 
Chapter III, this was accomplished by FITC-labeling compound 4 and conducting 
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a fluorescence polarization assay to determine binding affinity. While proven 
feasible, this methodology is not amenable to each compound series due to the 
difficulty in identifying an attachment point to add the FITC- fluorophore. 
Alternative approaches including surface plasmon resonance may enable the 
determination of compound binding affinities with higher-throughput to determine 
whether affinity coorelates best with EC50 or maximal percent activation.   
The question of what effect each of these biochemical parameters will 
have on cellular responses to these compounds also remains to be determined.  
Lower biochemical EC50 correlated with activity in cells at lower concentrations of 
compound within the amino-piperidine indole series.  However, maximal percent 
activation in this series is held relatively constant.  Whether increases in maximal 
percent activation will translate to a larger peak in ERK phosphorylation or alter 
the signaling observed in some way will require a more comprehensive analysis. 
To test this, a simple experiment can be conducted in which compounds with 
similar EC50’s and varying maximal percent activation are tested in cells.  A small 
number of compounds could be tested and analyzed by western blot as shown in 
Chapters III-VI.  Alternatively, In-Cell Western analyses and AlphaScreen 
SureFire assays could be used to study endogenous proteins from signal 
transduction pathways downstream of Ras in a higher-throughput format.  
Improved compounds will aid in answering many of the outstanding 
questions that remain surrounding nucleotide exchange activators and enable  a 
thorough investigation of this approach as a way to target Ras in cancer. To 
improve the activity of the nucleotide exchange activators, I have been testing 
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compounds synthesized in the Fesik lab in the nucleotide exchange assay which 
has served as this project’s primary assay. Results from this assay and 
collaborations with structural biologists and medicinal chemists in the Fesik lab 
have enabled the rapid improvement of these compounds through an iterative 
cycle of testing and synthesis. Results from this investigation will aid in the 
optimization of future compounds, improve our understanding of how these 
molecules function, and provide insight into their potential utility to treat Ras-
driven cancers. 
How these compounds activate SOS-catalyzed nucleotide exchange at 
the molecular level is also an area of interest.  The X-ray crystal structures 
obtained have provided a snapshot of these compound bound to the 
Ras:SOS:Ras complex; however, large conformational changes in Ras and SOS 
take place during the process of nucleotide exchange. How these compounds act 
at each stage in nucleotide exchange in order to lead to an increase in nucleotide 
exchange remains to be elucidated. This is particularly important with respect to 
how these compounds elicit different activities in biochemical assays.  The 
movement of the phenylalanine residue within the pocket is the largest 
conformational change observed to date. These differences however cannot 
explain how different compounds elicit greater or lower maximal rates of SOS-
catalyzed nucleotide exchange.  These compounds could also activate 
nucleotide exchange by either increasing the affinity of Ras for the catalytic site 
of SOS or by increasing the rate of GDP dissociation from Ras, the rate-limiting 
step in nucleotide exchange. These important mechanistic details into how these 
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compounds act could shed light on how SOS activates of Ras and potentially 
reveal new ways to inhibit the Ras:SOS interaction. 
The mechanism of action underlying the perturbed signaling downstream 
of Ras following compound treatment remains to be elucidated. The paradoxical 
signaling observed in MAPK the pathway is reminiscent of the paradoxical 
activation induced by B-Raf inhibitors in the setting of wild-type Raf. This 
observation suggests that both events may be regulated at the level of the 
Ras:Raf interaction.  The observation that the biphasic response pattern can be 
abrogated by V600E mutations in B-Raf or changed to solely an inhibitory 
response by mutations in the P-loop of B-Raf suggests that the Ras-Raf 
interaction may have some bearing on the MAPK signaling elicited by these 
compounds.  While the mechanism governing the inhibition observed at high 
concentrations remains unclear, the peak in ERK phosphorylation is likely due to 
a relief of an inhibitory autophosphorylation on the P-loop based on the results 
obtained using the MDA-MB-231 cell line and the paradoxical activation 
mechanism elucidated.(103)  
To further investigate this, I have cloned phosphomimetic and 
phosphodead mutant versions of the serine 359 located on the P-loop of C-Raf 
into a mammalian expression vector in addition to the wild-type protein.  Using 
these proteins, I am designing an experiment in which each protein is 
overexpressed in mammalian cells followed by compound treatment and western 
blot analysis.  If the peak in ERK phosphorylation results from the relief of 
autophosphorylation of the P-loop following treatment with the nucleotide 
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exchange activators, then three results might be expected. First, a biphasic 
MAPK signaling response will be observed when wild-type C-Raf is 
overexpressed as seen previously.  Second, an inhibition signaling pattern only 
will be observed when C-RafS359A is present similar to that seen in the MDA-
MB-231 cell line, since this Raf construct does not permit the inhibitory 
phosphorylation.  Third, the phosphomimetic C-RafS359D should prevent any 
peak in MAPK activity from being observed, since it will remain in the inhibited 
state.  These experiments will provide insights into how Ras activates Raf, and 
potentially reveal new aspects of how the biphasic signaling in response to 
nucleotide exchange activators is brought about.  
There is an ongoing hypothesis that the inhibition of PI3K signaling and 
MAPK signaling, at high concentrations of compound, results from a negative 
feedback loop following treatment of cells with nucleotide exchange activators. 
The identification of an inhibitory phosphorylation site on EGFR that is regulated 
in both a compound and SOS-dependent manner is of interest; however, it is 
currently unclear if this is related to the PI3K and MAPK signaling observed or a 
distinct, unconnected activity of these compounds. Immediate future directions 
for this aspect of the project involve determining whether this phosphorylation 
event results in an internalization and degradation of the EGF receptor as 
described in literature. Degradation can be easily studied by western blot using 
an extended timecourse of compound treatment. Internalization of receptor is 
being investigated by confocal microscopy.  Immunofluorescence antibodies 
directed against the EGF receptor have been identified as suitable for these 
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studies.  Additionally, the full length EGF receptor as well as constructs 
containing phosphomimetic and phosphodead mutations of serines 1046 and 
1047 have been cloned into a mammalian expression vector to verify that either 
internalization and/or degradation are specifically regulated by phosphorylation at 
this site. Since this inhibitory phosphorylation event has been shown to be 
specific to both compound and SOS, it represents a promising avenue of 
research on novel aspects of a negative feedback loop, regardless of whether it 
is related to the MAPK and PI3K signaling observed.  
 
Conclusion 
Despite being considered one of the most highly validated targets in 
cancer, clinically efficacious inhibitors of oncogenic Ras have yet to emerge. The 
scientific community has therefore sought unique, functionally active small-
molecules to provide a path forward for the discovery of Ras-targeted 
therapeutics. This dissertation describes the discoveries I have made together 
with other members of the Fesik lab on how small molecules can both inhibit and 
activate SOS-catalyzed Ras activation.  This work provides new insights into how 
the Ras-SOS interaction can be modulated and how specifically perturbing this 
important node can alter signal output through pathways downstream of Ras. 
Multiple novel tool compounds capable of intervening in the Ras signaling 
pathway have been discovered, and powerful approaches to ascertain and 
improve such compounds have been described. Exciting new avenues of 
research have been realized based on this work and further investigation of 
	  	   151	  
these approaches as avenues to inhibit Ras function in cells may enable the 
discovery of therapeutics for the treatment of Ras-driven tumors. 
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APPENDIX I 
 
Final High-Throughput Screening Hits 
 The final high-throughput screening hits including Vanderbilt University 
identification number (VU Number), structure, molecular weight, and activity in 
the nucleotide exchange assay are shown below.   
 
 
Final High-Throughput Screening Hits 
VU Number Structure Mol. Wt. of Structure Activity 
VU0035509 
  
361.8 Inhibitor 
VU0002920 
  
412.5 Inhibitor 
VU0002969 
  
406.5 Inhibitor 
VU0002982 
  
390.5 Inhibitor 
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VU0003018 
  
423.4 Inhibitor 
VU0139276 
 
358.8 Inhibitor 
VU0025212 
  
405.8 Inhibitor 
VU0044463 
  
392.4 Inhibitor 
VU0001947 
  
396.2 Inhibitor 
VU0092104 
  
380.8 Inhibitor 
VU0051909 
  
347.7 Inhibitor 
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VU0064787 
  
423.4 Inhibitor 
VU0064807 
  
329.4 Inhibitor 
VU0102467 
  
374.4 Inhibitor 
VU0104138 
  
504.2 Inhibitor 
VU0096721 
  
302.4 Inhibitor 
VU0100324 
  
431.5 Inhibitor 
VU0100334 
  
395.5 Inhibitor 
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VU0093489 
  
264.3 Inhibitor 
VU0085457 
  
305.6 Inhibitor 
VU0028521 
  
458.7 Inhibitor 
VU0016234 
  
318.1 Inhibitor 
VU0023960 
  
333.4 Inhibitor 
VU0067008 
  
389.4 Inhibitor 
VU0066939 
  
468.3 Inhibitor 
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VU0133701 
  
427.6 Inhibitor 
VU0055123 
  
475.3 Inhibitor 
VU0136043 
  
247.6 Inhibitor 
VU0137079 
  
313.4 Inhibitor 
VU0118544 
  
180.2 Inhibitor 
VU0063275 
  
270.4 Activator  
VU0006265 
  
289.8 Activator  
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VU0063036 
  
350.8 Activator  
VU0002032 
  
428.0 Activator  
VU0087471 
  
384.5 Activator  
VU0019562 
  
336.5 Activator  
VU0061570 
  
281.3 Activator  
VU0145298 
  
326.8 Activator  
VU0124029 
  
404.0 Activator  
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VU0120832 
  
291.4 Activator  
VU0063026 
  
334.4 Activator  
 
	  	   159	  
APPENDIX II 
 
Kinase profiling report for three nucleotide exchange activators 
 In order to identify off-target driven activities, compound 4 from Chapter III, 
VU0486993 a more active analogue of VU0063036, and VU0484204 a more 
active analogue of VU0145298 were tested for their ability to inhibit 342 kinases.  
At a concentration of 20 µM compound 4 only inhibited 1 out of 342 kinases 
supporting the conclusion that it has little to no activity on this class of signaling 
proteins.  VU0484204 was also show to inhibit only a few kinases at 20 µM; 
whereas VU0486993 was shown to significantly inhibit over 100 kinases 
indicating a possible liability to be considered when progressing this quinazoline 
chemical series in the future. Detailed kinase profiling data are provided in table 
below.  Compounds were tested in duplicate at 20µM.  Staurospaurine was used 
as a positive control unless otherwise indicated.  Reactions were carried out 
using 10µM ATP and percent enzyme activity is reported relative to DMSO 
control.  This experiment was carried out by Reaction Biology Corp. 
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Kinase Profiling Report for:   
Vanderbilt University Quote # 20131118-VU 
 
3 compounds tested against 342 kinases. 
          
Compounds were tested in single dose duplicate mode at a concentration of 20 
µM. 
 
Control Compound, Staurosporine, was tested in 10-dose IC50 mode with 4-fold 
serial dilution starting at 20 µM. 
 
Alternate Control Compounds were tested in 10-dose IC50 mode with 3-fold serial 
dilution starting at 20 µM. 
 
Reactions were carried out at 10 µM ATP. 
          
Percent (%) Enzyme activity (relative to DMSO controls) is reported.  
 
*Curve fits were performed where the enzyme activities at the highest 
concentration of compounds were less than 65%. 
          
Enzyme Activity Summary: 
          
          
 
% Enzyme Activity (relative to DMSO controls) 
IC50 (M) 
Staurosporine* 
IC50 (M) 
Alternate 
Control 
cpd*.  
Alternate 
compound 
ID 
 
 VU0484204-1 VU0486993-1 VU0466234-2 
    
Kinase: n=1 n=2 n=1 n=2 n=1 n=2 
ABL1 101.8 104.7 69.1 70.0 96.8 100.2 4.94E-08     
ABL2/ARG 92.6 94.2 66.4 65.1 95.9 97.0 2.01E-08     
ACK1 93.9 94.0 60.7 58.5 92.6 92.1 4.91E-08     
AKT1 103.9 102.4 85.9 82.0 90.1 84.9 9.10E-09     
AKT2 90.9 91.8 64.2 73.1 84.1 86.2 2.43E-08     
AKT3 90.2 88.3 63.1 61.4 69.1 69.8 4.29E-09     
ALK 97.2 93.5 70.3 70.0 97.0 98.7 2.86E-09     
ALK1/ACVRL1 102.4 101.7 87.4 97.2 113.9 112.5 ND 6.41E-09 LDN193189 
ALK2/ACVR1 83.9 73.1 57.2 53.1 82.0 82.1 ND 1.86E-08 LDN193189 
ALK3/BMPR1A 115.9 106.5 129.6 148.2 101.9 100.3 ND 4.97E-09 LDN193189 
ALK4/ACVR1B 91.4 89.5 70.9 69.2 103.2 97.8 ND 4.88E-07 LDN193189 
ALK5/TGFBR1 96.9 101.0 53.0 58.9 103.2 97.5 ND 3.20E-07 LDN193189 
ALK6/BMPR1B 89.2 101.5 139.3 131.1 93.2 103.8 ND 3.67E-09 LDN193189 
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ARAF 64.8 59.7 83.9 76.1 105.0 97.0 ND 5.68E-09 GW5074 
ARK5/NUAK1 87.8 88.5 52.7 52.1 80.5 81.5 7.94E-10     
ASK1/MAP3K5 94.4 98.1 63.3 62.7 94.4 100.3 2.44E-08     
Aurora A 92.4 94.8 66.6 72.5 93.3 99.1 1.71E-09     
Aurora B 82.3 87.1 20.7 23.0 84.2 81.9 1.28E-08     
Aurora C 78.4 82.5 36.7 36.4 89.8 86.7 3.15E-09     
AXL 89.6 88.7 24.5 24.2 92.3 95.8 1.13E-08     
BLK 98.5 102.6 29.5 33.3 96.0 94.5 2.80E-09     
BMPR2 86.6 85.5 62.1 64.2 102.8 100.7 5.23E-07     
BMX/ETK 93.6 96.0 80.6 79.7 92.9 89.7 8.67E-09     
BRAF 107.3 103.1 85.4 83.8 93.8 96.8 ND 9.88E-09 GW5074 
BRK 78.2 76.2 43.2 42.5 84.0 78.2 1.09E-07     
BRSK1 94.5 97.7 74.1 72.0 93.2 87.5 2.96E-10     
BRSK2 97.0 102.5 101.4 96.5 102.4 98.0 5.78E-09     
BTK 97.6 93.3 70.9 68.3 74.8 70.0 1.73E-08     
c-Kit 96.4 103.8 115.2 111.5 80.3 89.6 2.27E-08     
c-MER 79.7 88.3 61.9 62.3 94.2 94.6 1.82E-08     
c-MET 84.6 87.6 18.1 16.5 86.4 82.6 5.91E-08     
c-Src 91.7 97.5 90.3 88.3 90.9 89.0 3.08E-09     
CAMK1a 49.4 49.8 0.3 0.2 80.1 77.2 3.15E-09     
CAMK1b 56.3 60.8 0.3 0.4 80.5 77.0 2.25E-08     
CAMK1d 59.8 59.9 1.8 0.7 82.5 86.0 3.97E-10     
CAMK1g 119.1 105.7 3.2 7.1 104.5 104.6 7.73E-09     
CAMK2a 94.1 101.0 1.3 0.8 103.9 105.3 1.08E-10     
CAMK2b 78.4 82.8 7.8 7.2 89.9 93.1 9.85E-11     
CAMK2d 54.3 51.9 1.5 1.8 101.7 91.5 <7.63E-11     
CAMK2g 41.1 40.4 1.4 0.6 94.9 92.4 1.24E-09     
CAMK4 29.8 29.3 1.8 1.0 72.1 73.0 5.20E-07     
CAMKK1 88.0 94.3 7.2 4.3 91.5 104.7 2.95E-08     
CAMKK2 120.0 125.1 70.7 70.0 119.3 127.4 4.47E-08     
CDC7/DBF4 97.9 98.7 96.3 90.5 98.6 98.1 3.46E-08     
CDK1/cyclin A 94.8 101.9 55.1 53.0 95.5 96.0 5.46E-09     
CDK1/cyclin B 91.7 100.7 51.1 55.1 100.3 94.4 3.06E-09     
CDK1/cyclin E 93.8 93.1 25.2 30.8 93.9 91.8 3.49E-09     
CDK16/cyclin Y 
(PCTAIRE) 99.5 105.1 26.9 29.7 90.9 91.6 1.75E-08     
CDK2/cyclin A 97.2 101.6 66.5 66.0 101.0 98.6 1.27E-09     
CDK2/Cyclin A1 82.4 89.1 44.7 47.5 91.9 98.3 2.47E-09     
CDK2/cyclin E 93.7 93.9 64.5 67.9 92.7 98.3 1.10E-09     
CDK3/cyclin E 105.8 109.3 62.4 62.3 95.3 93.2 7.80E-09     
CDK4/cyclin D1 104.9 104.8 63.9 55.6 109.0 106.2 2.12E-08     
CDK4/cyclin D3 93.8 94.8 76.4 74.7 88.8 89.5 7.11E-08     
CDK5/p25 102.8 102.7 86.2 85.1 96.5 97.5 3.19E-09     
CDK5/p35 88.9 87.5 72.7 72.7 96.2 93.3 2.46E-09     
CDK6/cyclin D1 93.8 92.7 73.3 71.1 96.0 100.0 6.93E-09     
CDK6/cyclin D3 106.3 103.7 84.3 80.7 104.1 97.5 1.15E-07     
CDK7/cyclin H 94.3 93.5 94.0 90.7 87.0 86.0 4.65E-07     
CDK9/cyclin K 94.1 105.8 68.3 75.3 106.3 100.3 3.81E-08     
CDK9/cyclin T1 124.6 111.6 105.4 98.7 114.3 110.2 2.49E-08     
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CHK1 92.5 91.7 81.0 75.1 98.3 103.6 9.80E-11     
CHK2 91.4 93.9 55.5 55.4 95.9 94.2 6.03E-09     
CK1a1 92.3 93.0 45.2 41.7 106.6 104.1 7.27E-06     
CK1d 70.3 64.9 24.2 23.5 86.7 85.5 ND 1.51E-07 D4476 
CK1epsilon 77.8 76.8 39.1 38.4 87.2 89.6 ND 2.87E-07 D4476 
CK1g1 101.3 95.9 9.4 9.2 94.8 96.1 1.05E-05     
CK1g2 86.6 83.1 2.1 2.5 82.5 83.9 2.88E-06     
CK1g3 92.7 91.6 9.8 9.4 96.7 93.4 2.71E-06     
CK2a 112.4 99.8 74.3 71.7 106.2 105.3 ND 1.69E-07 GW5074 
CK2a2 89.5 86.3 151.5 142.5 90.3 96.3 6.04E-07     
CLK1 108.0 105.0 21.5 26.5 102.3 103.5 1.43E-08     
CLK2 105.7 102.1 8.5 7.9 103.3 104.2 6.40E-09     
CLK3 106.7 93.5 59.8 61.1 114.1 94.9 2.47E-06     
CLK4 96.3 101.6 21.6 22.8 102.9 104.8 3.56E-08     
COT1/MAP3K8 89.5 83.7 70.0 73.4 97.1 94.6 ND 1.56E-05 Ro-31-8220 
CSK 102.7 102.0 94.8 96.1 100.1 100.5 1.28E-08     
CTK/MATK 76.8 77.5 39.5 42.7 84.8 82.3 2.38E-06     
DAPK1 103.2 107.2 51.1 49.6 95.4 103.1 3.06E-08     
DAPK2 99.4 103.8 2.3 5.5 99.0 93.4 1.19E-08     
DCAMKL1 93.6 92.0 75.9 69.0 100.0 110.6 7.93E-07     
DCAMKL2 99.2 98.3 75.5 72.2 95.1 95.7 4.78E-08     
DDR1 71.1 79.5 47.5 51.7 92.0 89.3 3.71E-09     
DDR2 87.0 82.4 33.9 34.2 93.7 91.3 2.14E-08     
DLK/MAP3K12 76.1 76.6 44.7 45.7 79.3 81.2 6.74E-09     
DMPK 105.5 102.7 103.6 98.9 100.0 98.1 8.33E-08     
DMPK2 67.5 66.4 2.9 2.9 104.3 98.8 8.66E-10     
DRAK1/STK17A 87.0 87.8 3.9 1.9 92.9 92.8 2.51E-08     
DYRK1/DYRK1A 88.1 89.0 3.9 3.1 95.0 92.8 3.78E-09     
DYRK1B 93.4 90.8 6.6 5.0 93.3 94.8 1.47E-09     
DYRK2 95.5 92.2 76.7 71.5 98.4 94.3 3.50E-07     
DYRK3 85.1 89.4 53.6 57.2 95.5 96.9 4.97E-08     
DYRK4 98.9 101.7 87.5 88.8 93.8 100.3 ND 3.97E-06 GW5074 
EGFR 101.2 105.0 87.5 88.4 87.3 94.2 1.79E-07     
EPHA1 91.9 95.2 84.0 81.5 96.6 95.6 1.90E-07     
EPHA2 95.9 93.2 97.9 99.6 96.7 96.2 6.03E-08     
EPHA3 101.7 101.4 61.6 55.4 68.2 70.5 3.68E-08     
EPHA4 99.5 102.6 96.6 102.8 101.8 100.0 1.55E-08     
EPHA5 97.7 107.1 95.0 96.4 97.4 99.9 3.37E-08     
EPHA6 80.9 84.2 12.2 15.7 76.8 73.6 1.31E-08     
EPHA7 99.5 98.7 86.9 87.1 99.4 100.7 4.47E-08     
EPHA8 87.8 93.6 92.8 92.8 91.5 93.5 2.24E-07     
EPHB1 96.4 92.0 90.8 86.1 101.1 99.4 3.70E-08     
EPHB2 107.8 102.2 108.7 101.7 108.4 99.1 1.06E-07     
EPHB3 93.8 94.3 93.0 87.5 96.2 101.5 1.63E-06     
EPHB4 94.8 89.9 87.0 83.6 92.3 92.7 2.73E-07     
ERBB2/HER2 89.5 89.0 94.2 92.8 71.2 69.6 2.67E-07     
ERBB4/HER4 102.8 100.8 86.2 86.3 97.7 94.2 4.46E-07     
ERK1 97.2 96.9 89.3 94.1 97.5 92.6 >2.00E-05     
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ERK2/MAPK1 93.4 90.8 79.6 78.3 89.3 84.7 1.38E-05     
ERK5/MAPK7 104.9 113.3 51.3 61.2 107.4 113.8 >2.00E-05     
ERK7/MAPK15 87.8 96.0 31.9 27.3 100.6 93.5 1.22E-08     
FAK/PTK2 90.6 92.0 86.6 86.8 91.4 90.8 1.06E-08     
FER 95.8 95.6 51.3 50.9 87.7 87.0 6.78E-10     
FES/FPS 94.2 98.3 77.8 74.7 81.6 83.0 1.25E-09     
FGFR1 96.9 95.0 84.3 82.2 91.0 94.2 7.44E-09     
FGFR2 98.1 103.4 105.8 96.7 98.6 89.7 3.87E-09     
FGFR3 94.9 96.3 86.0 92.4 91.9 90.1 2.03E-08     
FGFR4 91.3 94.3 24.9 30.0 93.5 93.1 1.61E-07     
FGR 87.2 88.2 70.2 70.7 91.7 89.3 1.22E-09     
FLT1/VEGFR1 85.3 85.0 74.1 74.7 61.9 64.5 9.75E-09     
FLT3 63.5 60.7 1.6 1.6 84.2 83.5 9.57E-10     
FLT4/VEGFR3 99.5 104.3 102.3 98.6 86.2 82.8 5.85E-09     
FMS 81.4 82.5 57.7 60.2 83.6 82.8 1.29E-09     
FRK/PTK5 100.5 104.2 86.8 93.7 99.7 95.8 1.56E-08     
FYN 95.7 98.9 86.5 88.3 95.6 97.2 2.17E-09     
GCK/MAP4K2 92.5 94.4 62.5 55.6 91.8 88.5 3.44E-10     
GLK/MAP4K3 97.7 108.1 68.2 65.0 101.3 104.3 8.74E-11     
GRK1 103.2 101.2 112.8 135.3 99.9 98.9 9.49E-08     
GRK2 95.9 98.0 96.6 102.8 100.4 94.7 1.28E-06     
GRK3 84.7 88.6 122.2 128.4 83.5 83.0 7.31E-07     
GRK4 97.0 99.2 105.6 104.5 100.6 103.1 1.52E-07     
GRK5 94.7 89.0 102.4 101.4 86.7 84.1 8.99E-08     
GRK6 97.5 96.6 107.6 112.4 94.4 95.2 5.56E-08     
GRK7 102.1 104.3 210.2 215.8 98.5 100.8 7.08E-09     
GSK3a 103.8 104.5 77.1 75.9 107.5 114.0 1.00E-08     
GSK3b 82.1 93.2 76.9 72.6 97.8 93.9 1.38E-08     
Haspin 89.9 90.8 81.6 75.3 105.1 101.2 2.66E-08     
HCK 96.9 97.3 34.0 30.3 95.5 92.2 1.38E-09     
HGK/MAP4K4 106.7 105.8 35.1 37.6 104.5 112.3 5.51E-10     
HIPK1 84.7 82.4 38.1 39.9 98.7 100.6 ND 3.21E-07 Ro-31-8220 
HIPK2 95.8 99.6 71.2 72.1 102.9 102.5 2.37E-06     
HIPK3 104.5 96.5 78.0 76.3 95.4 100.2 1.89E-06     
HIPK4 95.4 95.7 48.6 41.7 95.6 90.7 8.27E-07     
HPK1/MAP4K1 105.5 107.8 78.7 80.7 105.9 103.1 ND 6.15E-08 Ro-31-8220 
IGF1R 101.9 96.0 90.4 90.4 103.7 95.9 3.88E-08     
IKKa/CHUK 93.4 93.9 51.1 47.9 93.2 91.5 2.42E-07     
IKKb/IKBKB 91.5 91.1 72.5 72.6 90.0 90.4 3.31E-07     
IKKe/IKBKE 108.8 111.6 122.5 134.5 102.8 103.2 2.55E-10     
IR 82.0 86.5 80.0 67.8 59.5 56.2 1.99E-08     
IRAK1 93.5 94.6 50.2 46.4 95.0 98.6 1.10E-07     
IRAK4 96.8 103.4 28.4 28.2 108.3 103.1 2.22E-08     
IRR/INSRR 80.1 76.1 3.2 3.3 82.8 83.1 2.01E-08     
ITK 100.7 98.9 47.5 44.7 103.2 107.1 3.14E-08     
JAK1 99.4 104.2 78.5 91.1 89.3 92.2 9.36E-10     
JAK2 88.0 90.5 52.4 51.8 90.5 89.1 7.25E-10     
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JAK3 94.5 97.0 74.4 74.3 94.9 96.8 7.68E-11     
JNK1 92.0 96.7 64.3 66.7 94.2 95.0 1.76E-06     
JNK2 84.8 84.7 59.2 57.6 96.4 100.1 4.97E-06     
JNK3 102.6 103.0 78.4 80.2 101.7 101.4 ND 3.27E-07 JNKi VIII 
KDR/VEGFR2 91.5 86.0 94.0 93.5 72.7 69.4 1.82E-08     
KHS/MAP4K5 99.6 96.9 59.8 58.6 93.4 95.0 3.29E-10     
LATS1 99.1 100.8 59.2 58.1 102.2 100.2 1.43E-08     
LATS2 92.0 92.2 26.8 26.2 98.0 92.1 5.68E-09     
LCK 82.0 83.3 37.4 36.0 96.4 97.2 2.63E-09     
LCK2/ICK 103.5 129.0 -0.7 3.7 113.8 116.7 1.54E-07     
LIMK1 101.9 97.7 99.9 99.8 100.8 99.3 7.85E-09     
LIMK2 98.0 102.8 76.2 80.2 97.3 96.7 1.54E-07     
LKB1 102.1 105.3 26.5 28.5 101.2 97.6 9.33E-08     
LOK/STK10 80.9 83.7 24.5 24.2 88.1 89.7 4.90E-09     
LRRK2 111.5 109.7 7.9 8.1 102.7 101.6 1.28E-08     
LYN 100.9 98.0 85.6 83.9 98.3 91.1 1.29E-09     
LYN B 96.5 97.2 104.1 103.8 97.8 98.5 4.58E-09     
MAPKAPK2 105.4 103.1 106.9 106.5 101.0 100.5 2.70E-07     
MAPKAPK3 98.9 102.7 55.6 59.8 94.5 100.4 4.48E-06     
MAPKAPK5/PRAK 91.7 94.8 81.8 77.2 90.0 89.8 4.14E-07     
MARK1 93.1 92.5 87.2 94.1 97.0 95.7 1.02E-10     
MARK2/PAR-1Ba 97.5 96.0 92.4 90.9 97.4 97.9 1.09E-10     
MARK3 98.3 92.7 95.3 93.5 93.7 94.0 2.59E-10     
MARK4 96.1 97.6 82.9 81.6 100.5 99.0 1.18E-10     
MEK1 103.2 101.6 98.9 93.6 101.8 104.0 3.33E-08     
MEK2 98.7 97.0 81.2 84.6 96.1 99.3 3.78E-08     
MEK3 79.0 83.7 98.3 88.1 115.8 113.1 6.86E-08     
MEKK1 109.1 121.3 104.2 104.3 107.8 113.6 8.09E-07     
MEKK2 118.6 121.7 99.8 95.8 103.9 98.1 2.70E-08     
MEKK3 102.1 106.2 74.6 79.7 96.1 96.1 9.01E-09     
MELK 76.4 76.2 1.4 0.6 93.9 91.6 5.05E-10     
MINK/MINK1 101.3 101.8 57.0 57.6 116.3 114.7 1.41E-09     
MKK4 99.5 97.0 87.3 90.0 97.9 102.6 1.84E-06     
MKK6 107.6 107.5 122.7 125.3 142.6 136.1 1.33E-08     
MLCK/MYLK 67.1 66.4 8.2 6.4 85.9 92.8 3.43E-08     
MLCK2/MYLK2 82.7 93.7 9.2 16.6 85.9 87.1 3.84E-08     
MLK1/MAP3K9 100.1 102.2 48.7 49.5 93.8 97.3 3.90E-10     
MLK2/MAP3K10 88.3 93.8 14.7 14.1 93.8 95.3 3.85E-09     
MLK3/MAP3K11 90.3 88.4 37.3 37.1 100.3 99.2 6.76E-09     
MNK1 85.2 84.4 17.9 18.4 96.8 94.1 6.80E-08     
MNK2 82.7 84.8 62.3 62.4 101.0 105.1 2.83E-08     
MRCKa/CDC42BPA 94.9 92.1 27.8 25.0 102.0 94.7 1.12E-08     
MRCKb/CDC42BPB 94.5 93.3 9.9 10.3 97.5 94.5 6.88E-09     
MSK1/RPS6KA5 90.1 92.7 12.5 12.9 88.3 84.4 7.22E-10     
MSK2/RPS6KA4 68.1 65.8 7.0 6.7 74.7 79.2 2.10E-09     
MSSK1/STK23 103.0 97.0 27.0 26.7 98.9 82.6 1.37E-06     
MST1/STK4 99.4 97.4 51.6 50.9 90.6 93.2 4.96E-10     
MST2/STK3 103.7 112.2 83.1 86.4 100.0 106.2 5.36E-09     
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MST3/STK24 104.5 122.4 59.9 54.9 117.7 141.5 2.61E-09     
MST4 90.2 87.7 8.2 8.5 100.2 97.7 3.96E-09     
MUSK 112.5 113.5 33.8 33.3 109.3 110.9 1.59E-07     
MYLK3 100.7 101.3 99.0 93.2 105.2 106.1 2.02E-07     
MYO3b 124.4 120.8 57.3 58.4 111.0 111.2 1.08E-08     
NEK1 102.4 98.9 108.6 96.5 98.8 97.9 1.96E-08     
NEK11 84.6 86.8 26.5 25.4 99.5 92.9 1.22E-06     
NEK2 77.4 79.5 -0.2 2.0 103.9 108.0 5.60E-07     
NEK3 96.2 98.2 103.2 109.9 105.6 108.7 1.24E-05     
NEK4 81.0 87.9 39.4 37.6 102.5 103.1 1.57E-07     
NEK5 88.3 86.1 50.6 52.1 90.1 84.6 9.17E-08     
NEK6 114.9 106.4 50.1 47.5 109.5 110.9 ND 
>2.00E-
05 
PKR 
Inhibitor 
NEK7 113.9 110.7 95.5 93.0 132.9 125.2 ND 2.71E-06 
PKR 
Inhibitor 
NEK9 104.5 102.4 59.5 52.2 104.6 106.1 1.85E-07     
NLK 103.8 99.4 62.2 67.2 88.6 89.5 8.34E-08     
OSR1/OXSR1 74.0 78.6 4.6 3.9 88.0 94.3 1.08E-07     
P38a/MAPK14 77.0 74.5 57.7 57.1 106.1 99.4 ND 7.10E-09 SB202190 
P38b/MAPK11 113.9 113.2 69.6 65.0 110.6 105.2 ND 1.64E-08 SB202190 
P38d/MAPK13 87.4 93.6 109.8 111.2 106.9 116.8 3.12E-07     
P38g 103.0 99.5 117.3 102.3 102.6 100.9 2.08E-07     
p70S6K/RPS6KB1 95.8 98.7 48.2 50.5 76.9 77.5 5.61E-10     
p70S6Kb/RPS6KB2 76.8 80.8 15.8 13.6 87.4 86.4 3.34E-09     
PAK1 105.5 101.3 87.6 99.9 101.9 97.7 5.00E-10     
PAK2 99.4 100.0 81.3 84.6 100.0 96.3 2.21E-09     
PAK3 109.2 102.6 97.7 90.5 96.6 99.9 4.07E-10     
PAK4 91.6 98.6 89.1 85.0 97.1 90.2 3.96E-08     
PAK5 103.8 104.4 98.6 100.5 96.6 100.7 3.56E-09     
PAK6 101.8 97.2 101.1 99.3 98.9 102.3 8.15E-08     
PASK 82.6 85.9 2.0 3.7 87.1 83.3 1.50E-08     
PBK/TOPK 87.3 92.5 65.2 76.4 92.6 93.2 8.26E-08     
PDGFRa 105.5 104.8 80.0 83.6 95.7 100.2 9.19E-10     
PDGFRb 89.3 91.4 66.7 65.3 85.9 90.2 1.60E-09     
PDK1/PDPK1 111.0 110.8 113.5 119.1 101.4 103.5 1.35E-09     
PHKg1 88.3 104.0 44.5 36.8 90.2 87.3 8.66E-10     
PHKg2 79.3 90.0 28.4 21.5 97.7 94.3 6.06E-10     
PIM1 92.9 90.9 6.1 4.9 84.7 84.5 5.86E-09     
PIM2 100.4 97.3 75.9 80.4 101.4 101.7 6.75E-08     
PIM3 95.2 98.4 12.1 14.5 96.5 95.7 1.58E-10     
PKA 101.7 101.9 82.7 83.5 90.8 93.6 1.64E-09     
PKAcb 96.6 105.5 15.4 15.5 101.1 96.6 2.21E-09     
PKAcg 88.1 103.8 24.8 23.3 96.9 96.5 1.25E-08     
PKCa 91.7 94.6 78.6 77.6 81.4 83.1 5.51E-10     
PKCb1 95.3 94.9 25.8 25.6 71.8 70.0 3.39E-09     
PKCb2 72.6 74.9 16.3 16.4 73.5 74.0 7.33E-10     
PKCd 103.4 101.4 71.7 72.9 94.7 100.2 1.16E-10     
PKCepsilon 99.0 94.5 38.8 35.7 89.7 84.0 1.62E-10     
PKCeta 98.5 95.5 50.0 48.1 81.2 80.8 3.72E-09     
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PKCg 118.6 105.1 81.6 65.3 88.4 79.5 2.49E-09     
PKCiota 94.2 92.2 72.2 72.9 94.1 93.6 2.54E-08     
PKCmu/PRKD1 91.8 98.2 32.6 33.3 94.3 93.0 1.92E-09     
PKCnu/PRKD3 87.0 90.8 15.9 15.8 92.0 93.5 1.46E-09     
PKCtheta 119.7 122.8 55.1 56.7 68.3 70.6 1.58E-09     
PKCzeta 97.0 100.2 80.7 83.0 100.0 97.7 9.76E-08     
PKD2/PRKD2 89.0 91.1 31.9 34.9 81.6 86.9 1.96E-09     
PKG1a 107.1 106.6 88.2 89.0 98.8 91.6 1.06E-09     
PKG1b 86.1 92.4 90.6 91.0 94.8 97.2 2.49E-09     
PKG2/PRKG2 112.7 113.1 95.2 91.7 110.3 110.9 3.73E-09     
PKN1/PRK1 100.8 102.8 18.5 18.5 94.3 91.7 7.76E-11     
PKN2/PRK2 92.2 95.2 36.5 38.3 95.9 99.7 5.42E-10     
PKN3/PRK3 111.3 113.5 112.2 112.5 107.8 106.5 2.51E-08     
PLK1 93.7 95.0 91.2 89.6 100.5 100.7 2.16E-07     
PLK2 98.4 93.5 93.6 102.1 100.3 90.3 1.05E-06     
PLK3 101.5 102.6 93.2 102.1 84.9 85.4 4.04E-07     
PLK4/SAK 92.5 102.8 103.4 98.9 109.4 105.9 2.08E-08     
PRKX 118.1 113.6 97.7 96.4 105.5 102.1 2.71E-09     
PYK2 100.9 101.8 82.3 83.3 97.9 98.0 5.75E-09     
RAF1 88.1 88.4 90.2 96.2 93.3 98.0 ND 3.26E-09 GW5074 
RET 104.3 102.5 28.3 28.9 94.6 99.2 3.72E-09     
RIPK2 96.3 98.2 63.1 62.8 98.4 88.8 2.21E-07     
RIPK3 97.9 99.4 117.8 115.6 97.2 99.5 ND 1.08E-05 GW5074 
RIPK5 49.7 48.8 10.0 10.1 85.5 87.1 6.68E-08     
ROCK1 101.4 96.2 87.9 86.2 91.6 87.6 1.05E-09     
ROCK2 97.3 96.0 92.9 89.0 84.1 93.0 4.27E-10     
RON/MST1R 92.4 95.4 39.5 42.4 69.0 70.0 3.17E-07     
ROS/ROS1 92.6 89.9 15.8 14.4 96.1 102.7 1.77E-10     
RSK1 89.5 91.4 26.4 24.9 80.7 71.6 2.39E-10     
RSK2 95.9 95.3 55.1 57.1 79.0 78.8 1.97E-10     
RSK3 98.2 94.5 36.9 40.5 81.1 88.0 2.95E-10     
RSK4 99.8 103.4 33.2 32.1 88.9 86.1 1.44E-10     
SGK1 83.5 87.4 49.4 57.1 90.2 88.0 1.37E-08     
SGK2 99.7 106.5 6.6 9.8 110.1 105.7 3.52E-08     
SGK3/SGKL 109.9 113.3 76.0 78.5 109.5 107.5 1.19E-07     
SIK1 101.6 97.4 69.5 62.4 89.2 88.9 5.17E-10     
SIK2 87.9 86.7 34.7 34.9 85.9 84.7 2.38E-10     
SIK3 84.4 82.9 32.3 34.5 88.3 85.7 1.74E-09     
SLK/STK2 92.2 90.7 72.3 71.2 101.2 99.9 5.10E-09     
SNARK/NUAK2 81.1 87.8 91.1 91.1 82.9 90.3 4.11E-08     
SRMS 77.8 78.3 28.2 29.9 80.7 79.1 1.91E-05     
SRPK1 96.9 96.2 25.7 21.7 91.8 95.1 3.94E-08     
SRPK2 99.7 101.6 62.2 65.5 99.2 98.5 2.95E-07     
SSTK/TSSK6 100.2 101.4 64.9 70.7 93.6 94.0 2.51E-07     
STK16 97.5 102.5 66.5 75.6 89.5 94.8 3.70E-07     
STK22D/TSSK1 97.4 98.9 89.6 89.9 97.1 94.6 8.50E-11     
STK25/YSK1 87.7 87.8 57.1 55.7 87.2 93.0 1.64E-09     
STK32B/YANK2 99.5 104.3 98.9 98.9 105.5 106.4 1.75E-07     
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STK32C/YANK3 104.9 103.3 61.8 54.7 105.1 106.0 2.86E-07     
STK33 80.9 82.4 16.1 17.9 83.4 85.1 2.71E-08     
STK38/NDR1 108.6 102.4 89.0 93.7 106.5 105.4 1.99E-08     
STK38L/NDR2 101.5 104.1 81.1 79.9 104.2 107.3 1.60E-09     
STK39/STLK3 48.0 48.4 2.2 1.0 85.6 82.0 5.78E-08     
SYK 94.0 92.2 80.3 75.4 96.5 94.5 1.89E-10     
TAK1 96.0 95.2 74.5 79.0 93.8 90.9 3.77E-08     
TAOK1 96.9 97.0 29.3 32.5 95.9 92.8 1.45E-09     
TAOK2/TAO1 93.2 89.2 23.6 25.8 86.9 105.9 3.23E-09     
TAOK3/JIK 99.2 119.9 48.3 50.7 97.7 104.3 1.67E-09     
TBK1 110.9 107.6 126.6 126.6 102.3 104.0 1.76E-09     
TEC 96.1 98.4 67.1 62.9 100.1 97.6 6.35E-08     
TESK1 96.1 92.1 26.4 36.7 98.8 97.6 9.39E-07     
TGFBR2 117.5 111.3 109.1 93.4 118.4 108.6 ND 7.20E-06 GW5074 
TIE2/TEK 85.4 85.4 52.0 50.1 45.3 45.4 9.51E-08     
TLK1 98.6 95.3 90.5 87.5 93.7 99.7 4.19E-08     
TLK2 99.4 101.4 93.0 99.7 109.1 105.3 4.02E-09     
TNIK 87.5 90.6 19.1 17.6 118.1 120.2 5.86E-10     
TNK1 79.7 75.4 27.6 26.5 88.5 89.1 1.41E-09     
TRKA 92.4 91.2 6.3 5.0 62.7 58.9 2.23E-09     
TRKB 100.1 101.0 88.8 87.8 102.3 99.1 1.23E-10     
TRKC 77.5 79.1 64.3 62.2 92.5 90.3 4.73E-10     
TSSK2 105.8 101.6 85.3 83.5 96.3 106.4 9.51E-09     
TSSK3/STK22C 94.8 96.8 1.3 0.7 99.4 102.4 1.01E-08     
TTBK1 106.7 104.4 76.8 75.2 99.1 109.1 >2.00E-05     
TTBK2 103.7 103.0 71.2 66.7 101.3 104.1 >2.00E-05     
TXK 110.7 105.9 34.5 33.2 95.9 102.4 2.28E-08     
TYK1/LTK 91.7 94.8 50.9 51.8 99.0 99.1 2.22E-08     
TYK2 90.0 86.1 41.2 41.8 92.9 92.2 2.47E-10     
TYRO3/SKY 99.4 93.5 63.5 62.5 93.6 97.2 6.22E-09     
ULK1 115.7 121.5 83.3 88.6 112.6 118.0 7.34E-09     
ULK2 117.8 116.3 91.2 87.0 107.6 107.8 4.16E-09     
ULK3 102.9 102.3 156.5 193.5 113.6 123.1 2.14E-09     
VRK1 111.3 111.8 93.3 95.8 87.1 84.1 ND 6.42E-07 Ro-31-8220 
VRK2 90.4 91.6 158.2 164.7 82.1 87.6 ND 1.39E-05 Ro-31-8220 
WEE1 113.1 109.5 101.1 100.2 109.0 102.9 ND 9.95E-08 
Wee1 
inhibitor 
WNK1 99.2 109.7 79.4 51.5 100.3 96.6 >2.00E-05     
WNK2 106.6 94.3 49.4 50.1 105.2 102.1 1.51E-06     
WNK3 112.2 112.8 78.4 73.0 105.0 101.9 ND 2.32E-06 
Wee1 
inhibitor 
YES/YES1 103.2 102.6 90.2 87.8 98.6 95.9 2.25E-09     
ZAK/MLTK 94.9 99.2 43.8 44.2 88.1 89.5 ND 1.18E-06 GW5074 
ZAP70 88.2 88.5 45.2 43.8 81.3 83.4 1.01E-08     
ZIPK/DAPK3 85.4 93.0 11.0 9.5 98.7 96.3 4.81E-09     
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